LABEL>1
Concurrent administration of a DRUG1 with DRUG2 has been associated with an increased risk of serious infections and no significant additional efficacy over use of the GE alone.
LABEL>1
Concurrent therapy with DRUG1 and DRUG2 is not recommended.
LABEL>1
There is insufficient experience to assess the safety and efficacy of DRUG1 administered concurrently with DRUG2, and therefore such use is not recommended.
LABEL>1
Co-administration of DRUG1 with DRUG2 produced a 25% increase in AUC and a 33% increase in the Cmax of GE.
LABEL>1
Patients taking DRUG1 concomitantly with DRUG2 more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.
LABEL>1
DRUG1 (e. g., GE) and GE containing carbohydrate-splitting enzymes (e. g., GE, GE) may reduce the effect of DRUG2 and should not be taken concomitantly.
LABEL>1
GE (e. g., DRUG1) and GE containing carbohydrate-splitting enzymes (e. g., GE, GE) may reduce the effect of DRUG2 and should not be taken concomitantly.
LABEL>1
GE (e. g., GE) and GE containing carbohydrate-splitting enzymes (e. g., DRUG1, GE) may reduce the effect of DRUG2 and should not be taken concomitantly.
LABEL>1
GE (e. g., GE) and GE containing carbohydrate-splitting enzymes (e. g., GE, DRUG1) may reduce the effect of DRUG2 and should not be taken concomitantly.
LABEL>1
DRUG1 has been shown to change the bioavailabillty DRUG2 when they are co-administered, which may require GE dose adjustment.
LABEL>1
However, the peak plasma level of DRUG1 was reduced by approximately 20% when taking DRUG2 due to a slight delay in the absorption of GE.
LABEL>1
However, the peak plasma level of GE was reduced by approximately 20% when taking DRUG1 due to a slight delay in the absorption of DRUG2.
LABEL>1
DRUG1, such as GE, may have an additive effect when given with DRUG2.
LABEL>1
GE, such as DRUG1, may have an additive effect when given with DRUG2.
LABEL>1
Patients treated with DRUG1 plus DRUG2 should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.
LABEL>1
Exaggerated hypertensive responses have been reported from the combined use of DRUG1 and DRUG2, including those contained in proprietary cold remedies and vasoconstrictive nasal drops.
LABEL>1
Blunting of the antihypertensive effect of DRUG1 by DRUG2 has been reported.
LABEL>1
DRUG1 modifies DRUG2 metabolism with increased serum levels of GE.
LABEL>1
DRUG1 modifies GE metabolism with increased serum levels of DRUG2.
LABEL>1
By decreasing the gastrointestinal absorption of GE, DRUG1 may decrease serum concentrations of DRUG2 and its metabolites, with a consequent possible decrease in anticonvulsant effect.
LABEL>1
Caution is advised when beginning, discontinuing, or changing the dose of DRUG1 in patients receiving DRUG2.
LABEL>1
DRUG1 may increase the effects of other DRUG2.
LABEL>1
DRUG1 decreases urinary excretion of DRUG2 and may enhance the magnitude and duration of their effect.
LABEL>1
DRUG1 reduces urinary excretion of DRUG2 and may enhance its effect.
LABEL>1
DRUG1 may prevent the urinary antiseptic effect of DRUG2.
LABEL>1
DRUG1 increases DRUG2 excretion and the GE may be decreased.
LABEL>1
DRUG1 and DRUG2 used concurrently increases the risk of renal calculus formation.
LABEL>1
DRUG1 may elevate DRUG2 levels.
LABEL>1
Co-administration of DRUG1 with DRUG2 has been shown to increase the mean half-life and the area under the concentration-time curve.
LABEL>1
GE:Clinical evidence has shown that GE can be formed with concurrent ingestion of DRUG1 and DRUG2.
LABEL>1
GE: In a study of 7 healthy male volunteers, DRUG1 treatment potentiated the blood glucose lowering effect of DRUG2 (a GE similar to GE) in 3 of the 7 subjects.
LABEL>1
However, it has been established that DRUG1 interferes with the contraceptive effect of microdosed DRUG2 minipill preparations.
LABEL>1
Microdosed minipill DRUG1 preparations are not recommended for use with DRUG2.
LABEL>1
GE: An increased risk of hepatitis has been reported to result from combined use of DRUG1 and DRUG2.
LABEL>1
Consequently, the combination of DRUG1 with DRUG2 is also contraindicated.
LABEL>1
GE: If DRUG1 is given concurrently with DRUG2, the protein binding of GE may be reduced.
LABEL>1
GE: Since both DRUG1 and DRUG2 can cause increased intracranial pressure, their combined use is contraindicated.
LABEL>1
GE and oral GE: Concomitant administration of DRUG1 and/or other oral GE with DRUG2 must be avoided because of the risk of hypervitaminosis A.
LABEL>1
GE and oral GE: Concomitant administration of GE and/or other oral DRUG1 with DRUG2 must be avoided because of the risk of hypervitaminosis A.
LABEL>1
GE: Concurrent administration of DRUG1 (an GE) and another DRUG2 has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
LABEL>1
GE: Concurrent administration of GE (an DRUG1) and another DRUG2 has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
LABEL>1
Therefore the, combination of DRUG1 with other DRUG2, including GE, may also result i n similar toxicities.
LABEL>1
Therefore the, combination of DRUG1 with other GE, including DRUG2, may also result i n similar toxicities.
LABEL>1
DRUG1 and GE use may be rarely associated with ventricular fibrillation when combined with DRUG2.
LABEL>1
GE and DRUG1 use may be rarely associated with ventricular fibrillation when combined with DRUG2.
LABEL>1
The use of DRUG1 in patients receiving DRUG2 may be rarely associated with ventricular fibrillation.
LABEL>1
The effects of DRUG1 are antagonized by DRUG2 such as GE and GE.
LABEL>1
The effects of DRUG1 are antagonized by GE such as DRUG2 and GE.
LABEL>1
The effects of DRUG1 are antagonized by GE such as GE and DRUG2.
LABEL>1
In the presence of these DRUG1, larger doses of DRUG2 may be required or GE may not be effective.
LABEL>1
In the presence of these DRUG1, larger doses of GE may be required or DRUG2 may not be effective.
LABEL>1
DRUG1 effects are potentiated by DRUG2.
LABEL>1
Thus, smaller doses of DRUG1 may be effective in the presence of DRUG2.
LABEL>1
As the primary effect of DRUG1 is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of DRUG2.
LABEL>1
DRUG1, GE, GE (consider DRUG2 dose reduction).
LABEL>1
GE, DRUG1, GE (consider DRUG2 dose reduction).
LABEL>1
GE, GE, DRUG1 (consider DRUG2 dose reduction).
LABEL>1
GE: Steady-state trough concentrations of GE were about 56% higher when 8 mg DRUG1 was coadministered with each dose of DRUG2 (15 mg/kg/day) in eight neurocysticercosis patients.
LABEL>1
GE: In the fed state, DRUG1 (40 mg/kg) increased mean maximum plasma concentration and area under the curve of DRUG2 by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given GE alone.
LABEL>1
GE: DRUG1 concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with DRUG2 (10 mg/kg/day) (n=7) compared with GE (20 mg/kg/day) alone (n=12).
LABEL>1
Concurrent administration of drugs possessing nephrotoxic (e.g., DRUG1, GE), myelotoxic (e.g., GE chemotherapy), cardiotoxic (e.g., GE) or hepatotoxic (e.g., GE, GE) effects with DRUG2 may increase toxicity in these organ systems.
LABEL>1
Concurrent administration of drugs possessing nephrotoxic (e.g., GE, DRUG1), myelotoxic (e.g., GE chemotherapy), cardiotoxic (e.g., GE) or hepatotoxic (e.g., GE, GE) effects with DRUG2 may increase toxicity in these organ systems.
LABEL>1
Concurrent administration of drugs possessing nephrotoxic (e.g., GE, GE), myelotoxic (e.g., DRUG1 chemotherapy), cardiotoxic (e.g., GE) or hepatotoxic (e.g., GE, GE) effects with DRUG2 may increase toxicity in these organ systems.
LABEL>1
Concurrent administration of drugs possessing nephrotoxic (e.g., GE, GE), myelotoxic (e.g., GE chemotherapy), cardiotoxic (e.g., DRUG1) or hepatotoxic (e.g., GE, GE) effects with DRUG2 may increase toxicity in these organ systems.
LABEL>1
Concurrent administration of drugs possessing nephrotoxic (e.g., GE, GE), myelotoxic (e.g., GE chemotherapy), cardiotoxic (e.g., GE) or hepatotoxic (e.g., DRUG1, GE) effects with DRUG2 may increase toxicity in these organ systems.
LABEL>1
Concurrent administration of drugs possessing nephrotoxic (e.g., GE, GE), myelotoxic (e.g., GE chemotherapy), cardiotoxic (e.g., GE) or hepatotoxic (e.g., GE, DRUG1) effects with DRUG2 may increase toxicity in these organ systems.
LABEL>1
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose DRUG1 and DRUG2, specifically, GE, GE, GE and GE.
LABEL>1
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose DRUG1 and GE, specifically, DRUG2, GE, GE and GE.
LABEL>1
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose DRUG1 and GE, specifically, GE, DRUG2, GE and GE.
LABEL>1
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose DRUG1 and GE, specifically, GE, GE, DRUG2 and GE.
LABEL>1
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose DRUG1 and GE, specifically, GE, GE, GE and DRUG2.
LABEL>1
Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving DRUG1 and DRUG2 concurrently.
LABEL>1
Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of DRUG1 and DRUG2, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.
LABEL>1
Although DRUG1 have been shown to reduce DRUG2-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with GE may reduce the antitumor effectiveness of GE and thus should be avoided. 12 GE and other GE may potentiate the hypotension seen with GE.
LABEL>1
Although GE have been shown to reduce GE-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with GE may reduce the antitumor effectiveness of GE and thus should be avoided. 12 DRUG1 and other GE may potentiate the hypotension seen with DRUG2.
LABEL>1
Although GE have been shown to reduce GE-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with GE may reduce the antitumor effectiveness of GE and thus should be avoided. 12 GE and other DRUG1 may potentiate the hypotension seen with DRUG2.
LABEL>1
Delayed Adverse Reactions to GE: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various DRUG1 containing regimens who were subsequently administered DRUG2 experienced acute, atypical adverse reactions.
LABEL>1
Intravenous DRUG1 was shown to double the bioavailability of oral DRUG2.
LABEL>1
Products containing DRUG1 and other GE likely will interfere with absorption of DRUG2.
LABEL>1
Products containing GE and other DRUG1 likely will interfere with absorption of DRUG2.
LABEL>1
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when DRUG1 is administered in combination with other DRUG2 such as GE, GE, GE, or inhalation general GE.
LABEL>1
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when DRUG1 is administered in combination with other GE such as DRUG2, GE, GE, or inhalation general GE.
LABEL>1
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when DRUG1 is administered in combination with other GE such as GE, DRUG2, GE, or inhalation general GE.
LABEL>1
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when DRUG1 is administered in combination with other GE such as GE, GE, DRUG2, or inhalation general GE.
LABEL>1
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when DRUG1 is administered in combination with other GE such as GE, GE, GE, or inhalation general DRUG2.
LABEL>1
Limited clinical experience indicates that requirements for DRUG1 are reduced by 30 to 50% for the first sixty (60) minutes following DRUG2 induction The concomitant use of GE with GE can significantly inhibit GE clearance and may increase the risk of prolonged or delayed respiratory depression.
LABEL>1
Limited clinical experience indicates that requirements for GE are reduced by 30 to 50% for the first sixty (60) minutes following GE induction The concomitant use of DRUG1 with DRUG2 can significantly inhibit GE clearance and may increase the risk of prolonged or delayed respiratory depression.
LABEL>1
DRUG1 reduces the clearance of DRUG2.
LABEL>1
However, interactions may be expected, and DRUG1 should NOT be used in combination with other DRUG2.
LABEL>1
Co-administration of DRUG1 reduced DRUG2 Cmax up to 50% after multiple dosing.
LABEL>1
Co-administration of DRUG1 resulted in about a 50% increase in DRUG2 Cmax and AUC after multiple dosing.
LABEL>1
GE: Co-administration of 200 mg twice-daily DRUG1 with DRUG2 resulted in an approximate 80% increase in plasma levels of GE.
LABEL>1
GE: When DRUG1 was co-administered with DRUG2, the AUC and Cmax of GE were reduced by about 30% and 50%, respectively.
LABEL>1
Patients who are applying DRUG1 gel should not concurrently use products that contain DRUG2 (N, GE), a common component of insect repellent products.
LABEL>1
Patients who are applying DRUG1 gel should not concurrently use products that contain GE (N, DRUG2), a common component of insect repellent products.
LABEL>1
GE/GE: DRUG1 inhibits the enzymatic oxidation of DRUG2 and GE to GE.
LABEL>1
GE/GE: DRUG1 inhibits the enzymatic oxidation of GE and DRUG2 to GE.
LABEL>1
In patients receiving GE (GE) or GE (GE), the concomitant administration of 300-600 mg of DRUG1 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of DRUG2 or GE.
LABEL>1
In patients receiving GE (GE) or GE (GE), the concomitant administration of 300-600 mg of DRUG1 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of GE or DRUG2.
LABEL>1
GE: It has been reported that DRUG1 prolongs the half-life of the GE, DRUG2.
LABEL>1
GE: Since the excretion of GE is similar to that of urate, DRUG1, which increase the excretion of urate, are also likely to increase the excretion of DRUG2 and thus lower the degree of inhibition of xanthine oxidase.
LABEL>1
The concomitant administration of DRUG1 and DRUG2 has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with GE alone.
LABEL>1
GE: The reports that the concomitant use of DRUG1 and DRUG2 may contribute to the enhancement of GE toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
LABEL>1
Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on DRUG1 and DRUG2 even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected..
LABEL>1
GE/GE: An increase in the frequency of skin rash has been reported among patients receiving DRUG1 or GE concurrently with DRUG2 compared to patients who are not receiving both drugs.
LABEL>1
GE/GE: An increase in the frequency of skin rash has been reported among patients receiving GE or DRUG1 concurrently with DRUG2 compared to patients who are not receiving both drugs.
LABEL>1
GE: Enhanced bone marrow suppression by DRUG1 and other GE has been reported among patients with neoplastic disease, except leukemia, in the presence of DRUG2.
LABEL>1
GE: Enhanced bone marrow suppression by GE and other DRUG1 has been reported among patients with neoplastic disease, except leukemia, in the presence of DRUG2.
LABEL>1
GE: DRUG1s plasma half-life may be prolonged by DRUG2, since GE and GE may compete for excretion in the renal tubule.
LABEL>1
GE: GEs plasma half-life may be prolonged by GE, since DRUG1 and DRUG2 may compete for excretion in the renal tubule.
LABEL>1
The risk of hypoglycemia secondary to this mechanism may be increased if DRUG1 and DRUG2 are given concomitantly in the presence of renal insufficiency.
LABEL>1
GE: Reports indicate that DRUG1 levels may be increased during concomitant treatment with DRUG2 for injection.
LABEL>1
Because there is a theoretical basis that these effects may be additive, use of DRUG1-containing or GE (like GE or GE) and DRUG2 within 24 hours of each other should be avoided.
LABEL>1
Because there is a theoretical basis that these effects may be additive, use of GE-containing or DRUG1 (like GE or GE) and DRUG2 within 24 hours of each other should be avoided.
LABEL>1
Because there is a theoretical basis that these effects may be additive, use of GE-containing or GE (like DRUG1 or GE) and DRUG2 within 24 hours of each other should be avoided.
LABEL>1
Because there is a theoretical basis that these effects may be additive, use of GE-containing or GE (like GE or DRUG1) and DRUG2 within 24 hours of each other should be avoided.
LABEL>1
GE: Coadministration of DRUG1 resulted in a 27% decrease in DRUG2 clearance and an increase in Cmax of approximately 6%.
LABEL>1
Other GE Concomitant use of other DRUG1 within 24 hours of treatment with DRUG2 is contraindicated.
LABEL>1
GE (GE): DRUG1 (e.g., GE, GE, GE, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2.
LABEL>1
GE (GE): GE (e.g., DRUG1, GE, GE, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2.
LABEL>1
GE (GE): GE (e.g., GE, DRUG1, GE, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2.
LABEL>1
GE (GE): GE (e.g., GE, GE, DRUG1, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2.
LABEL>1
GE (GE): GE (e.g., GE, GE, GE, DRUG1) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2.
LABEL>1
If concomitant treatment with DRUG1 and an DRUG2 is clinically warranted, appropriate observation of the patient is advised.
LABEL>1
GE: Coadministration of DRUG1 and DRUG2 resulted in a 24% increase in plasma concentrations of GE.
LABEL>1
Coadministration of DRUG1 and the potent CYP3A4 inhibitor DRUG2 (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of GE.
LABEL>1
Although the interaction between GE and other potent CYP3A4 inhibitors (e.g., DRUG1, GE, and GE) has not been studied, increased exposures to GE may be expected when DRUG2 is used concomitantly with these medications.
LABEL>1
Although the interaction between GE and other potent CYP3A4 inhibitors (e.g., GE, DRUG1, and GE) has not been studied, increased exposures to GE may be expected when DRUG2 is used concomitantly with these medications.
LABEL>1
Although the interaction between GE and other potent CYP3A4 inhibitors (e.g., GE, GE, and DRUG1) has not been studied, increased exposures to GE may be expected when DRUG2 is used concomitantly with these medications.
LABEL>1
DRUG1 increased mean DRUG2 plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.
LABEL>1
Concomitant administration of DRUG1 and DRUG2 is contraindicated.
LABEL>1
Concomitant administration of DRUG1 and moderate CYP1A2 inhibitors, including DRUG2 and GE, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.
LABEL>1
Concomitant administration of DRUG1 and moderate CYP1A2 inhibitors, including GE and DRUG2, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.
LABEL>1
DRUG1 increased mean DRUG2 plasma concentrations (AUC) by 29%.
LABEL>1
Caution should be used when DRUG1 and DRUG2 are administered concomitantly.
LABEL>1
Coadministration of DRUG1 and strong CYP3A4 inhibitors, such as DRUG2, GE, GE, GE, and GE has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
LABEL>1
Coadministration of DRUG1 and strong CYP3A4 inhibitors, such as GE, DRUG2, GE, GE, and GE has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
LABEL>1
Coadministration of DRUG1 and strong CYP3A4 inhibitors, such as GE, GE, DRUG2, GE, and GE has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
LABEL>1
Coadministration of DRUG1 and strong CYP3A4 inhibitors, such as GE, GE, GE, DRUG2, and GE has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
LABEL>1
Coadministration of DRUG1 and strong CYP3A4 inhibitors, such as GE, GE, GE, GE, and DRUG2 has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
LABEL>1
Although not studied with DRUG1, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as DRUG2, GE, and GE.
LABEL>1
Although not studied with DRUG1, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as GE, DRUG2, and GE.
LABEL>1
Although not studied with DRUG1, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as GE, GE, and DRUG2.
LABEL>1
The DRUG1, including GE, produce additive CNS depressant effects when co-administered with other DRUG2, GE, GE, GE, and other drugs which themselves produce CNS depression.
LABEL>1
The DRUG1, including GE, produce additive CNS depressant effects when co-administered with other GE, DRUG2, GE, GE, and other drugs which themselves produce CNS depression.
LABEL>1
The DRUG1, including GE, produce additive CNS depressant effects when co-administered with other GE, GE, DRUG2, GE, and other drugs which themselves produce CNS depression.
LABEL>1
The DRUG1, including GE, produce additive CNS depressant effects when co-administered with other GE, GE, GE, DRUG2, and other drugs which themselves produce CNS depression.
LABEL>1
The GE, including DRUG1, produce additive CNS depressant effects when co-administered with other DRUG2, GE, GE, GE, and other drugs which themselves produce CNS depression.
LABEL>1
The GE, including DRUG1, produce additive CNS depressant effects when co-administered with other GE, DRUG2, GE, GE, and other drugs which themselves produce CNS depression.
LABEL>1
The GE, including DRUG1, produce additive CNS depressant effects when co-administered with other GE, GE, DRUG2, GE, and other drugs which themselves produce CNS depression.
LABEL>1
The GE, including DRUG1, produce additive CNS depressant effects when co-administered with other GE, GE, GE, DRUG2, and other drugs which themselves produce CNS depression.
LABEL>1
The steady state plasma concentrations of DRUG1 and GE have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of DRUG2 tablets in doses up to 4 mg/day.
LABEL>1
The steady state plasma concentrations of GE and DRUG1 have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of DRUG2 tablets in doses up to 4 mg/day.
LABEL>1
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving GE (caution is recommended during coadministration with GE): Coadministration of DRUG1 with DRUG2 increased the maximum plasma concentration of GE by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
LABEL>1
Coadministration of DRUG1 decreased the maximum plasma concentration of DRUG2 by 6%, decreased clearance by 38%, and increased half-life by 58%.
LABEL>1
Coadministration of oral DRUG1 increased the maximum plasma concentration of DRUG2 by 18%, decreased clearance by 22%, and increased half-life by 29%.
LABEL>1
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with DRUG1 for the following: DRUG2, GE, GE such as GE and GE, and grapefruit juice.
LABEL>1
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with DRUG1 for the following: GE, DRUG2, GE such as GE and GE, and grapefruit juice.
LABEL>1
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with DRUG1 for the following: GE, GE, DRUG2 such as GE and GE, and grapefruit juice.
LABEL>1
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with DRUG1 for the following: GE, GE, GE such as DRUG2 and GE, and grapefruit juice.
LABEL>1
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with DRUG1 for the following: GE, GE, GE such as GE and DRUG2, and grapefruit juice.
LABEL>1
Data from in vitro studies of GE suggest a possible drug interaction with DRUG1 for the following: DRUG2 and GE.
LABEL>1
Data from in vitro studies of GE suggest a possible drug interaction with DRUG1 for the following: GE and DRUG2.
LABEL>1
Data from in vitro studies of DRUG1 other than GE suggest a possible drug interaction for the following: DRUG2, GE, GE, GE, and GE.
LABEL>1
Data from in vitro studies of DRUG1 other than GE suggest a possible drug interaction for the following: GE, DRUG2, GE, GE, and GE.
LABEL>1
Data from in vitro studies of DRUG1 other than GE suggest a possible drug interaction for the following: GE, GE, DRUG2, GE, and GE.
LABEL>1
Data from in vitro studies of DRUG1 other than GE suggest a possible drug interaction for the following: GE, GE, GE, DRUG2, and GE.
LABEL>1
Data from in vitro studies of DRUG1 other than GE suggest a possible drug interaction for the following: GE, GE, GE, GE, and DRUG2.
LABEL>1
Data from in vitro studies of GE other than DRUG1 suggest a possible drug interaction for the following: DRUG2, GE, GE, GE, and GE.
LABEL>1
Data from in vitro studies of GE other than DRUG1 suggest a possible drug interaction for the following: GE, DRUG2, GE, GE, and GE.
LABEL>1
Data from in vitro studies of GE other than DRUG1 suggest a possible drug interaction for the following: GE, GE, DRUG2, GE, and GE.
LABEL>1
Data from in vitro studies of GE other than DRUG1 suggest a possible drug interaction for the following: GE, GE, GE, DRUG2, and GE.
LABEL>1
Data from in vitro studies of GE other than DRUG1 suggest a possible drug interaction for the following: GE, GE, GE, GE, and DRUG2.
LABEL>1
In addition to bleeding associated with DRUG1 and GE, drugs that alter platelet function (such as GE, GE and GE) may increase the risk of bleeding if administered prior to, during, or after DRUG2 therapy.
LABEL>1
In addition to bleeding associated with GE and DRUG1, drugs that alter platelet function (such as GE, GE and GE) may increase the risk of bleeding if administered prior to, during, or after DRUG2 therapy.
LABEL>1
In addition to bleeding associated with GE and GE, drugs that alter platelet function (such as DRUG1, GE and GE) may increase the risk of bleeding if administered prior to, during, or after DRUG2 therapy.
LABEL>1
In addition to bleeding associated with GE and GE, drugs that alter platelet function (such as GE, DRUG1 and GE) may increase the risk of bleeding if administered prior to, during, or after DRUG2 therapy.
LABEL>1
In addition to bleeding associated with GE and GE, drugs that alter platelet function (such as GE, GE and DRUG1) may increase the risk of bleeding if administered prior to, during, or after DRUG2 therapy.
LABEL>1
Concurrent administration of DRUG1 and DRUG2 may cause severe orthostatic hypotension.GE, an inhibitor of microsomal drug metabolism, increased GEs half-life and toxicity in a rat model.
LABEL>1
Concurrent administration of GE and GE may cause severe orthostatic hypotension.DRUG1, an inhibitor of microsomal drug metabolism, increased DRUG2s half-life and toxicity in a rat model.
LABEL>1
Data from a randomized trial of DRUG1 and DRUG2 plus or minus GE in ovarian cancer indicated that GE significantly reduced neurotoxicity;
LABEL>1
however, it adversely affected response duration suggesting that DRUG1 should not be administered with DRUG2 and/or GE.1
LABEL>1
however, it adversely affected response duration suggesting that DRUG1 should not be administered with GE and/or DRUG2.1
LABEL>1
Careful observation is required when DRUG1 is administered concurrently with DRUG2.
LABEL>1
Special consideration should be given to the administration of DRUG1 in patients receiving DRUG2 or other drugs that could cause or potentiate hypotension.
LABEL>1
When DRUG1 HCl is administered concomitantly with an DRUG2, the risk of hyperkalemia may be increased.
LABEL>1
DRUG1 generally should not be given with DRUG2 because they reduce its renal clearance and add a high risk of lithium toxicity.
LABEL>1
In some patients, the administration of a DRUG1 can reduce the diuretic, natriuretic, and antihypertensive effects of DRUG2, GE and GE.
LABEL>1
In some patients, the administration of a DRUG1 can reduce the diuretic, natriuretic, and antihypertensive effects of GE, DRUG2 and GE.
LABEL>1
In some patients, the administration of a DRUG1 can reduce the diuretic, natriuretic, and antihypertensive effects of GE, GE and DRUG2.
LABEL>1
Therefore, when DRUG1 and DRUG2 are used concomitantly, the patient should be observed closely to determine if the desired effect of the GE is obtained.
LABEL>1
Since DRUG1 and DRUG2, including GE, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.
LABEL>1
Since DRUG1 and GE, including DRUG2, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.
LABEL>1
DRUG1 accelerates the metabolism of DRUG2;
LABEL>1
DRUG1 diminishes the effect of DRUG2 and GE.
LABEL>1
DRUG1 diminishes the effect of GE and DRUG2.
LABEL>1
Renal clearance measurements of DRUG1 cannot be made with any significant accuracy in patients receiving DRUG2, GE, or GE.
LABEL>1
Renal clearance measurements of DRUG1 cannot be made with any significant accuracy in patients receiving GE, DRUG2, or GE.
LABEL>1
Renal clearance measurements of DRUG1 cannot be made with any significant accuracy in patients receiving GE, GE, or DRUG2.
LABEL>1
DRUG1 depresses tubular secretion of certain weak acids such as DRUG2.
LABEL>1
Therefore, patients receiving DRUG1 will have erroneously low ERPF and Tm DRUG2 values.
LABEL>1
It is, however, possible that concomitant use of other known DRUG1 such as GE, GE, GE, GE, GE and GE might increase the photosensitivity reaction of actinic keratoses treated with the DRUG2 for Topical Solution.
LABEL>1
It is, however, possible that concomitant use of other known GE such as DRUG1, GE, GE, GE, GE and GE might increase the photosensitivity reaction of actinic keratoses treated with the DRUG2 for Topical Solution.
LABEL>1
It is, however, possible that concomitant use of other known GE such as GE, DRUG1, GE, GE, GE and GE might increase the photosensitivity reaction of actinic keratoses treated with the DRUG2 for Topical Solution.
LABEL>1
It is, however, possible that concomitant use of other known GE such as GE, GE, DRUG1, GE, GE and GE might increase the photosensitivity reaction of actinic keratoses treated with the DRUG2 for Topical Solution.
LABEL>1
It is, however, possible that concomitant use of other known GE such as GE, GE, GE, DRUG1, GE and GE might increase the photosensitivity reaction of actinic keratoses treated with the DRUG2 for Topical Solution.
LABEL>1
It is, however, possible that concomitant use of other known GE such as GE, GE, GE, GE, DRUG1 and GE might increase the photosensitivity reaction of actinic keratoses treated with the DRUG2 for Topical Solution.
LABEL>1
It is, however, possible that concomitant use of other known GE such as GE, GE, GE, GE, GE and DRUG1 might increase the photosensitivity reaction of actinic keratoses treated with the DRUG2 for Topical Solution.
LABEL>1
DRUG1 may decrease the amount of DRUG2 (GE, GE) that gets absorbed into your body.
LABEL>1
DRUG1 may decrease the amount of GE (DRUG2, GE) that gets absorbed into your body.
LABEL>1
In the case that you are taking DRUG1 while taking DRUG2, higher doses of GE may be needed.
LABEL>1
DRUG1 may also decrease the absorption of DRUG2, which can lead to a deficiency.
LABEL>1
Therefore you may need to take a DRUG1 supplement while taking DRUG2.
LABEL>1
A case report of one patient taking DRUG1 200 mg and DRUG2 800 mg three times a day resulted in increases in GE concentrations from 0.9 mg/L to 1.3 mg/L.
LABEL>1
Monitoring for GE toxicity and serial measurement of DRUG1 serum concentration during concomitant DRUG2 therapy should be considered.
LABEL>1
DRUG1: DRUG2 inhibits CYP3A4 and can increase serum GE levels.
LABEL>1
On administration of oral DRUG1, the need for DRUG2 therapy should be reviewed and the dose reduced by approximately 50% or discontinued.
LABEL>1
The extent to which DRUG1-DRUG2 interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the GE involved.
LABEL>1
Nevertheless, caution is indicated in the coadministration of DRUG1 with any of the DRUG2 and also in switching from one class to the other.
LABEL>1
Hyperpyrexia has been reported when DRUG1 is administered with DRUG2 agents or with GE drugs, particularly during hot weather.
LABEL>1
Paralytic ileus may occur in patients taking DRUG1 in combination with DRUG2-type drugs.
LABEL>1
DRUG1 is reported to reduce hepatic metabolism of certain DRUG2, thereby delaying elimination and increasing steady-state concentrations of these GE.
LABEL>1
Clinically significant effects have been reported with the DRUG1 when used concomitantly with DRUG2.
LABEL>1
Increases in plasma levels of DRUG1, and in the frequency and severity of side effects, particularly GE, have been reported when DRUG2 was added to the GE regimen.
LABEL>1
Discontinuation of GE in well-controlled patients receiving DRUG1 and DRUG2 may decrease the plasma levels and efficacy of the GE.
LABEL>1
Transient delirium has been reported in patients who were treated with one gram of DRUG1 and 75 - 150 mg of DRUG2.
LABEL>1
When administered concurrently, the following drugs may interact with DRUG1: DRUG2: may enhance the potential for renal toxicity, bronchospasm and hypotension.
LABEL>1
DRUG1 and GE (GE): may potentiate DRUG2- induced hypokalemia which may predispose the patient to cardiac dysfunction.
LABEL>1
GE and DRUG1 (GE): may potentiate DRUG2- induced hypokalemia which may predispose the patient to cardiac dysfunction.
LABEL>1
GE and GE (DRUG1): may potentiate DRUG2- induced hypokalemia which may predispose the patient to cardiac dysfunction.
LABEL>1
GE: DRUG1-induced hypokalemia may potentiate DRUG2 toxicity.
LABEL>1
GE: while a synergistic relationship with DRUG1 has been reported, concomitant use may increase the toxicity of DRUG2 by possibly increasing its cellular uptake and/or impairing its renal excretion.
LABEL>1
GE (e. g., GE, GE, GE, GE, etc.): in vitro and animal studies with the combination of GE and GE suggest that DRUG1 may induce fungal resistance to DRUG2.
LABEL>1
GE: DRUG1-induced hypokalemia may enhance the curariform effect of DRUG2 (e.g., GE).
LABEL>1
GE: DRUG1-induced hypokalemia may enhance the curariform effect of GE (e.g., DRUG2).
LABEL>1
GE: acute pulmonary toxicity has been reported in patients receiving intravenous DRUG1 and DRUG2.
LABEL>1
GE: DRUG1, GE, GE, or GE may interfere with the bactericidal effect of DRUG2.
LABEL>1
GE: GE, DRUG1, GE, or GE may interfere with the bactericidal effect of DRUG2.
LABEL>1
GE: GE, GE, DRUG1, or GE may interfere with the bactericidal effect of DRUG2.
LABEL>1
GE: GE, GE, GE, or DRUG1 may interfere with the bactericidal effect of DRUG2.
LABEL>1
DRUG1: May decrease renal tubular secretion of DRUG2 resulting in increased blood levels and/or GE toxicity.
LABEL>1
DRUG1 steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant DRUG2.
LABEL>1
DRUG1 steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant DRUG2.
LABEL>1
DRUG1 steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant DRUG2.
LABEL>1
GE: Coadministration of DRUG1 and DRUG2 can decrease plasma levels of GE.
LABEL>1
Coadministration of DRUG1 and DRUG2 as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum GE AUC, Cmax, andCmin, respectively.
LABEL>1
Laboratory Tests: The combination of DRUG1 and low-dose DRUG2 has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.
LABEL>1
Appropriate laboratory testing should be considered prior to initiating combination therapy with DRUG1 and DRUG2 and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.
LABEL>1
Taking DRUG1 after drinking DRUG2 may worsen side effects and may cause severe hypotension and cardiovascular collapse.
LABEL>1
DRUG1 alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by DRUG2.
LABEL>1
It is known that CYP1A2 is inhibited by several medicinal products, including DRUG1, and such medicinal products could theoretically adversely influence the clearance of DRUG2.
LABEL>1
DRUG1 demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. DRUG2.
LABEL>1
The effects of medicinal products with similar properties such as inotropes DRUG1, GE, GE, GE and GE may be exacerbated by DRUG2.
LABEL>1
The effects of medicinal products with similar properties such as inotropes GE, DRUG1, GE, GE and GE may be exacerbated by DRUG2.
LABEL>1
The effects of medicinal products with similar properties such as inotropes GE, GE, DRUG1, GE and GE may be exacerbated by DRUG2.
LABEL>1
The effects of medicinal products with similar properties such as inotropes GE, GE, GE, DRUG1 and GE may be exacerbated by DRUG2.
LABEL>1
The effects of medicinal products with similar properties such as inotropes GE, GE, GE, GE and DRUG1 may be exacerbated by DRUG2.
LABEL>1
There is a single case report, which suggests that DRUG1 may interfere with DRUG2 absorption.
LABEL>1
In a study in which patients with active RA were treated for up to 24 weeks with concurrent DRUG1 and DRUG2 therapy, a 7% rate of serious infections was observed, which was higher than that observed with GE alone (0%).
LABEL>1
Two percent of patients treated concurrently with DRUG1 and DRUG2 developed neutropenia (ANC  1 x 109/L).
LABEL>1
Based on clinical and pharmacokinetic results from the ATAC trial, DRUG1 should not be administered with DRUG2 (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).
LABEL>1
Co-administration of DRUG1 and DRUG2 resulted in a reduction of GE plasma levels by 27% compared with those achieved with GE alone.
LABEL>1
DRUG1-containing therapies should not be used with DRUG2 as they may diminish its pharmacologic action.
LABEL>1
Caution should be observed when DRUG1 is coadministered with other DRUG2, GE, GE, or GE, as these agents may increase respiratory and circulatory depression.
LABEL>1
Caution should be observed when DRUG1 is coadministered with other GE, DRUG2, GE, or GE, as these agents may increase respiratory and circulatory depression.
LABEL>1
Caution should be observed when DRUG1 is coadministered with other GE, GE, DRUG2, or GE, as these agents may increase respiratory and circulatory depression.
LABEL>1
Caution should be observed when DRUG1 is coadministered with other GE, GE, GE, or DRUG2, as these agents may increase respiratory and circulatory depression.
LABEL>1
For example, since DRUG1 may reduce the gastrointestinal absorption of both the oral DRUG2 and GE, the net effects are unpredictable.
LABEL>1
For example, since DRUG1 may reduce the gastrointestinal absorption of both the oral GE and DRUG2, the net effects are unpredictable.
LABEL>1
DRUG1 may cause an increased prothrombin response by displacing the DRUG2 from protein binding sites or a diminished prothrombin response through increased metabolism of the unbound drug by hepatic enzyme induction, thus leading to inter-patient variation in ultimate prothrombin effect.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: DRUG2;
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: DRUG2;GE*;GE;GE;GE;GE;GE*;GE;GE;diet high in GE;GE*;GE;GE;GE;GE;GE;oral GE;GE;GE;GE*;GE;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;DRUG2*;GE;GE;GE;GE;GE*;GE;GE;diet high in GE;GE*;GE;GE;GE;GE;GE;oral GE;GE;GE;GE*;GE;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;DRUG2;GE;GE;GE;GE*;GE;GE;diet high in GE;GE*;GE;GE;GE;GE;GE;oral GE;GE;GE;GE*;GE;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;GE;DRUG2;GE;GE;GE*;GE;GE;diet high in GE;GE*;GE;GE;GE;GE;GE;oral GE;GE;GE;GE*;GE;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;GE;GE;DRUG2;GE;GE*;GE;GE;diet high in GE;GE*;GE;GE;GE;GE;GE;oral GE;GE;GE;GE*;GE;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;GE;GE;GE;DRUG2;GE*;GE;GE;diet high in GE;GE*;GE;GE;GE;GE;GE;oral GE;GE;GE;GE*;GE;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;GE;GE;GE;GE;DRUG2*;GE;GE;diet high in GE;GE*;GE;GE;GE;GE;GE;oral GE;GE;GE;GE*;GE;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;GE;GE;GE;GE;GE*;DRUG2;GE;diet high in GE;GE*;GE;GE;GE;GE;GE;oral GE;GE;GE;GE*;GE;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;GE;GE;GE;GE;GE*;GE;DRUG2;diet high in GE;GE*;GE;GE;GE;GE;GE;oral GE;GE;GE;GE*;GE;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;GE;GE;GE;GE;GE*;GE;GE;diet high in DRUG2;GE*;GE;GE;GE;GE;GE;oral GE;GE;GE;GE*;GE;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;GE;GE;GE;GE;GE*;GE;GE;diet high in GE;DRUG2*;GE;GE;GE;GE;GE;oral GE;GE;GE;GE*;GE;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;GE;GE;GE;GE;GE*;GE;GE;diet high in GE;GE*;DRUG2;GE;GE;GE;GE;oral GE;GE;GE;GE*;GE;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;GE;GE;GE;GE;GE*;GE;GE;diet high in GE;GE*;GE;DRUG2;GE;GE;GE;oral GE;GE;GE;GE*;GE;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;GE;GE;GE;GE;GE*;GE;GE;diet high in GE;GE*;GE;GE;DRUG2;GE;GE;oral GE;GE;GE;GE*;GE;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;GE;GE;GE;GE;GE*;GE;GE;diet high in GE;GE*;GE;GE;GE;DRUG2;GE;oral GE;GE;GE;GE*;GE;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;GE;GE;GE;GE;GE*;GE;GE;diet high in GE;GE*;GE;GE;GE;GE;DRUG2;oral GE;GE;GE;GE*;GE;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;GE;GE;GE;GE;GE*;GE;GE;diet high in GE;GE*;GE;GE;GE;GE;GE;oral DRUG2;GE;GE;GE*;GE;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;GE;GE;GE;GE;GE*;GE;GE;diet high in GE;GE*;GE;GE;GE;GE;GE;oral GE;DRUG2;GE;GE*;GE;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;GE;GE;GE;GE;GE*;GE;GE;diet high in GE;GE*;GE;GE;GE;GE;GE;oral GE;GE;DRUG2;GE*;GE;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;GE;GE;GE;GE;GE*;GE;GE;diet high in GE;GE*;GE;GE;GE;GE;GE;oral GE;GE;GE;DRUG2*;GE;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;GE;GE;GE;GE;GE*;GE;GE;diet high in GE;GE*;GE;GE;GE;GE;GE;oral GE;GE;GE;GE*;DRUG2;unreliable prothrombin time determinations;GE;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;GE;GE;GE;GE;GE*;GE;GE;diet high in GE;GE*;GE;GE;GE;GE;GE;oral GE;GE;GE;GE*;GE;unreliable prothrombin time determinations;DRUG2;GE under-dosage.
LABEL>1
Drugs that have been reported to diminish oral DRUG1 response, ie, decreased prothrom-bin time response, in man significantly include: GE;GE*;GE;GE;GE;GE;GE*;GE;GE;diet high in GE;GE*;GE;GE;GE;GE;GE;oral GE;GE;GE;GE*;GE;unreliable prothrombin time determinations;GE;DRUG2 under-dosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:DRUG2*;
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:DRUG2*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;DRUG2;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;DRUG2;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;DRUG2;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;DRUG2;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;DRUG2;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;DRUG2;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;DRUG2*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;DRUG2;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;DRUG2;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;DRUG2;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;DRUG2;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;DRUG2;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;DRUG2;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;DRUG2;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;DRUG2;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;DRUG2;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;DRUG2;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;DRUG2;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;DRUG2;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;DRUG2;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;DRUG2;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;DRUG2;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;DRUG2;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation DRUG2;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;DRUG2;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;DRUG2;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;DRUG2;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;DRUG2;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;DRUG2;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;DRUG2;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;DRUG2;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;DRUG2;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;DRUG2;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;DRUG2;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;DRUG2;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;DRUG2;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;DRUG2;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;DRUG2;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;DRUG2;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;DRUG2;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;DRUG2;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;DRUG2;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;DRUG2*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;DRUG2;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;DRUG2;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;DRUG2, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;DRUG2;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;DRUG2;GE;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;DRUG2;GE;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;DRUG2;GE/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;DRUG2/GE;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/DRUG2;unreliable prothrombin time determinations;GE overdosage.
LABEL>1
Drugs that reportedly may increase oral DRUG1 response, ie, increased prothrombin response, in man include:GE*;GE;GE;GE;GE;GE;GE;GE*;GE;GE;GE;GE;GE;GE;GE;GE;dietary deficiencies;GE;GE;drugs affecting blood elements;GE;GE;GE;hepatotoxic drugs;GE;GE;GE;inhalation GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;GE;prolonged hot weather;GE;GE;GE;GE;GE*;GE;GE;GE, long acting;GE;GE;GE;GE;GE/GE;unreliable prothrombin time determinations;DRUG2 overdosage.
LABEL>1
Oral DRUG1 may potentiate the hypoglycemic action of DRUG2, eg, GE and GE, by inhibiting their metabolism in the liver.
LABEL>1
Oral DRUG1 may potentiate the hypoglycemic action of GE, eg, DRUG2 and GE, by inhibiting their metabolism in the liver.
LABEL>1
Oral DRUG1 may potentiate the hypoglycemic action of GE, eg, GE and DRUG2, by inhibiting their metabolism in the liver.
LABEL>1
Because oral DRUG1 may interfere with the hepatic metabolism of DRUG2, toxic levels of the GE may occur when an oral GE and GE are administered concurrently.
LABEL>1
Because oral GE may interfere with the hepatic metabolism of GE, toxic levels of the GE may occur when an oral DRUG1 and DRUG2 are administered concurrently.
LABEL>1
Drugs that reduce the number of blood platelets by causing bone marrow depression (such as DRUG1) or drugs which inhibit platelet function (eg, GE and other GE, GE, GE, GE, GE) may increase the bleeding tendency produced by DRUG2 without altering prothrombin time determinations.
LABEL>1
Drugs that reduce the number of blood platelets by causing bone marrow depression (such as GE) or drugs which inhibit platelet function (eg, DRUG1 and other GE, GE, GE, GE, GE) may increase the bleeding tendency produced by DRUG2 without altering prothrombin time determinations.
LABEL>1
Drugs that reduce the number of blood platelets by causing bone marrow depression (such as GE) or drugs which inhibit platelet function (eg, GE and other DRUG1, GE, GE, GE, GE) may increase the bleeding tendency produced by DRUG2 without altering prothrombin time determinations.
LABEL>1
Drugs that reduce the number of blood platelets by causing bone marrow depression (such as GE) or drugs which inhibit platelet function (eg, GE and other GE, DRUG1, GE, GE, GE) may increase the bleeding tendency produced by DRUG2 without altering prothrombin time determinations.
LABEL>1
Drugs that reduce the number of blood platelets by causing bone marrow depression (such as GE) or drugs which inhibit platelet function (eg, GE and other GE, GE, DRUG1, GE, GE) may increase the bleeding tendency produced by DRUG2 without altering prothrombin time determinations.
LABEL>1
Drugs that reduce the number of blood platelets by causing bone marrow depression (such as GE) or drugs which inhibit platelet function (eg, GE and other GE, GE, GE, DRUG1, GE) may increase the bleeding tendency produced by DRUG2 without altering prothrombin time determinations.
LABEL>1
Drugs that reduce the number of blood platelets by causing bone marrow depression (such as GE) or drugs which inhibit platelet function (eg, GE and other GE, GE, GE, GE, DRUG1) may increase the bleeding tendency produced by DRUG2 without altering prothrombin time determinations.
LABEL>1
The beneficial effects on arterial thrombus formation from combined therapy with DRUG1 and DRUG2 must be weighed against an increased risk of inducing hemorrhage.
LABEL>1
GE: Based on reports of profound hypotension and loss of consciousness when DRUG1 was administered with DRUG2, the concomitant use of GE with drugs of the GE (including, for example, GE, GE, GE, GE, and GE) is contraindicated .
LABEL>1
GE: Based on reports of profound hypotension and loss of consciousness when GE was administered with GE, the concomitant use of DRUG1 with drugs of the DRUG2 (including, for example, GE, GE, GE, GE, and GE) is contraindicated .
LABEL>1
GE: Based on reports of profound hypotension and loss of consciousness when GE was administered with GE, the concomitant use of DRUG1 with drugs of the GE (including, for example, DRUG2, GE, GE, GE, and GE) is contraindicated .
LABEL>1
GE: Based on reports of profound hypotension and loss of consciousness when GE was administered with GE, the concomitant use of DRUG1 with drugs of the GE (including, for example, GE, DRUG2, GE, GE, and GE) is contraindicated .
LABEL>1
GE: Based on reports of profound hypotension and loss of consciousness when GE was administered with GE, the concomitant use of DRUG1 with drugs of the GE (including, for example, GE, GE, DRUG2, GE, and GE) is contraindicated .
LABEL>1
GE: Based on reports of profound hypotension and loss of consciousness when GE was administered with GE, the concomitant use of DRUG1 with drugs of the GE (including, for example, GE, GE, GE, DRUG2, and GE) is contraindicated .
LABEL>1
GE: Based on reports of profound hypotension and loss of consciousness when GE was administered with GE, the concomitant use of DRUG1 with drugs of the GE (including, for example, GE, GE, GE, GE, and DRUG2) is contraindicated .
LABEL>1
GEs and GE: The following adverse events were experienced more commonly in patients receiving concomitant DRUG1 or DRUG2 (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.
LABEL>1
GE: Since GE is a GE, it is possible that DRUG1, such as the GE (GE, GE, GE) or DRUG2, may diminish the effectiveness of GE.
LABEL>1
GE: Since GE is a GE, it is possible that GE, such as the GE (DRUG1, GE, GE) or GE, may diminish the effectiveness of DRUG2.
LABEL>1
GE: Since GE is a GE, it is possible that GE, such as the GE (GE, DRUG1, GE) or GE, may diminish the effectiveness of DRUG2.
LABEL>1
GE: Since GE is a GE, it is possible that GE, such as the GE (GE, GE, DRUG1) or GE, may diminish the effectiveness of DRUG2.
LABEL>1
GE: Since GE is a GE, it is possible that GE, such as the GE (GE, GE, GE) or DRUG1, may diminish the effectiveness of DRUG2.
LABEL>1
Patients with major psychotic disorders, treated with DRUG1, should be treated with DRUG2 only if the potential benefits outweigh the risks.
LABEL>1
DRUG1 should not be used in patients receiving DRUG2..
LABEL>1
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of DRUG1 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with DRUG2 (GE, GE, GE, GE, GE) should be considered.
LABEL>1
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of DRUG1 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with GE (DRUG2, GE, GE, GE, GE) should be considered.
LABEL>1
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of DRUG1 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with GE (GE, DRUG2, GE, GE, GE) should be considered.
LABEL>1
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of DRUG1 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with GE (GE, GE, DRUG2, GE, GE) should be considered.
LABEL>1
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of DRUG1 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with GE (GE, GE, GE, DRUG2, GE) should be considered.
LABEL>1
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of DRUG1 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with GE (GE, GE, GE, GE, DRUG2) should be considered.
LABEL>1
DRUG1 have been reported to blunt the hypotensive effect of systemic DRUG2.
LABEL>1
An additive hypotensive effect has been reported with the combination of systemic DRUG1 and DRUG2 therapy.
LABEL>1
Since DRUG1 may reduce pulse and blood pressure, caution in using drugs such as DRUG2 (ophthalmic and systemic), GE, and GE is advised.
LABEL>1
Since DRUG1 may reduce pulse and blood pressure, caution in using drugs such as GE (ophthalmic and systemic), DRUG2, and GE is advised.
LABEL>1
Since DRUG1 may reduce pulse and blood pressure, caution in using drugs such as GE (ophthalmic and systemic), GE, and DRUG2 is advised.
LABEL>1
DRUG1 has been shown to induce the metabolism of DRUG2 and GE, which are metabolized through CYP2C9.
LABEL>1
DRUG1 has been shown to induce the metabolism of GE and DRUG2, which are metabolized through CYP2C9.
LABEL>1
Coadministration of DRUG1 with these drugs or other drugs that are known to be metabolized by CYP2C9, such as DRUG2, may result in lower plasma concentrations of these drugs.
LABEL>1
GE: GE: DRUG1, when given as a regimen of 125mg with DRUG2 coadministered orally as 20 mg on Day 1, and GE when given as 80 mg/day with GE coadministered orally as 8 mg on Days 2 through 5, increased the AUC of GE, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
LABEL>1
GE: GE: GE, when given as a regimen of 125mg with GE coadministered orally as 20 mg on Day 1, and DRUG1 when given as 80 mg/day with DRUG2 coadministered orally as 8 mg on Days 2 through 5, increased the AUC of GE, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
LABEL>1
The oral DRUG1 doses should be reduced by approximately 50% when coadministered with DRUG2, to achieve exposures of GE similar to those obtained when it is given without GE.
LABEL>1
The daily dose of DRUG1 administered in clinical studies with DRUG2 reflects an approximate 50% reduction of the dose of GE.
LABEL>1
DRUG1, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of DRUG2, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when GE was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.
LABEL>1
The IV DRUG1 dose should be reduced by approximately 25%, and the oral GE dose should be reduced by approximately 50% when coadministered with DRUG2 to achieve exposures of GE similar to those obtained when it is given without GE.
LABEL>1
The IV GE dose should be reduced by approximately 25%, and the oral DRUG1 dose should be reduced by approximately 50% when coadministered with DRUG2 to achieve exposures of GE similar to those obtained when it is given without GE.
LABEL>1
Although there was no effect of GE on the plasma AUC of GE or GE determined on Day 3, there was a 34% decrease in DRUG1 (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with DRUG2.
LABEL>1
In patients on chronic DRUG1 therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of DRUG2 with each chemotherapy cycle.
LABEL>1
GE: GE, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of GE (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of DRUG1 500 mg was admini,stered orally prior to the administration of the 3-day regimen of DRUG2 and on Days 4,8, and 15.
LABEL>1
Oral GE: DRUG1, when given once daily for 14 days as a 100-mg capsule with an oral GE containing 35 mcg of DRUG2 and 1 mg of GE, decreased the AUC of GE by 43%, and decreased the AUC of GE by 8%;
LABEL>1
Oral GE: DRUG1, when given once daily for 14 days as a 100-mg capsule with an oral GE containing 35 mcg of GE and 1 mg of DRUG2, decreased the AUC of GE by 43%, and decreased the AUC of GE by 8%;
LABEL>1
therefore, the efficacy of oral DRUG1 during administration of DRUG2 may be reduced.
LABEL>1
Although a 3-day regimen of DRUG1 given concomitantly with oral DRUG2 has not been studied, alternative or back-up methods of contraception should be used.
LABEL>1
GE: DRUG1 increased the AUC of DRUG2, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of GE 2 mg was coadministered on Day 1 and Day 5 of a regimen of GE 125 mg on Day 1 and 80 mg/day on Days 2 through 5.
LABEL>1
The potential effects of increased plasma concentrations of DRUG1 or other GE metabolized via CYP3A4 (GE, GE) should be considered when coadministering these agents with DRUG2.
LABEL>1
The potential effects of increased plasma concentrations of GE or other DRUG1 metabolized via CYP3A4 (GE, GE) should be considered when coadministering these agents with DRUG2.
LABEL>1
The potential effects of increased plasma concentrations of GE or other GE metabolized via CYP3A4 (DRUG1, GE) should be considered when coadministering these agents with DRUG2.
LABEL>1
The potential effects of increased plasma concentrations of GE or other GE metabolized via CYP3A4 (GE, DRUG1) should be considered when coadministering these agents with DRUG2.
LABEL>1
DRUG1 increased the AUC of DRUG2 by 25% on Day 4 and decreased the AUC of GE by 19% on Day 8 relative to the dosing of GE on Days 1 through 3.
LABEL>1
DRUG1 increased the AUC of GE by 25% on Day 4 and decreased the AUC of DRUG2 by 19% on Day 8 relative to the dosing of GE on Days 1 through 3.
LABEL>1
Consequently, concomitant administration of DRUG1 with strong CYP3A4 inhibitors (e.g., DRUG2, GE, GE, GE, GE, GE, GE) should be approached with caution.
LABEL>1
Consequently, concomitant administration of DRUG1 with strong CYP3A4 inhibitors (e.g., GE, DRUG2, GE, GE, GE, GE, GE) should be approached with caution.
LABEL>1
Consequently, concomitant administration of DRUG1 with strong CYP3A4 inhibitors (e.g., GE, GE, DRUG2, GE, GE, GE, GE) should be approached with caution.
LABEL>1
Consequently, concomitant administration of DRUG1 with strong CYP3A4 inhibitors (e.g., GE, GE, GE, DRUG2, GE, GE, GE) should be approached with caution.
LABEL>1
Consequently, concomitant administration of DRUG1 with strong CYP3A4 inhibitors (e.g., GE, GE, GE, GE, DRUG2, GE, GE) should be approached with caution.
LABEL>1
Consequently, concomitant administration of DRUG1 with strong CYP3A4 inhibitors (e.g., GE, GE, GE, GE, GE, DRUG2, GE) should be approached with caution.
LABEL>1
Consequently, concomitant administration of DRUG1 with strong CYP3A4 inhibitors (e.g., GE, GE, GE, GE, GE, GE, DRUG2) should be approached with caution.
LABEL>1
Because moderate CYP3A4 inhibitors (e.g., DRUG1) result in 2-fold increase in plasma concentrations of DRUG2, concomitant administration should also be approached with caution.
LABEL>1
therefore, coadministration of DRUG1 with drugs that strongly induce CYP3A4 activity (e.g., DRUG2, GE, GE) may result in reduced plasma concentrations of GE that may result in decreased efficacy of GE.
LABEL>1
therefore, coadministration of DRUG1 with drugs that strongly induce CYP3A4 activity (e.g., GE, GE, DRUG2) may result in reduced plasma concentrations of GE that may result in decreased efficacy of GE.
LABEL>1
therefore, coadministration of DRUG1 with drugs that strongly induce CYP3A4 activity (e.g., GE, GE, GE) may result in reduced plasma concentrations of DRUG2 that may result in decreased efficacy of GE.
LABEL>1
GE: When a single 125-mg dose of DRUG1 was administered on Day5 of a 10-day regimen of 400 mg/day of DRUG2, a strong CYP3A4 inhibitor, the AUC of GE increased approximately 5-fold and the mean terminal half-life of GE increased approximately 3-fold.
LABEL>1
GE: When a single 375-mg dose of DRUG1 was administered on Day9 of a 14-day regimen of 600 mg/day of DRUG2, a strong CYP3A4 inducer, the AUC of GE decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.
LABEL>1
GE: In patients with mild to moderate hypertension, administration of DRUG1 once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with DRUG2 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of GE AUC and a simultaneous 1.7-fold increase of GE AUC.
LABEL>1
GE: Coadministration of once daily doses of DRUG1, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with DRUG2 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both GE and GE.
LABEL>1
DRUG1 should be withdrawn at least 48 hours before conducting an DRUG2-mediated stress test.
LABEL>1
DRUG1 including coumarin derivatives, indandione derivatives, and GE such as GE (GE), and GE may increase the risk of bleeding when administered concomitantly with DRUG2.
LABEL>1
GE including coumarin derivatives, indandione derivatives, and DRUG1 such as GE (GE), and GE may increase the risk of bleeding when administered concomitantly with DRUG2.
LABEL>1
GE including coumarin derivatives, indandione derivatives, and GE such as DRUG1 (GE), and GE may increase the risk of bleeding when administered concomitantly with DRUG2.
LABEL>1
GE including coumarin derivatives, indandione derivatives, and GE such as GE (DRUG1), and GE may increase the risk of bleeding when administered concomitantly with DRUG2.
LABEL>1
GE including coumarin derivatives, indandione derivatives, and GE such as GE (GE), and DRUG1 may increase the risk of bleeding when administered concomitantly with DRUG2.
LABEL>1
If additional DRUG1 are to be administered by any route, they should be used with caution because the pharmacologically predictable sympathetic effects of DRUG2 may be potentiated.
LABEL>1
Concomitant treatment with DRUG1 (GE, GE), GE, or GE may potentiate any hypokalemic effect of DRUG2.
LABEL>1
Concomitant treatment with GE (DRUG1, GE), GE, or GE may potentiate any hypokalemic effect of DRUG2.
LABEL>1
Concomitant treatment with GE (GE, DRUG1), GE, or GE may potentiate any hypokalemic effect of DRUG2.
LABEL>1
Concomitant treatment with GE (GE, GE), DRUG1, or GE may potentiate any hypokalemic effect of DRUG2.
LABEL>1
Concomitant treatment with GE (GE, GE), GE, or DRUG1 may potentiate any hypokalemic effect of DRUG2.
LABEL>1
The ECG changes and/or hypokalemia that may result from the administration of DRUG1 (such as GE or GE) can be acutely worsened by DRUG2, especially when the recommended dose of the GE is exceeded.
LABEL>1
The ECG changes and/or hypokalemia that may result from the administration of GE (such as DRUG1 or GE) can be acutely worsened by DRUG2, especially when the recommended dose of the GE is exceeded.
LABEL>1
The ECG changes and/or hypokalemia that may result from the administration of GE (such as GE or DRUG1) can be acutely worsened by DRUG2, especially when the recommended dose of the GE is exceeded.
LABEL>1
Although the clinical significance of these effects is not known, caution is advised in the co-administration of DRUG1 with DRUG2.
LABEL>1
DRUG1, as with other GE, should be administered with extreme caution to patients being treated with DRUG2, GE, or drugs known to prolong the QTc interval because the action of GE on the cardiovascular system may be potentiated by these agents.
LABEL>1
DRUG1, as with other GE, should be administered with extreme caution to patients being treated with GE, DRUG2, or drugs known to prolong the QTc interval because the action of GE on the cardiovascular system may be potentiated by these agents.
LABEL>1
GE, as with other DRUG1, should be administered with extreme caution to patients being treated with DRUG2, GE, or drugs known to prolong the QTc interval because the action of GE on the cardiovascular system may be potentiated by these agents.
LABEL>1
GE, as with other DRUG1, should be administered with extreme caution to patients being treated with GE, DRUG2, or drugs known to prolong the QTc interval because the action of GE on the cardiovascular system may be potentiated by these agents.
LABEL>1
GE, as with other GE, should be administered with extreme caution to patients being treated with DRUG1, GE, or drugs known to prolong the QTc interval because the action of DRUG2 on the cardiovascular system may be potentiated by these agents.
LABEL>1
GE, as with other GE, should be administered with extreme caution to patients being treated with GE, DRUG1, or drugs known to prolong the QTc interval because the action of DRUG2 on the cardiovascular system may be potentiated by these agents.
LABEL>1
DRUG1 (GE) and DRUG2 may interfere with the effect of each other when administered concurrently.
LABEL>1
GE (DRUG1) and DRUG2 may interfere with the effect of each other when administered concurrently.
LABEL>1
DRUG1 not only block the therapeutic effects of DRUG2, but may produce severe bronchospasm in COPD patients.
LABEL>1
However, the concomitant use of DRUG1 and DRUG2 (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).
LABEL>1
Co-administration: Concomitant use of DRUG1 with DRUG2, GE, and other GE may increase the risk of bleeding.
LABEL>1
Co-administration: Concomitant use of DRUG1 with GE, DRUG2, and other GE may increase the risk of bleeding.
LABEL>1
Co-administration: Concomitant use of DRUG1 with GE, GE, and other DRUG2 may increase the risk of bleeding.
LABEL>1
Drug-Drug Interactions Given the primary CNS effects of GE, caution should be used when DRUG1 is taken in combination with other DRUG2 and GE.
LABEL>1
Drug-Drug Interactions Given the primary CNS effects of GE, caution should be used when DRUG1 is taken in combination with other GE and DRUG2.
LABEL>1
1- adrenergic receptor antagonism, DRUG1 has the potential to enhance the effect of certain DRUG2.
LABEL>1
Agents that induce CYP3A4 (eg, DRUG1) could cause an increase in DRUG2 clearance and lower blood levels.
LABEL>1
Inhibitors of CYP3A4 (eg, DRUG1) or CYP2D6 (eg, GE, GE, or GE) can inhibit DRUG2 elimination and cause increased blood levels.
LABEL>1
Inhibitors of CYP3A4 (eg, GE) or CYP2D6 (eg, DRUG1, GE, or GE) can inhibit DRUG2 elimination and cause increased blood levels.
LABEL>1
Inhibitors of CYP3A4 (eg, GE) or CYP2D6 (eg, GE, DRUG1, or GE) can inhibit DRUG2 elimination and cause increased blood levels.
LABEL>1
Inhibitors of CYP3A4 (eg, GE) or CYP2D6 (eg, GE, GE, or DRUG1) can inhibit DRUG2 elimination and cause increased blood levels.
LABEL>1
GE: Coadministration of DRUG1 (200 mg/day for 14 days) with a 15-mg single dose of DRUG2 increased the AUC of GE and its active metabolite by 63% and 77%, respectively.
LABEL>1
When concomitant administration of DRUG1 with DRUG2 occurs, GE dose should be reduced to one-half of its normal dose.
LABEL>1
GE: Coadministration of a 10-mg single dose of DRUG1 with DRUG2 (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of GE by 112% but decreased the AUC of its active metabolite, GE, by 35%.
LABEL>1
GE dose should be reduced to one-half of its normal dose when concomitant administration of DRUG1 with DRUG2 occurs.
LABEL>1
GE: Coadministration of DRUG1 (200 mg BID), a potent CYP3A4 inducer, with DRUG2 (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both GE and its active metabolite, GE.
LABEL>1
When DRUG1 is added to DRUG2 therapy, GE dose should be doubled.
LABEL>1
When DRUG1 is withdrawn from the combination therapy, DRUG2 dose should then be reduced.
LABEL>1
As with most psychoactive medications, patients should be advised to avoid DRUG1 while taking DRUG2
LABEL>1
Caution is advised when DRUG1 is coadministered with other medications that can prolong the QT interval (e.g. certain DRUG2 or GE) or lead to electrolyte abnormalities (such as GE or GE).
LABEL>1
Caution is advised when DRUG1 is coadministered with other medications that can prolong the QT interval (e.g. certain GE or DRUG2) or lead to electrolyte abnormalities (such as GE or GE).
LABEL>1
Caution is advised when DRUG1 is coadministered with other medications that can prolong the QT interval (e.g. certain GE or GE) or lead to electrolyte abnormalities (such as DRUG2 or GE).
LABEL>1
Caution is advised when DRUG1 is coadministered with other medications that can prolong the QT interval (e.g. certain GE or GE) or lead to electrolyte abnormalities (such as GE or DRUG2).
LABEL>1
Tissue culture and animal studies indicate that DRUG1 can diminish or abolish the effect of DRUG2 on malignant cells.14 This effect on GE activity persists as long as plasma asparagine levels are suppressed.
LABEL>1
These results would seem to dictate against the clinical use of DRUG1 with DRUG2, or during the period following GE therapy when plasma asparagine levels are below normal.
LABEL>1
GE: DRUG1 may decrease the effects of DRUG2, GE, and GE.
LABEL>1
GE: DRUG1 may decrease the effects of GE, DRUG2, and GE.
LABEL>1
GE: DRUG1 may decrease the effects of GE, GE, and DRUG2.
LABEL>1
DRUG1: Has a synergistic effect with DRUG2 in causing gastrointestinal bleeding.
LABEL>1
DRUG1: Concomitant administration with DRUG2 may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels.
LABEL>1
DRUG1 (GE, GE, and possibly GE): Concomitant administration with DRUG2 may increase the risk of gastrointestinal ulceration.
LABEL>1
GE (DRUG1, GE, and possibly GE): Concomitant administration with DRUG2 may increase the risk of gastrointestinal ulceration.
LABEL>1
GE (GE, DRUG1, and possibly GE): Concomitant administration with DRUG2 may increase the risk of gastrointestinal ulceration.
LABEL>1
GE (GE, GE, and possibly DRUG1): Concomitant administration with DRUG2 may increase the risk of gastrointestinal ulceration.
LABEL>1
GE Agents: DRUG1 is contraindicated in patients who are hypersensitive to DRUG2 agents.
LABEL>1
DRUG1: Decreases DRUG2 effectiveness by enzyme induction.
LABEL>1
GE: Serum DRUG1 levels may be increased by DRUG2.
LABEL>1
DRUG1: May decrease DRUG2 anti-inflammatory action by competing for the same receptors.
LABEL>1
GE: Enteric Coated DRUG1 should not be given concurrently with DRUG2, since an increase in the pH of the stomach may effect the enteric coating of the tablets.
LABEL>1
Catecholamine-depleting drugs (eg, DRUG1) may have an additive effect when given with DRUG2s.
LABEL>1
DRUG1 may also have an additive effect when given with DRUG2 .
LABEL>1
DRUG1 may exacerbate the rebound hypertension which can follow the withdrawal of DRUG2.
LABEL>1
If the two drugs are coadministered, the DRUG1 should be withdrawn several days before the gradual withdrawal of DRUG2.
LABEL>1
If replacing GE by GE therapy, the introduction of DRUG1 should be delayed for several days after DRUG2 administration has stopped.
LABEL>1
Concomitant use of prostaglandin synthase inhibiting drugs, eg, DRUG1, may decrease the hypotensive effects of DRUG2.
LABEL>1
Drug-Drug Interactions GE - DRUG1 should be administered with caution to patients being treated with systemically-administered (oral or intravenous) DRUG2 (or other GE) because the action of GE on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
LABEL>1
Dosage adjustment of DRUG1 may be necessary when coadministered with CYP2D6 inhibitors, e.g., DRUG2, GE, and GE.
LABEL>1
Dosage adjustment of DRUG1 may be necessary when coadministered with CYP2D6 inhibitors, e.g., GE, DRUG2, and GE.
LABEL>1
Dosage adjustment of DRUG1 may be necessary when coadministered with CYP2D6 inhibitors, e.g., GE, GE, and DRUG2.
LABEL>1
In EM individuals treated with DRUG1 or GE, the AUC of DRUG2 is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than GE alone.
LABEL>1
In EM individuals treated with GE or DRUG1, the AUC of DRUG2 is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than GE alone.
LABEL>1
GE: When DRUG1 and DRUG2 suspension were coadministered, plasma concentrations of GE decreased approximately 35%.
LABEL>1
GE: Plasma concentrations of GE decreased approximately 25% when DRUG1 and DRUG2 were coadministered.
LABEL>1
However, LDL-C reduction was greater when DRUG1 and DRUG2 were coadministered than when either drug was given alone.
LABEL>1
GE: When multiple doses of DRUG1 and DRUG2 were coadministered, steady-state plasma GE concentrations increased by approximately 20%.
LABEL>1
GE: In healthy individuals, plasma concentrations of GE increased approximately 40% with coadministration of DRUG1 and DRUG2, a known inhibitor of cytochrome P450 3A4.
LABEL>1
Oral GE: Coadministration of DRUG1 and an oral DRUG2 increased AUC values for GE and GE by approximately 30% and 20%.
LABEL>1
Oral GE: Coadministration of DRUG1 and an oral GE increased AUC values for DRUG2 and GE by approximately 30% and 20%.
LABEL>1
Oral GE: Coadministration of DRUG1 and an oral GE increased AUC values for GE and DRUG2 by approximately 30% and 20%.
LABEL>1
These increases should be considered when selecting an oral DRUG1 for a woman taking DRUG2.
LABEL>1
Caution should be exercised if an DRUG1 is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as DRUG2, GE, and GE.
LABEL>1
Caution should be exercised if an DRUG1 is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as GE, DRUG2, and GE.
LABEL>1
Caution should be exercised if an DRUG1 is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as GE, GE, and DRUG2.
LABEL>1
GE: Coadministration of DRUG1 and DRUG2 Suspension results in a significant decrease in average steady- state plasma GE concentrations.
LABEL>1
Alternatives to DRUG1 should be considered during the course of PCP treatment with DRUG2.
LABEL>1
Drugs which may enhance the neuromuscular blocking action of DRUG1 include: DRUG2;
LABEL>1
Drugs which may enhance the neuromuscular blocking action of DRUG1 include: DRUG2;GE;GE;certain GE, especially the GE and GE;GE;GE salts;GE;and GE.
LABEL>1
Drugs which may enhance the neuromuscular blocking action of DRUG1 include: GE;DRUG2;GE;certain GE, especially the GE and GE;GE;GE salts;GE;and GE.
LABEL>1
Drugs which may enhance the neuromuscular blocking action of DRUG1 include: GE;GE;DRUG2;certain GE, especially the GE and GE;GE;GE salts;GE;and GE.
LABEL>1
Drugs which may enhance the neuromuscular blocking action of DRUG1 include: GE;GE;GE;certain DRUG2, especially the GE and GE;GE;GE salts;GE;and GE.
LABEL>1
Drugs which may enhance the neuromuscular blocking action of DRUG1 include: GE;GE;GE;certain GE, especially the DRUG2 and GE;GE;GE salts;GE;and GE.
LABEL>1
Drugs which may enhance the neuromuscular blocking action of DRUG1 include: GE;GE;GE;certain GE, especially the GE and DRUG2;GE;GE salts;GE;and GE.
LABEL>1
Drugs which may enhance the neuromuscular blocking action of DRUG1 include: GE;GE;GE;certain GE, especially the GE and GE;DRUG2;GE salts;GE;and GE.
LABEL>1
Drugs which may enhance the neuromuscular blocking action of DRUG1 include: GE;GE;GE;certain GE, especially the GE and GE;GE;DRUG2 salts;GE;and GE.
LABEL>1
Drugs which may enhance the neuromuscular blocking action of DRUG1 include: GE;GE;GE;certain GE, especially the GE and GE;GE;GE salts;DRUG2;and GE.
LABEL>1
Drugs which may enhance the neuromuscular blocking action of DRUG1 include: GE;GE;GE;certain GE, especially the GE and GE;GE;GE salts;GE;and DRUG2.
LABEL>1
The prior administration of DRUG1 does not enhance the duration, but quickens the onset and may increase the depth, of neuromuscular block induced by DRUG2.
LABEL>1
DRUG1 should not be administered until a patient has recovered from DRUG2-induced neuromuscular block.
LABEL>1
When DRUG1 and DRUG2 are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when GE is used alone because GE may potentiate the effect of GE.
LABEL>1
When GE and GE are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when GE is used alone because DRUG1 may potentiate the effect of DRUG2.
LABEL>1
The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of DRUG1 and DRUG2.
LABEL>1
Since DRUG1 are potentiated by the DRUG2, they should be used cautiously in the treatment of convulsions.
LABEL>1
DRUG1 should be avoided by patients with a history of serious reaction to any DRUG2, including GE and GE.
LABEL>1
DRUG1 should be avoided by patients with a history of serious reaction to any GE, including DRUG2 and GE.
LABEL>1
DRUG1 should be avoided by patients with a history of serious reaction to any GE, including GE and DRUG2.
LABEL>1
DRUG1 should not be used together with DRUG2 (GE, GE), another arthritis medication.
LABEL>1
DRUG1 should not be used together with GE (DRUG2, GE), another arthritis medication.
LABEL>1
DRUG1 should not be used together with GE (GE, DRUG2), another arthritis medication.
LABEL>1
DRUG1 prolong and intensify the effects of DRUG2.
LABEL>1
Concomitant use of DRUG1 with DRUG2, GE, GE, or other GE may have an additive effect.
LABEL>1
Concomitant use of DRUG1 with GE, DRUG2, GE, or other GE may have an additive effect.
LABEL>1
Concomitant use of DRUG1 with GE, GE, DRUG2, or other GE may have an additive effect.
LABEL>1
Concomitant use of DRUG1 with GE, GE, GE, or other DRUG2 may have an additive effect.
LABEL>1
When DRUG1 are given to patients receiving DRUG2, hypertensive reactions, including hypertensive crises, may occur.
LABEL>1
The antihypertensive effects of DRUG1, GE, GE, and GE may be reduced by DRUG2.
LABEL>1
The antihypertensive effects of GE, DRUG1, GE, and GE may be reduced by DRUG2.
LABEL>1
The antihypertensive effects of GE, GE, DRUG1, and GE may be reduced by DRUG2.
LABEL>1
The antihypertensive effects of GE, GE, GE, and DRUG1 may be reduced by DRUG2.
LABEL>1
DRUG1 may also interact with DRUG2.
LABEL>1
Increased ectopic pacemaker activity can occur when DRUG1 is used concomitantly with DRUG2.
LABEL>1
DRUG1 increase the rate of absorption of DRUG2, while GE decreases it.
LABEL>1
GE increase the rate of absorption of DRUG1, while DRUG2 decreases it.
LABEL>1
Use with GE: The principal pathway for detoxification of DRUG1 is inhibited by DRUG2.
LABEL>1
Patients receiving DRUG1 and DRUG2 concomitantly should have a dose reduction of GE, to approximately 1/3 to 1/4 the usual dose.
LABEL>1
Use with GE: The use of DRUG1 to control hypertension in patients on DRUG2 has been reported to induce severe leukopenia.
LABEL>1
Co-administration of DRUG1 at steady-state with a single dose of DRUG2 (2 x 600 mg tablets) results in increased GE serum concentrations.
LABEL>1
Although a dose adjustment of DRUG1 is not recommended when administered in combination with DRUG2, close monitoring for known side effects of GE, such as liver enzyme abnormalities and hearing impairment, is warranted.
LABEL>1
However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with DRUG1 and DRUG2 concomitantly.
LABEL>1
Concurrent use of DRUG1 and DRUG2 in clinical practice has been associated with increased anticoagulant effects.
LABEL>1
When used in therapeutic doses, DRUG1 had a modest effect on the pharmacokinetics of DRUG2, GE, GE, GE, GE, GE, GE, GE, GE, GE, GE (intravenous and oral), GE, GE/GE or GE.
LABEL>1
When used in therapeutic doses, DRUG1 had a modest effect on the pharmacokinetics of GE, DRUG2, GE, GE, GE, GE, GE, GE, GE, GE, GE (intravenous and oral), GE, GE/GE or GE.
LABEL>1
When used in therapeutic doses, DRUG1 had a modest effect on the pharmacokinetics of GE, GE, DRUG2, GE, GE, GE, GE, GE, GE, GE, GE (intravenous and oral), GE, GE/GE or GE.
LABEL>1
When used in therapeutic doses, DRUG1 had a modest effect on the pharmacokinetics of GE, GE, GE, DRUG2, GE, GE, GE, GE, GE, GE, GE (intravenous and oral), GE, GE/GE or GE.
LABEL>1
When used in therapeutic doses, DRUG1 had a modest effect on the pharmacokinetics of GE, GE, GE, GE, DRUG2, GE, GE, GE, GE, GE, GE (intravenous and oral), GE, GE/GE or GE.
LABEL>1
When used in therapeutic doses, DRUG1 had a modest effect on the pharmacokinetics of GE, GE, GE, GE, GE, DRUG2, GE, GE, GE, GE, GE (intravenous and oral), GE, GE/GE or GE.
LABEL>1
When used in therapeutic doses, DRUG1 had a modest effect on the pharmacokinetics of GE, GE, GE, GE, GE, GE, DRUG2, GE, GE, GE, GE (intravenous and oral), GE, GE/GE or GE.
LABEL>1
When used in therapeutic doses, DRUG1 had a modest effect on the pharmacokinetics of GE, GE, GE, GE, GE, GE, GE, DRUG2, GE, GE, GE (intravenous and oral), GE, GE/GE or GE.
LABEL>1
When used in therapeutic doses, DRUG1 had a modest effect on the pharmacokinetics of GE, GE, GE, GE, GE, GE, GE, GE, DRUG2, GE, GE (intravenous and oral), GE, GE/GE or GE.
LABEL>1
When used in therapeutic doses, DRUG1 had a modest effect on the pharmacokinetics of GE, GE, GE, GE, GE, GE, GE, GE, GE, DRUG2, GE (intravenous and oral), GE, GE/GE or GE.
LABEL>1
When used in therapeutic doses, DRUG1 had a modest effect on the pharmacokinetics of GE, GE, GE, GE, GE, GE, GE, GE, GE, GE, DRUG2 (intravenous and oral), GE, GE/GE or GE.
LABEL>1
When used in therapeutic doses, DRUG1 had a modest effect on the pharmacokinetics of GE, GE, GE, GE, GE, GE, GE, GE, GE, GE, GE (intravenous and oral), DRUG2, GE/GE or GE.
LABEL>1
When used in therapeutic doses, DRUG1 had a modest effect on the pharmacokinetics of GE, GE, GE, GE, GE, GE, GE, GE, GE, GE, GE (intravenous and oral), GE, DRUG2/GE or GE.
LABEL>1
When used in therapeutic doses, DRUG1 had a modest effect on the pharmacokinetics of GE, GE, GE, GE, GE, GE, GE, GE, GE, GE, GE (intravenous and oral), GE, GE/DRUG2 or GE.
LABEL>1
When used in therapeutic doses, DRUG1 had a modest effect on the pharmacokinetics of GE, GE, GE, GE, GE, GE, GE, GE, GE, GE, GE (intravenous and oral), GE, GE/GE or DRUG2.
LABEL>1
Co-administration with DRUG1 or GE had a modest effect on the pharmacokinetics of DRUG2.
LABEL>1
Co-administration with GE or DRUG1 had a modest effect on the pharmacokinetics of DRUG2.
LABEL>1
DRUG1 should not be administered concomitantly with DRUG2, GE, GE, GE, or GE.
LABEL>1
DRUG1 should not be administered concomitantly with GE, DRUG2, GE, GE, or GE.
LABEL>1
DRUG1 should not be administered concomitantly with GE, GE, DRUG2, GE, or GE.
LABEL>1
DRUG1 should not be administered concomitantly with GE, GE, GE, DRUG2, or GE.
LABEL>1
DRUG1 should not be administered concomitantly with GE, GE, GE, GE, or DRUG2.
LABEL>1
Interactions attributed to the combined use of DRUG1 injection and epidural DRUG2 include hypotension and dyspnea.
LABEL>1
Total body clearance of DRUG1 was reduced by an average 22% and 51% when DRUG2 and GE, respectively, were added to a regimen consisting of GE, USP (MODIFIED) and GE.
LABEL>1
Total body clearance of DRUG1 was reduced by an average 22% and 51% when GE and DRUG2, respectively, were added to a regimen consisting of GE, USP (MODIFIED) and GE.
LABEL>1
GE: Patients on DRUG1, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with DRUG2.
LABEL>1
The possibility of hypotensive effects with GE can be minimized by either discontinuing the DRUG1 or increasing the salt intake prior to initiation of treatment with DRUG2.
LABEL>1
GE Supplements and DRUG1 Lotensin can attenuate potassium loss caused by DRUG2.
LABEL>1
GE: Increased serum GE levels and symptoms of GE toxicity have been reported in patients receiving DRUG1 during therapy with DRUG2.
LABEL>1
If a DRUG1 is also used, the risk of DRUG2 toxicity may be increased.
LABEL>1
DRUG1, like other GE, has had less than additive effects with DRUG2, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system
LABEL>1
GE, like other DRUG1, has had less than additive effects with DRUG2, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system
LABEL>1
May interact with the following: DRUG1, GE (use with DRUG2 may prevent the GE from working properly;
LABEL>1
May interact with the following: GE, DRUG1 (use with DRUG2 may prevent the GE from working properly;
LABEL>1
DRUG1 may interact with DRUG2 (e.g., GE), GE (e.g., GE), local GE (e.g., GE and GE), GE (GE)-containing preparations (e.g., sunscreens and some GE), GE (e.g., GE), GE (sulfa medicines), GE (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
LABEL>1
DRUG1 may interact with GE (e.g., DRUG2), GE (e.g., GE), local GE (e.g., GE and GE), GE (GE)-containing preparations (e.g., sunscreens and some GE), GE (e.g., GE), GE (sulfa medicines), GE (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
LABEL>1
DRUG1 may interact with GE (e.g., GE), DRUG2 (e.g., GE), local GE (e.g., GE and GE), GE (GE)-containing preparations (e.g., sunscreens and some GE), GE (e.g., GE), GE (sulfa medicines), GE (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
LABEL>1
DRUG1 may interact with GE (e.g., GE), GE (e.g., DRUG2), local GE (e.g., GE and GE), GE (GE)-containing preparations (e.g., sunscreens and some GE), GE (e.g., GE), GE (sulfa medicines), GE (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
LABEL>1
DRUG1 may interact with GE (e.g., GE), GE (e.g., GE), local DRUG2 (e.g., GE and GE), GE (GE)-containing preparations (e.g., sunscreens and some GE), GE (e.g., GE), GE (sulfa medicines), GE (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
LABEL>1
DRUG1 may interact with GE (e.g., GE), GE (e.g., GE), local GE (e.g., DRUG2 and GE), GE (GE)-containing preparations (e.g., sunscreens and some GE), GE (e.g., GE), GE (sulfa medicines), GE (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
LABEL>1
DRUG1 may interact with GE (e.g., GE), GE (e.g., GE), local GE (e.g., GE and DRUG2), GE (GE)-containing preparations (e.g., sunscreens and some GE), GE (e.g., GE), GE (sulfa medicines), GE (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
LABEL>1
DRUG1 may interact with GE (e.g., GE), GE (e.g., GE), local GE (e.g., GE and GE), DRUG2 (GE)-containing preparations (e.g., sunscreens and some GE), GE (e.g., GE), GE (sulfa medicines), GE (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
LABEL>1
DRUG1 may interact with GE (e.g., GE), GE (e.g., GE), local GE (e.g., GE and GE), GE (DRUG2)-containing preparations (e.g., sunscreens and some GE), GE (e.g., GE), GE (sulfa medicines), GE (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
LABEL>1
DRUG1 may interact with GE (e.g., GE), GE (e.g., GE), local GE (e.g., GE and GE), GE (GE)-containing preparations (e.g., sunscreens and some DRUG2), GE (e.g., GE), GE (sulfa medicines), GE (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
LABEL>1
DRUG1 may interact with GE (e.g., GE), GE (e.g., GE), local GE (e.g., GE and GE), GE (GE)-containing preparations (e.g., sunscreens and some GE), DRUG2 (e.g., GE), GE (sulfa medicines), GE (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
LABEL>1
DRUG1 may interact with GE (e.g., GE), GE (e.g., GE), local GE (e.g., GE and GE), GE (GE)-containing preparations (e.g., sunscreens and some GE), GE (e.g., DRUG2), GE (sulfa medicines), GE (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
LABEL>1
DRUG1 may interact with GE (e.g., GE), GE (e.g., GE), local GE (e.g., GE and GE), GE (GE)-containing preparations (e.g., sunscreens and some GE), GE (e.g., GE), DRUG2 (sulfa medicines), GE (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
LABEL>1
DRUG1 may interact with GE (e.g., GE), GE (e.g., GE), local GE (e.g., GE and GE), GE (GE)-containing preparations (e.g., sunscreens and some GE), GE (e.g., GE), GE (sulfa medicines), DRUG2 (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
LABEL>1
Hypertensive crises have resulted when DRUG1 have been used concomitantly within14 days following use of DRUG2.
LABEL>1
DRUG1 should not be used concomitantly with other DRUG2.
LABEL>1
DRUG1 may decrease the hypotensive effect of DRUG2.
LABEL>1
DRUG1 may enhance the effects of DRUG2.
LABEL>1
DRUG1 agents decrease blood levels and increase excretion of DRUG2.
LABEL>1
DRUG1 may interact with DRUG2, GEs, GE (allergy, cold, and sinus medicines), diabetic drugs, GE, GE, GE like GE or GE, and high blood pressure medications.
LABEL>1
DRUG1 may interact with GE, DRUG2s, GE (allergy, cold, and sinus medicines), diabetic drugs, GE, GE, GE like GE or GE, and high blood pressure medications.
LABEL>1
DRUG1 may interact with GE, GEs, DRUG2 (allergy, cold, and sinus medicines), diabetic drugs, GE, GE, GE like GE or GE, and high blood pressure medications.
LABEL>1
DRUG1 may interact with GE, GEs, GE (allergy, cold, and sinus medicines), diabetic drugs, DRUG2, GE, GE like GE or GE, and high blood pressure medications.
LABEL>1
DRUG1 may interact with GE, GEs, GE (allergy, cold, and sinus medicines), diabetic drugs, GE, DRUG2, GE like GE or GE, and high blood pressure medications.
LABEL>1
DRUG1 may interact with GE, GEs, GE (allergy, cold, and sinus medicines), diabetic drugs, GE, GE, DRUG2 like GE or GE, and high blood pressure medications.
LABEL>1
DRUG1 may interact with GE, GEs, GE (allergy, cold, and sinus medicines), diabetic drugs, GE, GE, GE like DRUG2 or GE, and high blood pressure medications.
LABEL>1
DRUG1 may interact with GE, GEs, GE (allergy, cold, and sinus medicines), diabetic drugs, GE, GE, GE like GE or DRUG2, and high blood pressure medications.
LABEL>1
GE: In controlled studies in healthy volunteers, DRUG1 either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum DRUG2 concentrations.
LABEL>1
DRUG1 and GE could exaggerate the prolongation of the QT interval observed with DRUG2.
LABEL>1
GE and DRUG1 could exaggerate the prolongation of the QT interval observed with DRUG2.
LABEL>1
DRUG1 could exaggerate the depression of AV nodal conduction observed with DRUG2.
LABEL>1
Catecholamine-depleting drugs (e.g., DRUG1) may have an additive effect when given with DRUG2 agents.
LABEL>1
Should it be decided to discontinue therapy in patients receiving DRUG1 and DRUG2 concurrently, the GE should be discontinued slowly over several days before the gradual withdrawal of GE.
LABEL>1
Should it be decided to discontinue therapy in patients receiving GE and GE concurrently, the DRUG1 should be discontinued slowly over several days before the gradual withdrawal of DRUG2.
LABEL>1
Literature reports suggest that oral DRUG1 may be used in combination with DRUG2 when heart function is normal, but should be avoided in patients with impaired cardiac function.
LABEL>1
Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving DRUG1 when an oral DRUG2 was added to the treatment regimen.
LABEL>1
Risk of Anaphylactic Reaction: Although it is known that patients on DRUG1 may be refractory to DRUG2 in the treatment of anaphylactic shock, GE can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.
LABEL>1
On the basis of the metabolism of GE by cytochrome P450 3A4, DRUG1, GE, GE, GE, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma DRUG2 concentrations.
LABEL>1
On the basis of the metabolism of GE by cytochrome P450 3A4, GE, DRUG1, GE, GE, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma DRUG2 concentrations.
LABEL>1
On the basis of the metabolism of GE by cytochrome P450 3A4, GE, GE, DRUG1, GE, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma DRUG2 concentrations.
LABEL>1
On the basis of the metabolism of GE by cytochrome P450 3A4, GE, GE, GE, DRUG1, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma DRUG2 concentrations.
LABEL>1
Furthermore, DRUG1, GE, GE, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma DRUG2 concentrations.
LABEL>1
Furthermore, GE, DRUG1, GE, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma DRUG2 concentrations.
LABEL>1
Furthermore, GE, GE, DRUG1, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma DRUG2 concentrations.
LABEL>1
Concomitant administration of DRUG1 capsules and DRUG2 resulted in substantial increases in plasma concentrations of GE, probably at least partially related to cytochrome P450 3A4 inhibition by GE.
LABEL>1
Concomitant administration of DRUG1 with DRUG2 capsules is not recommended.
LABEL>1
When GE or GE is used at the same time as other medicines or substances the following interactions must be taken into account: - DRUG1 and GE may enhance the action of DRUG2.
LABEL>1
When GE or GE is used at the same time as other medicines or substances the following interactions must be taken into account: - GE and DRUG1 may enhance the action of DRUG2.
LABEL>1
For this reason, the dose of the DRUG1 should be reduced by 30 - 50% at the start of treatment with DRUG2 or GE retard and then titrated according to the blood clotting parameters
LABEL>1
For this reason, the dose of the DRUG1 should be reduced by 30 - 50% at the start of treatment with GE or DRUG2 retard and then titrated according to the blood clotting parameters
LABEL>1
- The action of DRUG1 and GE may be enhanced by DRUG2 or GE.
LABEL>1
- The action of DRUG1 and GE may be enhanced by GE or DRUG2.
LABEL>1
- The action of GE and DRUG1 may be enhanced by DRUG2 or GE.
LABEL>1
- The action of GE and DRUG1 may be enhanced by GE or DRUG2.
LABEL>1
- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving DRUG1 therapy and concomitant DRUG2.
LABEL>1
- When DRUG1 or GE is used concurrently with DRUG2 (e.g. GE), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of GE or GE is impaired
LABEL>1
- When DRUG1 or GE is used concurrently with GE (e.g. DRUG2), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of GE or GE is impaired
LABEL>1
- When GE or DRUG1 is used concurrently with DRUG2 (e.g. GE), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of GE or GE is impaired
LABEL>1
- When GE or DRUG1 is used concurrently with GE (e.g. DRUG2), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of GE or GE is impaired
LABEL>1
- DRUG1 or GE (with hepatotoxic potential) must not be administered together with DRUG2 or GE.
LABEL>1
- DRUG1 or GE (with hepatotoxic potential) must not be administered together with GE or DRUG2.
LABEL>1
- GE or DRUG1 (with hepatotoxic potential) must not be administered together with DRUG2 or GE.
LABEL>1
- GE or DRUG1 (with hepatotoxic potential) must not be administered together with GE or DRUG2.
LABEL>1
In vitro studies have shown DRUG1 can displace DRUG2s, such as GE, from their protein-binding sites.
LABEL>1
In vitro studies have shown DRUG1 can displace GEs, such as DRUG2, from their protein-binding sites.
LABEL>1
It is recommended that if DRUG1 is started in patients already receiving DRUG2, prothrombin times should be closely monitored and adjustment of the GE dose may be necessary.
LABEL>1
It is recommended that if DRUG1 is started in patients already receiving GE, prothrombin times should be closely monitored and adjustment of the DRUG2 dose may be necessary.
LABEL>1
Drug Interactions: The central DRUG1 syndrome can occur when anticholinergic agents such as GE are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain DRUG2 such as GE, the GE and other GE, GE, certain GE such as the GE salts, and GE.
LABEL>1
Drug Interactions: The central DRUG1 syndrome can occur when anticholinergic agents such as GE are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain GE such as DRUG2, the GE and other GE, GE, certain GE such as the GE salts, and GE.
LABEL>1
Drug Interactions: The central DRUG1 syndrome can occur when anticholinergic agents such as GE are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain GE such as GE, the DRUG2 and other GE, GE, certain GE such as the GE salts, and GE.
LABEL>1
Drug Interactions: The central DRUG1 syndrome can occur when anticholinergic agents such as GE are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain GE such as GE, the GE and other DRUG2, GE, certain GE such as the GE salts, and GE.
LABEL>1
Drug Interactions: The central DRUG1 syndrome can occur when anticholinergic agents such as GE are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain GE such as GE, the GE and other GE, DRUG2, certain GE such as the GE salts, and GE.
LABEL>1
Drug Interactions: The central DRUG1 syndrome can occur when anticholinergic agents such as GE are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain GE such as GE, the GE and other GE, GE, certain DRUG2 such as the GE salts, and GE.
LABEL>1
Drug Interactions: The central DRUG1 syndrome can occur when anticholinergic agents such as GE are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain GE such as GE, the GE and other GE, GE, certain GE such as the DRUG2 salts, and GE.
LABEL>1
Drug Interactions: The central DRUG1 syndrome can occur when anticholinergic agents such as GE are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain GE such as GE, the GE and other GE, GE, certain GE such as the GE salts, and DRUG2.
LABEL>1
Drug Interactions: The central GE syndrome can occur when anticholinergic agents such as DRUG1 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain DRUG2 such as GE, the GE and other GE, GE, certain GE such as the GE salts, and GE.
LABEL>1
Drug Interactions: The central GE syndrome can occur when anticholinergic agents such as DRUG1 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain GE such as DRUG2, the GE and other GE, GE, certain GE such as the GE salts, and GE.
LABEL>1
Drug Interactions: The central GE syndrome can occur when anticholinergic agents such as DRUG1 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain GE such as GE, the DRUG2 and other GE, GE, certain GE such as the GE salts, and GE.
LABEL>1
Drug Interactions: The central GE syndrome can occur when anticholinergic agents such as DRUG1 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain GE such as GE, the GE and other DRUG2, GE, certain GE such as the GE salts, and GE.
LABEL>1
Drug Interactions: The central GE syndrome can occur when anticholinergic agents such as DRUG1 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain GE such as GE, the GE and other GE, DRUG2, certain GE such as the GE salts, and GE.
LABEL>1
Drug Interactions: The central GE syndrome can occur when anticholinergic agents such as DRUG1 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain GE such as GE, the GE and other GE, GE, certain DRUG2 such as the GE salts, and GE.
LABEL>1
Drug Interactions: The central GE syndrome can occur when anticholinergic agents such as DRUG1 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain GE such as GE, the GE and other GE, GE, certain GE such as the DRUG2 salts, and GE.
LABEL>1
Drug Interactions: The central GE syndrome can occur when anticholinergic agents such as DRUG1 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain GE such as GE, the GE and other GE, GE, certain GE such as the GE salts, and DRUG2.
LABEL>1
DRUG1 should not be combined with other DRUG2.
LABEL>1
Patients receiving catecholamine-depleting drugs, such as DRUG1 or GE, should be closely monitored, because the added beta-adrenergic blocking action of DRUG2 may produce excessive reduction of sympathetic activity.
LABEL>1
Patients receiving catecholamine-depleting drugs, such as GE or DRUG1, should be closely monitored, because the added beta-adrenergic blocking action of DRUG2 may produce excessive reduction of sympathetic activity.
LABEL>1
In patients receiving concurrent therapy with GE, if therapy is to be discontinued, it is suggested that DRUG1 be discontinued for several days before the withdrawal of DRUG2.
LABEL>1
DRUG1 should be used with care when DRUG2 or inhibitors of AV conduction, such as certain GE (particularly of the GE [GE] and GE [GE] classes), or GE, such as GE, are used concurrently.
LABEL>1
DRUG1 should be used with care when GE or inhibitors of AV conduction, such as certain DRUG2 (particularly of the GE [GE] and GE [GE] classes), or GE, such as GE, are used concurrently.
LABEL>1
DRUG1 should be used with care when GE or inhibitors of AV conduction, such as certain GE (particularly of the DRUG2 [GE] and GE [GE] classes), or GE, such as GE, are used concurrently.
LABEL>1
DRUG1 should be used with care when GE or inhibitors of AV conduction, such as certain GE (particularly of the GE [DRUG2] and GE [GE] classes), or GE, such as GE, are used concurrently.
LABEL>1
DRUG1 should be used with care when GE or inhibitors of AV conduction, such as certain GE (particularly of the GE [GE] and DRUG2 [GE] classes), or GE, such as GE, are used concurrently.
LABEL>1
DRUG1 should be used with care when GE or inhibitors of AV conduction, such as certain GE (particularly of the GE [GE] and GE [DRUG2] classes), or GE, such as GE, are used concurrently.
LABEL>1
DRUG1 should be used with care when GE or inhibitors of AV conduction, such as certain GE (particularly of the GE [GE] and GE [GE] classes), or DRUG2, such as GE, are used concurrently.
LABEL>1
DRUG1 should be used with care when GE or inhibitors of AV conduction, such as certain GE (particularly of the GE [GE] and GE [GE] classes), or GE, such as DRUG2, are used concurrently.
LABEL>1
Concurrent use of DRUG1 increases the metabolic clearance of DRUG2, resulting in a shortened elimination half-life of GE.
LABEL>1
If you are also using a DRUG1 inhaler, take DRUG2 first and then wait about 15 minutes before using the GE inhaler.
LABEL>1
If you are also using a GE inhaler, take DRUG1 first and then wait about 15 minutes before using the DRUG2 inhaler.
LABEL>1
This allows DRUG1 to open air passages, increasing the effectiveness of the DRUG2.
LABEL>1
In clinical trials in patients undergoing PTCA/PCI, co-administration of DRUG1 with DRUG2, GE, GE or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
LABEL>1
In clinical trials in patients undergoing PTCA/PCI, co-administration of DRUG1 with GE, DRUG2, GE or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
LABEL>1
In clinical trials in patients undergoing PTCA/PCI, co-administration of DRUG1 with GE, GE, DRUG2 or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
LABEL>1
Patients on oral DRUG1 receiving DRUG2 treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their GE.
LABEL>1
GE, Including Oral, Injectable, Transdermal, and Implantable GE: An interaction study demonstrated that co-administration of DRUG1 and the oral GE DRUG2 produced average decreases of GE and GE levels of 14% and 31%, respectively.
LABEL>1
Therefore, DRUG1, including oral, injectable, transdermal, and implantable forms, may not be reliable when DRUG2 is co-administered.
LABEL>1
Steady-state DRUG1 plasma concentrations were 3- to 4-fold higher than in the absence of DRUG2.
LABEL>1
The concomitant administration of DRUG1 and DRUG2 is contraindicated.
LABEL>1
Co-administration of DRUG1 decreased the plasma concentrations of DRUG2 (a CYP3A4 substrate) by approximately 50%.
LABEL>1
Co-administration of DRUG1 and DRUG2 resulted in markedly increased plasma concentrations of GE in animals.
LABEL>1
Caution should be exercised if DRUG1 and DRUG2 are used together.
LABEL>1
Therefore, the concomitant administration of DRUG1 and DRUG2 is contraindicated, and alternative GE should be considered.
LABEL>1
Co-administration of DRUG1 decreased the plasma concentrations of DRUG2 by approximately 40%.
LABEL>1
DRUG1 is also expected to reduce plasma concentrations of other oral DRUG2 that are predominantly metabolized by CYP2C9 or CYP3A4.
LABEL>1
GE: Co-administration of DRUG1 125 mg b.i.d. and DRUG2, a potent CYP3A4 inhibitor, increased the plasma concentrations of GE by approximately 2-fold.
LABEL>1
GE and Other GE: Co-administration of DRUG1 decreased the plasma concentrations of DRUG2 (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.
LABEL>1
DRUG1 is also expected to reduce plasma concentrations of other DRUG2 that have significant metabolism by CYP3A4, such as GE and GE.
LABEL>1
DRUG1 is also expected to reduce plasma concentrations of other GE that have significant metabolism by CYP3A4, such as DRUG2 and GE.
LABEL>1
DRUG1 is also expected to reduce plasma concentrations of other GE that have significant metabolism by CYP3A4, such as GE and DRUG2.
LABEL>1
Patients using CYP3A4 metabolized DRUG1 should have cholesterol levels monitored after DRUG2 is initiated to see whether the GE dose needs adjustment.
LABEL>1
GE: Co-administration of DRUG1 500 mg b.i.d. for 6 days decreased the plasma concentrations of both DRUG2 (a CYP2C9 substrate) and GE (a CYP3A4 substrate) by 29 and 38%, respectively.
LABEL>1
GE: Co-administration of DRUG1 500 mg b.i.d. for 6 days decreased the plasma concentrations of both GE (a CYP2C9 substrate) and DRUG2 (a CYP3A4 substrate) by 29 and 38%, respectively.
LABEL>1
Co-administration of DRUG1 and DRUG2 or other agents interfering with neuromuscular transmission (e.g., GE) should only be performed with caution as the effect of the GE may be potentiated.
LABEL>1
Co-administration of DRUG1 and GE or other agents interfering with neuromuscular transmission (e.g., DRUG2) should only be performed with caution as the effect of the GE may be potentiated.
LABEL>1
Excessive neuromuscular weakness may be exacerbated by administration of another DRUG1 prior to the resolution of the effects of a previously administered DRUG2.
LABEL>1
Co-administration of DRUG1 and DRUG2 or other agents interfering with neuromuscular transmission (e.g., GE) should only be performed with caution as the effect of the GE may be potentiated.
LABEL>1
Co-administration of DRUG1 and GE or other agents interfering with neuromuscular transmission (e.g., DRUG2) should only be performed with caution as the effect of the GE may be potentiated.
LABEL>1
DRUG1 toxicity may be aggravated by the initial release of norepinephrine caused by DRUG2 Injection.
LABEL>1
The pressor effects of DRUG1 such as GE or GE are enhanced by DRUG2.
LABEL>1
The pressor effects of GE such as DRUG1 or GE are enhanced by DRUG2.
LABEL>1
The pressor effects of GE such as GE or DRUG1 are enhanced by DRUG2.
LABEL>1
Although specific drug interaction studies have not been conducted with DRUG1, the possibility of an additive or potentiating effect with DRUG2 (GE, GE, GE, GE, or GE) should be considered.
LABEL>1
Although specific drug interaction studies have not been conducted with DRUG1, the possibility of an additive or potentiating effect with GE (DRUG2, GE, GE, GE, or GE) should be considered.
LABEL>1
Although specific drug interaction studies have not been conducted with DRUG1, the possibility of an additive or potentiating effect with GE (GE, DRUG2, GE, GE, or GE) should be considered.
LABEL>1
Although specific drug interaction studies have not been conducted with DRUG1, the possibility of an additive or potentiating effect with GE (GE, GE, DRUG2, GE, or GE) should be considered.
LABEL>1
Although specific drug interaction studies have not been conducted with DRUG1, the possibility of an additive or potentiating effect with GE (GE, GE, GE, DRUG2, or GE) should be considered.
LABEL>1
Although specific drug interaction studies have not been conducted with DRUG1, the possibility of an additive or potentiating effect with GE (GE, GE, GE, GE, or DRUG2) should be considered.
LABEL>1
DRUG1 have been reported to blunt the hypotensive effect of systemic DRUG2.It is not known whether the concurrent use of these agents with GE in humans can lead to resulting interference with the IOP lowering effect.
LABEL>1
However, in patients treated with oral DRUG1, rare instances of drug interactions have occurred with high-dose DRUG2 therapy.
LABEL>1
The risk of using GE in combination with other drugs has not been systematically evaluated, but DRUG1 may potentiate the side effects of DRUG2.
LABEL>1
DRUG1 may interact with DRUG2, GE, and certain other agents.
LABEL>1
DRUG1 may interact with GE, DRUG2, and certain other agents.
LABEL>1
Compounds in these categories result in a decreased efficacy of DRUG1: DRUG2, GE, GE, GE.
LABEL>1
Compounds in these categories result in a decreased efficacy of DRUG1: GE, DRUG2, GE, GE.
LABEL>1
Compounds in these categories result in a decreased efficacy of DRUG1: GE, GE, DRUG2, GE.
LABEL>1
Compounds in these categories result in a decreased efficacy of DRUG1: GE, GE, GE, DRUG2.
LABEL>1
Concomitant use of DRUG1 with other DRUG2 is not recommended.
LABEL>1
DRUG1 can interact with DRUG2 or other GE (may potentiate the CNS depressant effects of either these medications or GE), GE or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with GE), and GE (concurrent use with GE may prolong and intensify the anticholinergic and CNS depressant effects of GE).
LABEL>1
DRUG1 can interact with GE or other DRUG2 (may potentiate the CNS depressant effects of either these medications or GE), GE or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with GE), and GE (concurrent use with GE may prolong and intensify the anticholinergic and CNS depressant effects of GE).
LABEL>1
DRUG1 can interact with GE or other GE (may potentiate the CNS depressant effects of either these medications or GE), DRUG2 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with GE), and GE (concurrent use with GE may prolong and intensify the anticholinergic and CNS depressant effects of GE).
LABEL>1
DRUG1 can interact with GE or other GE (may potentiate the CNS depressant effects of either these medications or GE), GE or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with GE), and DRUG2 (concurrent use with GE may prolong and intensify the anticholinergic and CNS depressant effects of GE).
LABEL>1
Concomitant oral administration of DRUG1 (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral DRUG2.
LABEL>1
If treatment with inhibitors of CYP3A4 activity (such as DRUG1, GE, GE, GE, GE, GE, etc.) is indicated, reduction of the DRUG2 dose should be considered.
LABEL>1
If treatment with inhibitors of CYP3A4 activity (such as GE, DRUG1, GE, GE, GE, GE, etc.) is indicated, reduction of the DRUG2 dose should be considered.
LABEL>1
If treatment with inhibitors of CYP3A4 activity (such as GE, GE, DRUG1, GE, GE, GE, etc.) is indicated, reduction of the DRUG2 dose should be considered.
LABEL>1
If treatment with inhibitors of CYP3A4 activity (such as GE, GE, GE, DRUG1, GE, GE, etc.) is indicated, reduction of the DRUG2 dose should be considered.
LABEL>1
If treatment with inhibitors of CYP3A4 activity (such as GE, GE, GE, GE, DRUG1, GE, etc.) is indicated, reduction of the DRUG2 dose should be considered.
LABEL>1
If treatment with inhibitors of CYP3A4 activity (such as GE, GE, GE, GE, GE, DRUG1, etc.) is indicated, reduction of the DRUG2 dose should be considered.
LABEL>1
- Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered DRUG1 in patients to whom DRUG2 are also being given should be avoided, except in life-threatening conditions.
LABEL>1
- GE: DRUG1 should generally not be given with DRUG2 (such as GE) because they reduce its renal clearance and add a high risk of GE toxicity.
LABEL>1
- GE: DRUG1 should generally not be given with GE (such as DRUG2) because they reduce its renal clearance and add a high risk of GE toxicity.
LABEL>1
- GE: Pretreatment with DRUG1 reduces both the natriuresis and hyperreninemia produced by DRUG2.
LABEL>1
This antagonistic effect of DRUG1 on DRUG2 natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of GE.
LABEL>1
Thus, DRUG1 should not be administered concurrently with DRUG2.
LABEL>1
- GE: DRUG1 blunts the increases in urine volume and sodium excretion seen during DRUG2 treatment and inhibits the GE-induced increase in plasma renin activity.
LABEL>1
- GE: DRUG1 blunts the increases in urine volume and sodium excretion seen during GE treatment and inhibits the DRUG2-induced increase in plasma renin activity.
LABEL>1
- GE: DRUG1 may potentiate the effect of various DRUG2, necessitating a reduction in the dosage of these drugs.
LABEL>1
The administration of local GE containing DRUG1 or GE to patients receiving DRUG2 or GE may produce severe, prolonged hypertension.
LABEL>1
The administration of local GE containing DRUG1 or GE to patients receiving GE or DRUG2 may produce severe, prolonged hypertension.
LABEL>1
The administration of local GE containing GE or DRUG1 to patients receiving DRUG2 or GE may produce severe, prolonged hypertension.
LABEL>1
The administration of local GE containing GE or DRUG1 to patients receiving GE or DRUG2 may produce severe, prolonged hypertension.
LABEL>1
DRUG1 and GE may reduce or reverse the pressor effect of DRUG2.
LABEL>1
GE and DRUG1 may reduce or reverse the pressor effect of DRUG2.
LABEL>1
Based on anecdotal reports, there may be an interaction between DRUG1 and DRUG2.
LABEL>1
There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of DRUG1 and DRUG2 by addicts.
LABEL>1
DRUG1 and GE should be prescribed with caution to patients on DRUG2 or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.
LABEL>1
GE and DRUG1 should be prescribed with caution to patients on DRUG2 or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.
LABEL>1
Patients should be warned of the potential danger of the intravenous self-administration of DRUG1 while under treatment with DRUG2 or GE.
LABEL>1
Patients should be warned of the potential danger of the intravenous self-administration of DRUG1 while under treatment with GE or DRUG2.
LABEL>1
Therefore, the potential exists for a drug interaction between DRUG1 and drugs that affect the CYP2B6 isoenzyme (e.g., DRUG2 and GE).
LABEL>1
Therefore, the potential exists for a drug interaction between DRUG1 and drugs that affect the CYP2B6 isoenzyme (e.g., GE and DRUG2).
LABEL>1
While not systematically studied, certain drugs may induce the metabolism of DRUG1 (e.g., DRUG2, GE, GE).
LABEL>1
While not systematically studied, certain drugs may induce the metabolism of DRUG1 (e.g., GE, DRUG2, GE).
LABEL>1
While not systematically studied, certain drugs may induce the metabolism of DRUG1 (e.g., GE, GE, DRUG2).
LABEL>1
In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of DRUG1 given as 150 mg twice daily followed by a single dose of 50 mg DRUG2 increased the Cmax, AUC, and t1/2 of GE by an average of approximately 2-, 5- and 2-fold, respectively.
LABEL>1
Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain DRUG2 (e.g., GE, GE, GE, GE, GE, GE), GE (e.g., GE, GE, GE), GE (e.g., GE), and GE (e.g., GE, GE), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
LABEL>1
Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain GE (e.g., DRUG2, GE, GE, GE, GE, GE), GE (e.g., GE, GE, GE), GE (e.g., GE), and GE (e.g., GE, GE), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
LABEL>1
Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain GE (e.g., GE, DRUG2, GE, GE, GE, GE), GE (e.g., GE, GE, GE), GE (e.g., GE), and GE (e.g., GE, GE), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
LABEL>1
Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain GE (e.g., GE, GE, DRUG2, GE, GE, GE), GE (e.g., GE, GE, GE), GE (e.g., GE), and GE (e.g., GE, GE), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
LABEL>1
Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain GE (e.g., GE, GE, GE, DRUG2, GE, GE), GE (e.g., GE, GE, GE), GE (e.g., GE), and GE (e.g., GE, GE), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
LABEL>1
Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain GE (e.g., GE, GE, GE, GE, DRUG2, GE), GE (e.g., GE, GE, GE), GE (e.g., GE), and GE (e.g., GE, GE), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
LABEL>1
Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain GE (e.g., GE, GE, GE, GE, GE, DRUG2), GE (e.g., GE, GE, GE), GE (e.g., GE), and GE (e.g., GE, GE), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
LABEL>1
Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain GE (e.g., GE, GE, GE, GE, GE, GE), DRUG2 (e.g., GE, GE, GE), GE (e.g., GE), and GE (e.g., GE, GE), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
LABEL>1
Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain GE (e.g., GE, GE, GE, GE, GE, GE), GE (e.g., DRUG2, GE, GE), GE (e.g., GE), and GE (e.g., GE, GE), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
LABEL>1
Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain GE (e.g., GE, GE, GE, GE, GE, GE), GE (e.g., GE, DRUG2, GE), GE (e.g., GE), and GE (e.g., GE, GE), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
LABEL>1
Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain GE (e.g., GE, GE, GE, GE, GE, GE), GE (e.g., GE, GE, DRUG2), GE (e.g., GE), and GE (e.g., GE, GE), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
LABEL>1
Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain GE (e.g., GE, GE, GE, GE, GE, GE), GE (e.g., GE, GE, GE), DRUG2 (e.g., GE), and GE (e.g., GE, GE), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
LABEL>1
Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain GE (e.g., GE, GE, GE, GE, GE, GE), GE (e.g., GE, GE, GE), GE (e.g., DRUG2), and GE (e.g., GE, GE), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
LABEL>1
Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain GE (e.g., GE, GE, GE, GE, GE, GE), GE (e.g., GE, GE, GE), GE (e.g., GE), and DRUG2 (e.g., GE, GE), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
LABEL>1
Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain GE (e.g., GE, GE, GE, GE, GE, GE), GE (e.g., GE, GE, GE), GE (e.g., GE), and GE (e.g., DRUG2, GE), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
LABEL>1
Therefore, co-administration of DRUG1 with drugs that are metabolized by CYP2D6 isoenzyme including certain GE (e.g., GE, GE, GE, GE, GE, GE), GE (e.g., GE, GE, GE), GE (e.g., GE), and GE (e.g., GE, DRUG2), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
LABEL>1
GE: Studies in animals demonstrate that the acute toxicity of DRUG1 is enhanced by the GE DRUG2 .
LABEL>1
GE and GE: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving DRUG1 concurrently with either DRUG2 or GE.
LABEL>1
GE and GE: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving DRUG1 concurrently with either GE or DRUG2.
LABEL>1
Administration of DRUG1 Tablets to patients receiving either DRUG2 or GE concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.
LABEL>1
Administration of DRUG1 Tablets to patients receiving either GE or DRUG2 concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.
LABEL>1
Drugs that Lower Seizure Threshold: Concurrent administration of DRUG1 and agents (e.g., DRUG2, other GE, GE, systemic GE, etc.) that lower seizure threshold should be undertaken only with extreme caution.
LABEL>1
Drugs that Lower Seizure Threshold: Concurrent administration of DRUG1 and agents (e.g., GE, other DRUG2, GE, systemic GE, etc.) that lower seizure threshold should be undertaken only with extreme caution.
LABEL>1
Drugs that Lower Seizure Threshold: Concurrent administration of DRUG1 and agents (e.g., GE, other GE, DRUG2, systemic GE, etc.) that lower seizure threshold should be undertaken only with extreme caution.
LABEL>1
Drugs that Lower Seizure Threshold: Concurrent administration of DRUG1 and agents (e.g., GE, other GE, GE, systemic DRUG2, etc.) that lower seizure threshold should be undertaken only with extreme caution.
LABEL>1
GE: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced GE tolerance in patients who were drinking DRUG1 during treatment with DRUG2.
LABEL>1
The consumption of DRUG1 during treatment with DRUG2 should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)
LABEL>1
It is recommended that DRUG1 not be used concomitantly with DRUG2 Because the effects of concomitant administration of GE with most other GE have not been studied, the concomitant use of GE with other CNS-active drugs should be approached with caution.
LABEL>1
There is one report suggesting that the concomitant use of DRUG1 (GE) and DRUG2 may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.
LABEL>1
There is one report suggesting that the concomitant use of GE (DRUG1) and DRUG2 may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.
LABEL>1
In a study in normal volunteers, concomitant administration of DRUG1 and DRUG2 resulted in increased serum GE concentrations.
LABEL>1
However, there has been one report of prolonged prothrombin time when DRUG1 was added to the regimen of a patient treated with DRUG2.
LABEL>1
In vitro, DRUG1 may displace less firmly bound drugs like DRUG2.
LABEL>1
DRUG1 decreases DRUG2 clearance by up to 25%, and may produce AUCs   1500  M min in some patients.
LABEL>1
DRUG1 increases the clearance of DRUG2 by 15% or more, possibly due to the induction of glutathione-S-transferase.
LABEL>1
Since the pharmacokinetics of DRUG1 were studied in patients treated with DRUG2, the clearance of GE at the recommended dose may be lower and exposure (AUC) higher in patients not treated with GE.
LABEL>1
Because GE is eliminated from the body via conjugation with glutathione, use of DRUG1 prior to ( 72 hours) or concurrent with DRUG2 may result in reduced GE clearance based upon the known property of GE to decrease glutathione levels in the blood and tissues.
LABEL>1
Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), GE (GEs), GE, GE (GE may decrease the effects of these medicines), GE (using these medicines with GE may result in increased CNS depressant effects), GE, GE (using these medicines with GE may change the amount of either medicine that you need to take), and oral GE containing GE (DRUG1 may decrease the effectiveness of these oral DRUG2, and you may need to change to a different type of birth control).
LABEL>1
The CNS effects of DRUG1 may be enhanced by DRUG2.
LABEL>1
DRUG1, GE and GE may enhance the effects of: other DRUG2s, GE, general GE, GE such as GE, GE, or other GE, causing increased CNS depression.
LABEL>1
DRUG1, GE and GE may enhance the effects of: other GEs, DRUG2, general GE, GE such as GE, GE, or other GE, causing increased CNS depression.
LABEL>1
DRUG1, GE and GE may enhance the effects of: other GEs, GE, general DRUG2, GE such as GE, GE, or other GE, causing increased CNS depression.
LABEL>1
DRUG1, GE and GE may enhance the effects of: other GEs, GE, general GE, DRUG2 such as GE, GE, or other GE, causing increased CNS depression.
LABEL>1
DRUG1, GE and GE may enhance the effects of: other GEs, GE, general GE, GE such as DRUG2, GE, or other GE, causing increased CNS depression.
LABEL>1
DRUG1, GE and GE may enhance the effects of: other GEs, GE, general GE, GE such as GE, DRUG2, or other GE, causing increased CNS depression.
LABEL>1
DRUG1, GE and GE may enhance the effects of: other GEs, GE, general GE, GE such as GE, GE, or other DRUG2, causing increased CNS depression.
LABEL>1
GE, DRUG1 and GE may enhance the effects of: other DRUG2s, GE, general GE, GE such as GE, GE, or other GE, causing increased CNS depression.
LABEL>1
GE, DRUG1 and GE may enhance the effects of: other GEs, DRUG2, general GE, GE such as GE, GE, or other GE, causing increased CNS depression.
LABEL>1
GE, DRUG1 and GE may enhance the effects of: other GEs, GE, general DRUG2, GE such as GE, GE, or other GE, causing increased CNS depression.
LABEL>1
GE, DRUG1 and GE may enhance the effects of: other GEs, GE, general GE, DRUG2 such as GE, GE, or other GE, causing increased CNS depression.
LABEL>1
GE, DRUG1 and GE may enhance the effects of: other GEs, GE, general GE, GE such as DRUG2, GE, or other GE, causing increased CNS depression.
LABEL>1
GE, DRUG1 and GE may enhance the effects of: other GEs, GE, general GE, GE such as GE, DRUG2, or other GE, causing increased CNS depression.
LABEL>1
GE, DRUG1 and GE may enhance the effects of: other GEs, GE, general GE, GE such as GE, GE, or other DRUG2, causing increased CNS depression.
LABEL>1
GE, GE and DRUG1 may enhance the effects of: other DRUG2s, GE, general GE, GE such as GE, GE, or other GE, causing increased CNS depression.
LABEL>1
GE, GE and DRUG1 may enhance the effects of: other GEs, DRUG2, general GE, GE such as GE, GE, or other GE, causing increased CNS depression.
LABEL>1
GE, GE and DRUG1 may enhance the effects of: other GEs, GE, general DRUG2, GE such as GE, GE, or other GE, causing increased CNS depression.
LABEL>1
GE, GE and DRUG1 may enhance the effects of: other GEs, GE, general GE, DRUG2 such as GE, GE, or other GE, causing increased CNS depression.
LABEL>1
GE, GE and DRUG1 may enhance the effects of: other GEs, GE, general GE, GE such as DRUG2, GE, or other GE, causing increased CNS depression.
LABEL>1
GE, GE and DRUG1 may enhance the effects of: other GEs, GE, general GE, GE such as GE, DRUG2, or other GE, causing increased CNS depression.
LABEL>1
GE, GE and DRUG1 may enhance the effects of: other GEs, GE, general GE, GE such as GE, GE, or other DRUG2, causing increased CNS depression.
LABEL>1
Concurrent use of DRUG1 with DRUG2 (e.g., GE, GE, GE, and GE) may result in increased GE effects.
LABEL>1
Concurrent use of DRUG1 with GE (e.g., DRUG2, GE, GE, and GE) may result in increased GE effects.
LABEL>1
Concurrent use of DRUG1 with GE (e.g., GE, DRUG2, GE, and GE) may result in increased GE effects.
LABEL>1
Concurrent use of DRUG1 with GE (e.g., GE, GE, DRUG2, and GE) may result in increased GE effects.
LABEL>1
Concurrent use of DRUG1 with GE (e.g., GE, GE, GE, and DRUG2) may result in increased GE effects.
LABEL>1
However, in another study in healthy volunteers, the pharmacokinetics of GE were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of DRUG1 was administered 1 minute after a 20-mg dose of DRUG2 nasal spray.
LABEL>1
When the DRUG1 was administered 30 minutes after the DRUG2 nasal spray, the AUC of GE increased 11% and Cmax decreased 18%.
LABEL>1
These results suggest that the analgesic effect of DRUG1 may be diminished when it is administered shortly after DRUG2 nasal spray, but by 30 minutes any such reduction in effect should be minimal.
LABEL>1
It is not known if the effects of DRUG1 are altered by concomitant medications that affect hepatic metabolism of drugs (DRUG2, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.
LABEL>1
Therefore, a slower onset can be anticipated if DRUG1 is administered concomitantly with, or immediately following, a DRUG2.
LABEL>1
DRUG1 should not be administered concurrently with D2-antagonists, such as DRUG2, GE, GE, or GE.
LABEL>1
DRUG1 should not be administered concurrently with D2-antagonists, such as GE, DRUG2, GE, or GE.
LABEL>1
DRUG1 should not be administered concurrently with D2-antagonists, such as GE, GE, DRUG2, or GE.
LABEL>1
DRUG1 should not be administered concurrently with D2-antagonists, such as GE, GE, GE, or DRUG2.
LABEL>1
Based on adult data, lower doses of DRUG1 may be needed following coadministration of drugs which are reported to decrease GE elimination (e.g., DRUG2 and GE) and higher GE doses may be needed following coadministration of drugs that increase GE elimination (e.g., GE and GE).
LABEL>1
Based on adult data, lower doses of DRUG1 may be needed following coadministration of drugs which are reported to decrease GE elimination (e.g., GE and DRUG2) and higher GE doses may be needed following coadministration of drugs that increase GE elimination (e.g., GE and GE).
LABEL>1
Based on adult data, lower doses of GE may be needed following coadministration of drugs which are reported to decrease GE elimination (e.g., GE and GE) and higher DRUG1 doses may be needed following coadministration of drugs that increase GE elimination (e.g., DRUG2 and GE).
LABEL>1
Based on adult data, lower doses of GE may be needed following coadministration of drugs which are reported to decrease GE elimination (e.g., GE and GE) and higher DRUG1 doses may be needed following coadministration of drugs that increase GE elimination (e.g., GE and DRUG2).
LABEL>1
DRUG1 administered concurrently with DRUG2 reduced the urine volume in 4 healthy volunteers.
LABEL>1
Interactions for GE (GE, GE, GE, and GE): GE: DRUG1 has been reported to reduce intestinal absorption of DRUG2;
LABEL>1
GE/GE: The coadministration of DRUG1 or GE will not affect plasma concentrations of GE, but may reduce endogenous plasma levels of DRUG2/ergocalcitriol by accelerating metabolism.
LABEL>1
GE/GE: The coadministration of GE or DRUG1 will not affect plasma concentrations of GE, but may reduce endogenous plasma levels of DRUG2/ergocalcitriol by accelerating metabolism.
LABEL>1
Some reports have shown that the concomitant administration of DRUG1 with DRUG2 causes hypercalcemia.
LABEL>1
GE: DRUG1 dosage must be determined with care in patients undergoing treatment with DRUG2, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
LABEL>1
GE: DRUG1 may inhibit both synthetic and catabolic enzymes of DRUG2.
LABEL>1
GE: A relationship of functional antagonism exists between DRUG1, which promote calcium absorption, and DRUG2, which inhibit calcium absorption.
LABEL>1
GE: DRUG1-containing preparations (eg, GE) may cause hypermagnesemia and should therefore not be taken during therapy with DRUG2 by patients on chronic renal dialysis.
LABEL>1
GE: GE-containing preparations (eg, DRUG1) may cause hypermagnesemia and should therefore not be taken during therapy with DRUG2 by patients on chronic renal dialysis.
LABEL>1
Interactions for GE (GE, GE, GE, and GE): GE: DRUG1 has been reported to reduce intestinal absorption of DRUG2;
LABEL>1
GE/GE: The coadministration of DRUG1 or GE will not affect plasma concentrations of GE, but may reduce endogenous plasma levels of DRUG2/ergocalcitriol by accelerating metabolism.
LABEL>1
GE/GE: The coadministration of GE or DRUG1 will not affect plasma concentrations of GE, but may reduce endogenous plasma levels of DRUG2/ergocalcitriol by accelerating metabolism.
LABEL>1
Some reports have shown that the concomitant administration of DRUG1 with DRUG2 causes hypercalcemia.
LABEL>1
GE: DRUG1 dosage must be determined with care in patients undergoing treatment with DRUG2, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
LABEL>1
GE: DRUG1 may inhibit both synthetic and catabolic enzymes of DRUG2.
LABEL>1
GE: A relationship of functional antagonism exists between DRUG1, which promote calcium absorption, and DRUG2, which inhibit calcium absorption.
LABEL>1
GE: DRUG1-containing preparations (eg, GE) may cause hypermagnesemia and should therefore not be taken during therapy with DRUG2 by patients on chronic renal dialysis.
LABEL>1
GE: GE-containing preparations (eg, DRUG1) may cause hypermagnesemia and should therefore not be taken during therapy with DRUG2 by patients on chronic renal dialysis.
LABEL>1
Using DRUG1 with DRUG2 (heart medicine) may cause hypercalcemia (too much GE in the blood), which could increase the chance of developing an irregular heartbeat.
LABEL>1
GE Reversible increases in serum GE concentrations and toxicity have been reported during concomitant administration of DRUG1 with DRUG2, and with some GE.
LABEL>1
GE Reversible increases in serum GE concentrations and toxicity have been reported during concomitant administration of DRUG1 with GE, and with some DRUG2.
LABEL>1
An increase in serum GE concentration has been reported during concomitant administration of DRUG1 with DRUG2, so careful monitoring of serum GE levels is recommended during concomitant use.
LABEL>1
GE Altered coagulation parameters and/or bleeding have been reported in patients taking DRUG1 concomitantly with DRUG2 such as GE and GE.
LABEL>1
GE Altered coagulation parameters and/or bleeding have been reported in patients taking DRUG1 concomitantly with GE such as GE and DRUG2.
LABEL>1
Patients taking DRUG1 concomitantly with DRUG2 should be monitored regularly for alterations in their coagulation parameters (PT or INR).
LABEL>1
GE: The concentration of DRUG1 is increased and its toxicity may be enhanced by DRUG2.
LABEL>1
Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly DRUG1 and DRUG2.
LABEL>1
Hypotension   Patients on GE Therapy: Patients on DRUG1 and especially those in whom GE therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of DRUG2.
LABEL>1
The possibility of hypotensive effects with DRUG1 can be minimized by either discontinuing the DRUG2 or increasing the salt intake approximately one week prior to initiation of treatment with GE (GE tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).
LABEL>1
therefore, DRUG1 or other GE (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting DRUG2.
LABEL>1
therefore, GE or other DRUG1 (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting DRUG2.
LABEL>1
Agents Causing Renin Release DRUG1's effect will be augmented by DRUG2 that cause renin release.
LABEL>1
DRUG1 add some further antihypertensive effect to DRUG2, but the overall response is less than additive.
LABEL>1
Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that DRUG1 may reduce the antihypertensive effect of DRUG2, especially in cases of low renin hypertension.
LABEL>1
GE: Increased serum GE levels and symptoms of GE toxicity have been reported in patients receiving concomitant DRUG1 and DRUG2 therapy.
LABEL>1
If a DRUG1 is also used, it may increase the risk of DRUG2 toxicity.
LABEL>1
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of DRUG1 are the following: DRUG2, GE, GE, GE(1), GE, GE, GE, GE, GE(1), GE, GE, grapefruit juice, GE, GE, GE, GE, GE, GE, GE, GE, GE, GE, GE, GE, GE(1), GE, GE.
LABEL>1
Agents with Increased Levels in the Presence of GE: DRUG1 increases the plasma levels of the following agents: DRUG2, GE(6), and GE Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with GE, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.
LABEL>1
Agents with Increased Levels in the Presence of GE: DRUG1 increases the plasma levels of the following agents: GE, DRUG2(6), and GE Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with GE, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.
LABEL>1
Agents with Increased Levels in the Presence of GE: DRUG1 increases the plasma levels of the following agents: GE, GE(6), and DRUG2 Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with GE, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.
LABEL>1
Pharmacological/Pharmacodynamic Interactions with GE Concomitant administration of DRUG1 and DRUG2 may increase the risk of neurotoxic side effects.
LABEL>1
Additionally, DRUG1, such as GE and GE, may antagonize the activity of DRUG2.
LABEL>1
Additionally, GE, such as DRUG1 and GE, may antagonize the activity of DRUG2.
LABEL>1
Additionally, GE, such as GE and DRUG1, may antagonize the activity of DRUG2.
LABEL>1
Because of its primary CNS effect, caution should be used when DRUG1 is taken with other DRUG2 and GE.
LABEL>1
Because of its primary CNS effect, caution should be used when DRUG1 is taken with other GE and DRUG2.
LABEL>1
DRUG1 (GE) blood levels may be increased and prolonged by concurrent administration of DRUG2.
LABEL>1
GE (DRUG1) blood levels may be increased and prolonged by concurrent administration of DRUG2.
LABEL>1
DRUG1 (e.g., GE, GE, GE) and GE may reduce the therapeutic effects of DRUG2.
LABEL>1
GE (e.g., DRUG1, GE, GE) and GE may reduce the therapeutic effects of DRUG2.
LABEL>1
GE (e.g., GE, DRUG1, GE) and GE may reduce the therapeutic effects of DRUG2.
LABEL>1
GE (e.g., GE, GE, DRUG1) and GE may reduce the therapeutic effects of DRUG2.
LABEL>1
GE (e.g., GE, GE, GE) and DRUG1 may reduce the therapeutic effects of DRUG2.
LABEL>1
In addition, the beneficial effects of DRUG1 in Parkinsons disease have been reported to be reversed by DRUG2 and GE.
LABEL>1
In addition, the beneficial effects of DRUG1 in Parkinsons disease have been reported to be reversed by GE and DRUG2.
LABEL>1
DRUG1 salts may reduce the bioavailability of DRUG2 and GE.
LABEL>1
DRUG1 salts may reduce the bioavailability of GE and DRUG2.
LABEL>1
Although DRUG1 may increase the bioavailability of DRUG2 by increasing gastric emptying, GE may also adversely affect disease control by its dopamine receptor antagonistic properties.
LABEL>1
DRUG1 or GE excess may decrease the effect of DRUG2, and an GE deficiency can increase the effect of GE.
LABEL>1
GE or GE excess may decrease the effect of GE, and an DRUG1 deficiency can increase the effect of DRUG2.
LABEL>1
Serum concentration of DRUG1 and GE may increase when patients take DRUG2.
LABEL>1
Serum concentration of GE and DRUG1 may increase when patients take DRUG2.
LABEL>1
DRUG1 may decrease thyroidal uptake of DRUG2, a rebound in uptake may occur up to 5 days after sudden withdrawal of GE.
LABEL>1
DRUG1 may enhance the effects of DRUG2, GE, GE, and other GE.
LABEL>1
DRUG1 may enhance the effects of GE, DRUG2, GE, and other GE.
LABEL>1
DRUG1 may enhance the effects of GE, GE, DRUG2, and other GE.
LABEL>1
DRUG1 may enhance the effects of GE, GE, GE, and other DRUG2.
LABEL>1
DRUG1 prolong and intensify the anticholinergic effects of DRUG2.
LABEL>1
DRUG1 may reduce the antihypertensive effects of DRUG2, GE, GE and GE.
LABEL>1
DRUG1 may reduce the antihypertensive effects of GE, DRUG2, GE and GE.
LABEL>1
DRUG1 may reduce the antihypertensive effects of GE, GE, DRUG2 and GE.
LABEL>1
DRUG1 may reduce the antihypertensive effects of GE, GE, GE and DRUG2.
LABEL>1
Effects of DRUG1 are increased with DRUG2 and GE.
LABEL>1
Effects of DRUG1 are increased with GE and DRUG2.
LABEL>1
DRUG1 may augment the activity of other DRUG2.
LABEL>1
DRUG1 should be used with caution in patients who are receiving a DRUG2 orally because of the potential for additive effects on systemic beta-blockade.
LABEL>1
Close observation of the patient is recommended when a DRUG1 is administered to patients receiving catecholamine-depleting drugs such as DRUG2, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.
LABEL>1
poor metabolizers of GE: Interactions of GE with strong inhibitors of CYP2D6 (such as DRUG1, GE, GE, and GE) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of DRUG2 .
LABEL>1
poor metabolizers of GE: Interactions of GE with strong inhibitors of CYP2D6 (such as GE, DRUG1, GE, and GE) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of DRUG2 .
LABEL>1
poor metabolizers of GE: Interactions of GE with strong inhibitors of CYP2D6 (such as GE, GE, DRUG1, and GE) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of DRUG2 .
LABEL>1
poor metabolizers of GE: Interactions of GE with strong inhibitors of CYP2D6 (such as GE, GE, GE, and DRUG1) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of DRUG2 .
LABEL>1
Catecholamine-depleting Agents: Patients taking both DRUG1 and a drug that can deplete catecholamines (e.g., DRUG2 and GE) should be observed closely for signs of hypotension and/or severe bradycardia.
LABEL>1
Catecholamine-depleting Agents: Patients taking both DRUG1 and a drug that can deplete catecholamines (e.g., GE and DRUG2) should be observed closely for signs of hypotension and/or severe bradycardia.
LABEL>1
GE: Concomitant administration of DRUG1 with DRUG2 may potentiate blood-pressure- and heart-rate-lowering effects.
LABEL>1
When concomitant treatment with DRUG1 and DRUG2 is to be terminated, the GE should be discontinued first.
LABEL>1
GE: Modest increases in mean trough DRUG1 concentrations were observed following initiation of DRUG2 treatment in 21 renal transplant patients suffering from chronic vascular rejection.
LABEL>1
Due to wide interindividual variability in the dose adjustment required, it is recommended that DRUG1 concentrations be monitored closely after initiation of DRUG2 therapy and that the dose of GE be adjusted as appropriate.
LABEL>1
Due to wide interindividual variability in the dose adjustment required, it is recommended that GE concentrations be monitored closely after initiation of DRUG1 therapy and that the dose of DRUG2 be adjusted as appropriate.
LABEL>1
GE: GE concentrations are increased by about 15% when DRUG1 and DRUG2 are administered concomitantly.
LABEL>1
Both DRUG1 and DRUG2 slow AV conduction.
LABEL>1
Therefore, increased monitoring of DRUG1 is recommended when initiating, adjusting, or discontinuing DRUG2.
LABEL>1
Inducers and Inhibitors of Hepatic Metabolism: DRUG1 reduced plasma concentrations of DRUG2 by about 70%.
LABEL>1
GE: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when DRUG1 is co-administered with DRUG2.
LABEL>1
As with other GE, if DRUG1 is to be administered orally with GE of the DRUG2 or GE type, it is recommended that ECG and blood pressure be monitored.
LABEL>1
As with other GE, if DRUG1 is to be administered orally with GE of the GE or DRUG2 type, it is recommended that ECG and blood pressure be monitored.
LABEL>1
GE or Oral GE: DRUG1 may enhance the blood-sugar-reducing effect of DRUG2 and oral GE.
LABEL>1
GE or Oral GE: DRUG1 may enhance the blood-sugar-reducing effect of GE and oral DRUG2.
LABEL>1
DRUG1 reduced the blood AUC0-12 of DRUG2 by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when GE (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of GE 70 mg daily, as compared to results from a control period in which GE was administered alone.
LABEL>1
In two clinical studies, DRUG1 (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of DRUG2 by approximately 35%.
LABEL>1
There were transient increases in liver ALT and AST when DRUG1 and DRUG2 were co-administered.
LABEL>1
A drug-drug interaction study with DRUG1 in healthy volunteers has shown a 30% decrease in DRUG2 trough concentrations.
LABEL>1
Patients on DRUG1 should receive 70 mg of DRUG2 daily.
LABEL>1
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (DRUG1, GE, GE, GE, or GE) with DRUG2 may result in clinically meaningful reductions in GE concentrations.
LABEL>1
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (GE, DRUG1, GE, GE, or GE) with DRUG2 may result in clinically meaningful reductions in GE concentrations.
LABEL>1
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (GE, GE, DRUG1, GE, or GE) with DRUG2 may result in clinically meaningful reductions in GE concentrations.
LABEL>1
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (GE, GE, GE, DRUG1, or GE) with DRUG2 may result in clinically meaningful reductions in GE concentrations.
LABEL>1
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (GE, GE, GE, GE, or DRUG1) with DRUG2 may result in clinically meaningful reductions in GE concentrations.
LABEL>1
When DRUG1 is co-administered with inducers of drug clearance, such as DRUG2, GE, GE, GE, or GE, use of a daily dose of 70 mg of GE should be considered
LABEL>1
When DRUG1 is co-administered with inducers of drug clearance, such as GE, DRUG2, GE, GE, or GE, use of a daily dose of 70 mg of GE should be considered
LABEL>1
When DRUG1 is co-administered with inducers of drug clearance, such as GE, GE, DRUG2, GE, or GE, use of a daily dose of 70 mg of GE should be considered
LABEL>1
When DRUG1 is co-administered with inducers of drug clearance, such as GE, GE, GE, DRUG2, or GE, use of a daily dose of 70 mg of GE should be considered
LABEL>1
When DRUG1 is co-administered with inducers of drug clearance, such as GE, GE, GE, GE, or DRUG2, use of a daily dose of 70 mg of GE should be considered
LABEL>1
DRUG1 may decrease renal tubular secretion of DRUG2 when used concurrently, resulting in increased and more prolonged GE blood levels.
LABEL>1
GE (GE- or GE-containing): Concomitant administration of 300-mg DRUG1 capsules with 30 mL DRUG2 suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.
LABEL>1
If GE are required during GE therapy, DRUG1 should be taken at least 2 hours before or after the DRUG2.
LABEL>1
GE: As with other DRUG1, GE inhibits the renal excretion of DRUG2, resulting in an approximate doubling in A.C. a 54% increase in peak GE plasma levels, and a 50% prolongation in the apparent elimination half-life.
LABEL>1
GE: As with other GE, DRUG1 inhibits the renal excretion of DRUG2, resulting in an approximate doubling in A.C. a 54% increase in peak GE plasma levels, and a 50% prolongation in the apparent elimination half-life.
LABEL>1
GE and Foods Fortified With GE Concomitant administration of DRUG1 with a therapeutic GE containing 60 mg of elemental DRUG2 (as FeSO4) or GE supplemented with 10 mg of elemental GE reduced extent of absorption by 80% and 31%, respectively.
LABEL>1
GE and Foods Fortified With GE Concomitant administration of DRUG1 with a therapeutic GE containing 60 mg of elemental GE (as FeSO4) or GE supplemented with 10 mg of elemental DRUG2 reduced extent of absorption by 80% and 31%, respectively.
LABEL>1
If DRUG1 are required during GE therapy, DRUG2 should be taken at least 2 hours before or after the supplement.
LABEL>1
The reddish color is due to the formation of a nonabsorbable complex between DRUG1 or its breakdown products and DRUG2 in the gastrointestinal tract.
LABEL>1
Although the clinical significance is not known, it is not recommended that DRUG1 be taken concomitantly with DRUG2.
LABEL>1
GE: Co-administration of a single dose of intravenously administered DRUG1 (20 mg) reduced the oral absorption of a single 400 mg dose of DRUG2 administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.
LABEL>1
GE: As with other DRUG1, co-administration of GE with DRUG2 resulted in an increase in the plasma exposure of GE, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.
LABEL>1
GE: As with other GE, co-administration of DRUG1 with DRUG2 resulted in an increase in the plasma exposure of GE, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.
LABEL>1
Renal function should be monitored carefully if high doses of DRUG1 are to be administered with DRUG2 because of the increased potential of nephrotoxicity and ototoxicity of GE.
LABEL>1
Nephrotoxicity has been reported following concomitant administration of other DRUG1 with potent DRUG2 such as GE.
LABEL>1
Nephrotoxicity has been reported following concomitant administration of other DRUG1 with potent GE such as DRUG2.
LABEL>1
GE: Elevated DRUG1 levels have been reported in postmarketing experience when DRUG2 is administered concomitantly.
LABEL>1
DRUG1 and GE: Increased prothrombin time, with or without clinical bleeding, has been reported when DRUG2 is administered concomitantly.
LABEL>1
GE and DRUG1: Increased prothrombin time, with or without clinical bleeding, has been reported when DRUG2 is administered concomitantly.
LABEL>1
Increased nephrotoxicity has been reported following concomitant administration of DRUG1 and DRUG2.
LABEL>1
If DRUG1 and an DRUG2 are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.
LABEL>1
Increased nephrotoxicity has been reported following concomitant administration of DRUG1 and DRUG2.
LABEL>1
Nephrotoxicity has been reported following concomitant administration of DRUG1 and DRUG2.
LABEL>1
Concomitant administration of DRUG1 doubled the AUC for DRUG2.
LABEL>1
Nephrotoxicity has been reported following concomitant administration of DRUG1 with DRUG2 or potent GE such as GE.
LABEL>1
Nephrotoxicity has been reported following concomitant administration of DRUG1 with GE or potent DRUG2 such as GE.
LABEL>1
Nephrotoxicity has been reported following concomitant administration of DRUG1 with GE or potent GE such as DRUG2.
LABEL>1
DRUG1 has been shown to be antagonistic to DRUG2, including GE, based on in vitro studies and time kill curves with enteric gram-negative bacilli.
LABEL>1
DRUG1 has been shown to be antagonistic to GE, including DRUG2, based on in vitro studies and time kill curves with enteric gram-negative bacilli.
LABEL>1
however, 150 mg of DRUG1 q12h for 3 days increased the DRUG2 C max by 23% and GE AUC by 16%.
LABEL>1
however, 150 mg of DRUG1 q12h for 3 days increased the GE C max by 23% and DRUG2 AUC by 16%.
LABEL>1
Although the occurrence has not been reported with GE, nephrotoxicity has been reported following concomitant administration of other DRUG1 and DRUG2.
LABEL>1
Clinical studies with DRUG1 have identified potentially significant interactions with DRUG2 and GE.
LABEL>1
Clinical studies with DRUG1 have identified potentially significant interactions with GE and DRUG2.
LABEL>1
Experience with DRUG1 (GE) suggests the potential for interactions with DRUG2 and GE.
LABEL>1
Experience with DRUG1 (GE) suggests the potential for interactions with GE and DRUG2.
LABEL>1
Experience with GE (DRUG1) suggests the potential for interactions with DRUG2 and GE.
LABEL>1
Experience with GE (DRUG1) suggests the potential for interactions with GE and DRUG2.
LABEL>1
GE: Reports suggest that DRUG1 may diminish the antihypertensive effect of DRUG2.
LABEL>1
This interaction should be given consideration in patients taking DRUG1 concomitantly with DRUG2.
LABEL>1
GE: Clinical studies, as well as post marketing observations, have shown that DRUG1 can reduce the natriuretic effect of DRUG2 and GE in some patients.
LABEL>1
GE: Clinical studies, as well as post marketing observations, have shown that DRUG1 can reduce the natriuretic effect of GE and DRUG2 in some patients.
LABEL>1
GE: DRUG1 can be used with low dose DRUG2.
LABEL>1
However, concomitant administration of DRUG1 with DRUG2 may result in an increased rate of GI ulceration or other complications, compared to use of GE alone.
LABEL>1
GE: Concomitant administration of DRUG1 at 200 mg QD resulted in a two-fold increase in DRUG2 plasma concentration.
LABEL>1
This increase is due to the inhibition of DRUG1 metabolism via P450 2C9 by DRUG2 (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).
LABEL>1
DRUG1 should be introduced at the lowest recommended dose in patients receiving DRUG2.
LABEL>1
GE: In a study conducted in healthy subjects, mean steady-state GE plasma levels increased approximately 17% in subjects receiving DRUG1 450 mg BID with DRUG2 200 mg BID as compared to subjects receiving GE alone.
LABEL>1
Patients on DRUG1 treatment should be closely monitored when DRUG2 is introduced or withdrawn.
LABEL>1
However, caution should be used when administering DRUG1 with DRUG2 since these patients are at increased risk of bleeding complications.
LABEL>1
GE: In healthy subjects given single 500 mg doses of DRUG1 and DRUG2, plasma GE mean cmax and AUC increased by an average of 34% and 24%, respectively, and GE mean renal clearance decreased by 14%.
LABEL>1
Although not observed in this study, adverse effects could potentially arise from co-administration of DRUG1 and DRUG2 by inhibition of tubular secretion via organic cationic transporter systems.
LABEL>1
Accordingly, careful patient monitoring and dose adjustment of GE is recommended in patients concomitantly taking DRUG1 and DRUG2.
LABEL>1
GE: As with other GE, the renal excretion of DRUG1 is inhibited by DRUG2.
LABEL>1
In the first study, concomitant administration of 0.2 mg DRUG1 and 12 g DRUG2 resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing GE alone.
LABEL>1
However, in the second study, administration of 12 g DRUG1 1 hour before the evening meal and 0.3 mg DRUG2 approximately 4 hours after the same evening meal resulted in a decrease in the GE AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing GE alone.
LABEL>1
GE: In hypercholesterolemic patients, steady-state DRUG1 AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of DRUG2, a known inhibitor of cytochrome P450 3A4.
LABEL>1
In a multiple dose study of DRUG1 (400 mg once daily for 3 days) and DRUG2 (20 mg once daily for 3 days), a 16% decrease in the clearance of GE was observed.
LABEL>1
There was a small decrease in the clearance of DRUG1 caused by a 400-mg dose of DRUG2;
LABEL>1
DRUG1 should be administered with caution to patients taking DRUG2, because of the possibility of conduction disturbances.
LABEL>1
Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral DRUG1 and DRUG2.
LABEL>1
The administration of local DRUG1 containing GE or GE to patients receiving GE, DRUG2 or GE may produce severe, prolonged hypotension or hypertension.
LABEL>1
The administration of local DRUG1 containing GE or GE to patients receiving GE, GE or DRUG2 may produce severe, prolonged hypotension or hypertension.
LABEL>1
The administration of local GE containing DRUG1 or GE to patients receiving DRUG2, GE or GE may produce severe, prolonged hypotension or hypertension.
LABEL>1
The administration of local GE containing DRUG1 or GE to patients receiving GE, DRUG2 or GE may produce severe, prolonged hypotension or hypertension.
LABEL>1
The administration of local GE containing DRUG1 or GE to patients receiving GE, GE or DRUG2 may produce severe, prolonged hypotension or hypertension.
LABEL>1
The administration of local GE containing GE or DRUG1 to patients receiving DRUG2, GE or GE may produce severe, prolonged hypotension or hypertension.
LABEL>1
The administration of local GE containing GE or DRUG1 to patients receiving GE, DRUG2 or GE may produce severe, prolonged hypotension or hypertension.
LABEL>1
The administration of local GE containing GE or DRUG1 to patients receiving GE, GE or DRUG2 may produce severe, prolonged hypotension or hypertension.
LABEL>1
Concurrent administration of DRUG1 (for the treatment of hypotension related to obstetric blocks) and DRUG2 may cause severe, persistent hypertension or cerebrovascular accidents.
LABEL>1
Therefore, DRUG1 should not be used in any condition in which a DRUG2 is being employed.
LABEL>1
GE and GE: DRUG1 and GE can reduce absorption of DRUG2;
LABEL>1
GE and GE: GE and DRUG1 can reduce absorption of DRUG2;
LABEL>1
GE: DRUG1 can inhibit the metabolism of DRUG2, increasing its plasma level.
LABEL>1
GE: In a study of healthy volunteers, DRUG1 significantly reduced the bioavailability of DRUG2.
LABEL>1
GE: After introduction of DRUG1 (oral form), a sudden increase in serum DRUG2 level has been reported.
LABEL>1
- GE and GE GE: DRUG1 and GE GE have the potential of binding DRUG2 and reducing GE absorption from the gastrointestinal tract
LABEL>1
- GE and GE GE: GE and DRUG1 GE have the potential of binding DRUG2 and reducing GE absorption from the gastrointestinal tract
LABEL>1
- DRUG1: Generally should not be given with DRUG2.
LABEL>1
DRUG1 reduce the renal clearance of DRUG2 and add a high risk of GE toxicity.
LABEL>1
DRUG1 reduce the renal clearance of GE and add a high risk of DRUG2 toxicity.
LABEL>1
Refer to the package insert for DRUG1 preparations before use of such preparations with DRUG2
LABEL>1
- GE: In some patients, the administration of a DRUG1 can reduce the diuretic, natriuretic, and antihypertensive effects of DRUG2, GE and GE.
LABEL>1
- GE: In some patients, the administration of a DRUG1 can reduce the diuretic, natriuretic, and antihypertensive effects of GE, DRUG2 and GE.
LABEL>1
- GE: In some patients, the administration of a DRUG1 can reduce the diuretic, natriuretic, and antihypertensive effects of GE, GE and DRUG2.
LABEL>1
Therefore, when DRUG1 and DRUG2 are used concomitantly, the patient should be observed closely to determine if the desired effect of the GE is obtained
LABEL>1
DRUG1 may interact with DRUG2, GE, GE, GE, GE supplements, GE, GE, GE, GE, GE, GE, GE, and GE.
LABEL>1
DRUG1 may interact with GE, DRUG2, GE, GE, GE supplements, GE, GE, GE, GE, GE, GE, GE, and GE.
LABEL>1
DRUG1 may interact with GE, GE, DRUG2, GE, GE supplements, GE, GE, GE, GE, GE, GE, GE, and GE.
LABEL>1
DRUG1 may interact with GE, GE, GE, DRUG2, GE supplements, GE, GE, GE, GE, GE, GE, GE, and GE.
LABEL>1
DRUG1 may interact with GE, GE, GE, GE, DRUG2 supplements, GE, GE, GE, GE, GE, GE, GE, and GE.
LABEL>1
DRUG1 may interact with GE, GE, GE, GE, GE supplements, DRUG2, GE, GE, GE, GE, GE, GE, and GE.
LABEL>1
DRUG1 may interact with GE, GE, GE, GE, GE supplements, GE, DRUG2, GE, GE, GE, GE, GE, and GE.
LABEL>1
DRUG1 may interact with GE, GE, GE, GE, GE supplements, GE, GE, DRUG2, GE, GE, GE, GE, and GE.
LABEL>1
DRUG1 may interact with GE, GE, GE, GE, GE supplements, GE, GE, GE, DRUG2, GE, GE, GE, and GE.
LABEL>1
DRUG1 may interact with GE, GE, GE, GE, GE supplements, GE, GE, GE, GE, DRUG2, GE, GE, and GE.
LABEL>1
DRUG1 may interact with GE, GE, GE, GE, GE supplements, GE, GE, GE, GE, GE, DRUG2, GE, and GE.
LABEL>1
DRUG1 may interact with GE, GE, GE, GE, GE supplements, GE, GE, GE, GE, GE, GE, DRUG2, and GE.
LABEL>1
DRUG1 may interact with GE, GE, GE, GE, GE supplements, GE, GE, GE, GE, GE, GE, GE, and DRUG2.
LABEL>1
The concurrent use of two or more drugs with anticholinergic activity--such as an DRUG1 (eg, GE), an DRUG2 (eg, GE), and/or a GE (eg, GE)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
LABEL>1
The concurrent use of two or more drugs with anticholinergic activity--such as an DRUG1 (eg, GE), an GE (eg, DRUG2), and/or a GE (eg, GE)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
LABEL>1
The concurrent use of two or more drugs with anticholinergic activity--such as an DRUG1 (eg, GE), an GE (eg, GE), and/or a DRUG2 (eg, GE)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
LABEL>1
The concurrent use of two or more drugs with anticholinergic activity--such as an DRUG1 (eg, GE), an GE (eg, GE), and/or a GE (eg, DRUG2)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
LABEL>1
The concurrent use of two or more drugs with anticholinergic activity--such as an GE (eg, DRUG1), an DRUG2 (eg, GE), and/or a GE (eg, GE)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
LABEL>1
The concurrent use of two or more drugs with anticholinergic activity--such as an GE (eg, DRUG1), an GE (eg, DRUG2), and/or a GE (eg, GE)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
LABEL>1
The concurrent use of two or more drugs with anticholinergic activity--such as an GE (eg, DRUG1), an GE (eg, GE), and/or a DRUG2 (eg, GE)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
LABEL>1
The concurrent use of two or more drugs with anticholinergic activity--such as an GE (eg, DRUG1), an GE (eg, GE), and/or a GE (eg, DRUG2)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
LABEL>1
The concurrent use of two or more drugs with anticholinergic activity--such as an GE (eg, GE), an DRUG1 (eg, GE), and/or a DRUG2 (eg, GE)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
LABEL>1
The concurrent use of two or more drugs with anticholinergic activity--such as an GE (eg, GE), an DRUG1 (eg, GE), and/or a GE (eg, DRUG2)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
LABEL>1
The concurrent use of two or more drugs with anticholinergic activity--such as an GE (eg, GE), an GE (eg, DRUG1), and/or a DRUG2 (eg, GE)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
LABEL>1
The concurrent use of two or more drugs with anticholinergic activity--such as an GE (eg, GE), an GE (eg, DRUG1), and/or a GE (eg, DRUG2)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.
LABEL>1
The hypoglycemic action of DRUG1 may be potentiated by certain drugs including DRUG2 and other drugs that are highly protein bound, GE, GE, GE, GE, GE, GE, and GE.
LABEL>1
The hypoglycemic action of DRUG1 may be potentiated by certain drugs including GE and other drugs that are highly protein bound, DRUG2, GE, GE, GE, GE, GE, and GE.
LABEL>1
The hypoglycemic action of DRUG1 may be potentiated by certain drugs including GE and other drugs that are highly protein bound, GE, DRUG2, GE, GE, GE, GE, and GE.
LABEL>1
The hypoglycemic action of DRUG1 may be potentiated by certain drugs including GE and other drugs that are highly protein bound, GE, GE, DRUG2, GE, GE, GE, and GE.
LABEL>1
The hypoglycemic action of DRUG1 may be potentiated by certain drugs including GE and other drugs that are highly protein bound, GE, GE, GE, DRUG2, GE, GE, and GE.
LABEL>1
The hypoglycemic action of DRUG1 may be potentiated by certain drugs including GE and other drugs that are highly protein bound, GE, GE, GE, GE, DRUG2, GE, and GE.
LABEL>1
The hypoglycemic action of DRUG1 may be potentiated by certain drugs including GE and other drugs that are highly protein bound, GE, GE, GE, GE, GE, DRUG2, and GE.
LABEL>1
The hypoglycemic action of DRUG1 may be potentiated by certain drugs including GE and other drugs that are highly protein bound, GE, GE, GE, GE, GE, GE, and DRUG2.
LABEL>1
Since animal studies suggest that the action of DRUG1 may be prolonged by therapy with DRUG2, GE should be employed with caution.
LABEL>1
A potential interaction between oral DRUG1 and oral DRUG2 leading to severe hypoglycemia has been reported.
LABEL>1
DRUG1 may increase the plasma-level of concomitantly given DRUG2.
LABEL>1
If DRUG1 is given concomitantly with DRUG2, the GE dose should be reduced (by approx. 50%), because GE amplifies the therapeutic actions and side-effects of GE massively.
LABEL>1
If GE is given concomitantly with GE, the GE dose should be reduced (by approx. 50%), because DRUG1 amplifies the therapeutic actions and side-effects of DRUG2 massively.
LABEL>1
Avoid the concomitant use of DRUG1 and DRUG2 (GE).
LABEL>1
Avoid the concomitant use of DRUG1 and GE (DRUG2).
LABEL>1
Consider additive sedative effects and confusional states to emerge, if DRUG1 is given with DRUG2 or GE.
LABEL>1
Consider additive sedative effects and confusional states to emerge, if DRUG1 is given with GE or DRUG2.
LABEL>1
Exert particular caution in combining DRUG1 with other DRUG2 (GE and GE): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
LABEL>1
Exert particular caution in combining DRUG1 with other GE (DRUG2 and GE): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
LABEL>1
Exert particular caution in combining DRUG1 with other GE (GE and DRUG2): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
LABEL>1
DRUG1 may add to or potentiate the action of other DRUG2.
LABEL>1
DRUG1 and related drugs may increase the responsiveness to DRUG2.
LABEL>1
DRUG1 and related drugs may decrease arterial responsiveness to DRUG2.
LABEL>1
Interactions for GE analogues (GE, GE, GE, and GE): GE: DRUG1 has been reported to reduce intestinal absorption of DRUG2;
LABEL>1
Some reports have shown that the concomitant administration of DRUG1 with DRUG2 causes hypercalcemia.
LABEL>1
GE: DRUG1 dosage must be determined with care in patients undergoing treatment with DRUG2, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
LABEL>1
GE: DRUG1 may inhibit both synthetic and catabolic enzymes of DRUG2.
LABEL>1
GE: A relationship of functional antagonism exists between DRUG1 analogues, which promote calcium absorption, and DRUG2, which inhibit calcium absorption.
LABEL>1
GE: DRUG1-containing preparations (eg, GE) may cause hypermagnesemia and should therefore not be taken during therapy with DRUG2 by patients on chronic renal dialysis.
LABEL>1
GE: GE-containing preparations (eg, DRUG1) may cause hypermagnesemia and should therefore not be taken during therapy with DRUG2 by patients on chronic renal dialysis.
LABEL>1
DRUG1 GE may delay or reduce the absorption of concomitant oral medication such as DRUG2, GE, GE (acidic) or GE (basic), as well as GE GE, GE, thyroid and GE preparations, GE and GE, and GE.
LABEL>1
DRUG1 GE may delay or reduce the absorption of concomitant oral medication such as GE, DRUG2, GE (acidic) or GE (basic), as well as GE GE, GE, thyroid and GE preparations, GE and GE, and GE.
LABEL>1
DRUG1 GE may delay or reduce the absorption of concomitant oral medication such as GE, GE, DRUG2 (acidic) or GE (basic), as well as GE GE, GE, thyroid and GE preparations, GE and GE, and GE.
LABEL>1
DRUG1 GE may delay or reduce the absorption of concomitant oral medication such as GE, GE, GE (acidic) or DRUG2 (basic), as well as GE GE, GE, thyroid and GE preparations, GE and GE, and GE.
LABEL>1
DRUG1 GE may delay or reduce the absorption of concomitant oral medication such as GE, GE, GE (acidic) or GE (basic), as well as DRUG2 GE, GE, thyroid and GE preparations, GE and GE, and GE.
LABEL>1
DRUG1 GE may delay or reduce the absorption of concomitant oral medication such as GE, GE, GE (acidic) or GE (basic), as well as GE DRUG2, GE, thyroid and GE preparations, GE and GE, and GE.
LABEL>1
DRUG1 GE may delay or reduce the absorption of concomitant oral medication such as GE, GE, GE (acidic) or GE (basic), as well as GE GE, DRUG2, thyroid and GE preparations, GE and GE, and GE.
LABEL>1
DRUG1 GE may delay or reduce the absorption of concomitant oral medication such as GE, GE, GE (acidic) or GE (basic), as well as GE GE, GE, thyroid and DRUG2 preparations, GE and GE, and GE.
LABEL>1
DRUG1 GE may delay or reduce the absorption of concomitant oral medication such as GE, GE, GE (acidic) or GE (basic), as well as GE GE, GE, thyroid and GE preparations, DRUG2 and GE, and GE.
LABEL>1
DRUG1 GE may delay or reduce the absorption of concomitant oral medication such as GE, GE, GE (acidic) or GE (basic), as well as GE GE, GE, thyroid and GE preparations, GE and DRUG2, and GE.
LABEL>1
DRUG1 GE may delay or reduce the absorption of concomitant oral medication such as GE, GE, GE (acidic) or GE (basic), as well as GE GE, GE, thyroid and GE preparations, GE and GE, and DRUG2.
LABEL>1
GE GE may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of DRUG1 GE could pose a hazard to health if a potentially toxic drug such as DRUG2 has been filtrated to a maintenance level while the patient was taking GE GE.
LABEL>1
In another drug interaction study, co-administration of orally inhaled DRUG1 and oral DRUG2, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of GE by approximately 3.6-fold at steady state, while levels of GE remained unchanged.
LABEL>1
Therefore, DRUG1 should be administered with caution with intranasal DRUG2.
LABEL>1
GE : DRUG1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., DRUG2, GE, GE, GE, GE, GE, GE, GE, GE, GE, GE, GE agents, GE, and GE).
LABEL>1
GE : DRUG1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., GE, DRUG2, GE, GE, GE, GE, GE, GE, GE, GE, GE, GE agents, GE, and GE).
LABEL>1
GE : DRUG1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., GE, GE, DRUG2, GE, GE, GE, GE, GE, GE, GE, GE, GE agents, GE, and GE).
LABEL>1
GE : DRUG1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., GE, GE, GE, DRUG2, GE, GE, GE, GE, GE, GE, GE, GE agents, GE, and GE).
LABEL>1
GE : DRUG1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., GE, GE, GE, GE, DRUG2, GE, GE, GE, GE, GE, GE, GE agents, GE, and GE).
LABEL>1
GE : DRUG1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., GE, GE, GE, GE, GE, DRUG2, GE, GE, GE, GE, GE, GE agents, GE, and GE).
LABEL>1
GE : DRUG1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., GE, GE, GE, GE, GE, GE, DRUG2, GE, GE, GE, GE, GE agents, GE, and GE).
LABEL>1
GE : DRUG1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., GE, GE, GE, GE, GE, GE, GE, DRUG2, GE, GE, GE, GE agents, GE, and GE).
LABEL>1
GE : DRUG1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., GE, GE, GE, GE, GE, GE, GE, GE, DRUG2, GE, GE, GE agents, GE, and GE).
LABEL>1
GE : DRUG1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., GE, GE, GE, GE, GE, GE, GE, GE, GE, DRUG2, GE, GE agents, GE, and GE).
LABEL>1
GE : DRUG1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., GE, GE, GE, GE, GE, GE, GE, GE, GE, GE, DRUG2, GE agents, GE, and GE).
LABEL>1
GE : DRUG1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., GE, GE, GE, GE, GE, GE, GE, GE, GE, GE, GE, DRUG2 agents, GE, and GE).
LABEL>1
GE : DRUG1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., GE, GE, GE, GE, GE, GE, GE, GE, GE, GE, GE, GE agents, DRUG2, and GE).
LABEL>1
GE : DRUG1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., GE, GE, GE, GE, GE, GE, GE, GE, GE, GE, GE, GE agents, GE, and DRUG2).
LABEL>1
DRUG1 should either be temporarily discontinued or decreased by 50% when coadministered with DRUG2 on the day of GE infusion.
LABEL>1
Nephrotoxic agents : Concomitant administration of DRUG1 and agents with nephrotoxic potential [e.g., intravenous DRUG2 (e.g., GE, GE, and GE), GE, GE, intravenous GE, GE, and GE] is contraindicated.
LABEL>1
Nephrotoxic agents : Concomitant administration of DRUG1 and agents with nephrotoxic potential [e.g., intravenous GE (e.g., DRUG2, GE, and GE), GE, GE, intravenous GE, GE, and GE] is contraindicated.
LABEL>1
Nephrotoxic agents : Concomitant administration of DRUG1 and agents with nephrotoxic potential [e.g., intravenous GE (e.g., GE, DRUG2, and GE), GE, GE, intravenous GE, GE, and GE] is contraindicated.
LABEL>1
Nephrotoxic agents : Concomitant administration of DRUG1 and agents with nephrotoxic potential [e.g., intravenous GE (e.g., GE, GE, and DRUG2), GE, GE, intravenous GE, GE, and GE] is contraindicated.
LABEL>1
Nephrotoxic agents : Concomitant administration of DRUG1 and agents with nephrotoxic potential [e.g., intravenous GE (e.g., GE, GE, and GE), DRUG2, GE, intravenous GE, GE, and GE] is contraindicated.
LABEL>1
Nephrotoxic agents : Concomitant administration of DRUG1 and agents with nephrotoxic potential [e.g., intravenous GE (e.g., GE, GE, and GE), GE, DRUG2, intravenous GE, GE, and GE] is contraindicated.
LABEL>1
Nephrotoxic agents : Concomitant administration of DRUG1 and agents with nephrotoxic potential [e.g., intravenous GE (e.g., GE, GE, and GE), GE, GE, intravenous DRUG2, GE, and GE] is contraindicated.
LABEL>1
Nephrotoxic agents : Concomitant administration of DRUG1 and agents with nephrotoxic potential [e.g., intravenous GE (e.g., GE, GE, and GE), GE, GE, intravenous GE, DRUG2, and GE] is contraindicated.
LABEL>1
Nephrotoxic agents : Concomitant administration of DRUG1 and agents with nephrotoxic potential [e.g., intravenous GE (e.g., GE, GE, and GE), GE, GE, intravenous GE, GE, and DRUG2] is contraindicated.
LABEL>1
Since GE is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when DRUG1 is coadministered with inhibitors of C.P.A. such as DRUG2 and GE or inhibitors of CYP2C19 such as GE.
LABEL>1
Since GE is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when DRUG1 is coadministered with inhibitors of C.P.A. such as GE and DRUG2 or inhibitors of CYP2C19 such as GE.
LABEL>1
Since GE is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when DRUG1 is coadministered with inhibitors of C.P.A. such as GE and GE or inhibitors of CYP2C19 such as DRUG2.
LABEL>1
Pharmacokinetic studies have demonstrated that DRUG1 and GE significantly increased the systemic exposure of DRUG2 and/or its major metabolites.
LABEL>1
Pharmacokinetic studies have demonstrated that GE and DRUG1 significantly increased the systemic exposure of DRUG2 and/or its major metabolites.
LABEL>1
Population pharmacokinetic studies showed higher concentrations of DRUG1 among patients concurrently treated with DRUG2, an inhibitor of C.P.A..
LABEL>1
DRUG1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of DRUG2, GE, GE, GE, GE, GE, certain GE, GE, GE and GE, thereby delaying elimination and increasing blood levels of these drugs.
LABEL>1
DRUG1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of GE, DRUG2, GE, GE, GE, GE, certain GE, GE, GE and GE, thereby delaying elimination and increasing blood levels of these drugs.
LABEL>1
DRUG1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of GE, GE, DRUG2, GE, GE, GE, certain GE, GE, GE and GE, thereby delaying elimination and increasing blood levels of these drugs.
LABEL>1
DRUG1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of GE, GE, GE, DRUG2, GE, GE, certain GE, GE, GE and GE, thereby delaying elimination and increasing blood levels of these drugs.
LABEL>1
DRUG1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of GE, GE, GE, GE, DRUG2, GE, certain GE, GE, GE and GE, thereby delaying elimination and increasing blood levels of these drugs.
LABEL>1
DRUG1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of GE, GE, GE, GE, GE, DRUG2, certain GE, GE, GE and GE, thereby delaying elimination and increasing blood levels of these drugs.
LABEL>1
DRUG1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of GE, GE, GE, GE, GE, GE, certain DRUG2, GE, GE and GE, thereby delaying elimination and increasing blood levels of these drugs.
LABEL>1
DRUG1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of GE, GE, GE, GE, GE, GE, certain GE, DRUG2, GE and GE, thereby delaying elimination and increasing blood levels of these drugs.
LABEL>1
DRUG1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of GE, GE, GE, GE, GE, GE, certain GE, GE, DRUG2 and GE, thereby delaying elimination and increasing blood levels of these drugs.
LABEL>1
DRUG1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of GE, GE, GE, GE, GE, GE, certain GE, GE, GE and DRUG2, thereby delaying elimination and increasing blood levels of these drugs.
LABEL>1
therefore, close monitoring of prothrombin time is recommended, and adjustment of the DRUG1 dose may be necessary when DRUG2 is administered concomitantly.
LABEL>1
However, a crossover study in healthy subjects receiving either DRUG1 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of DRUG2 (GE , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state GE peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.
LABEL>1
However, a crossover study in healthy subjects receiving either DRUG1 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of GE (DRUG2 , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state GE peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.
LABEL>1
GE: Concurrent administration of 25 mg or 100 mg DRUG1 with 50 mg DRUG2 increased GE exposure and GE (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.
LABEL>1
Co-administration of DRUG1, a strong inhibitor of CYP3A4, increased DRUG2 exposure following a single 90 mg dose of GE by 2.3 fold.
LABEL>1
Dose adjustment of DRUG1 may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., DRUG2, GE, GE;
LABEL>1
Dose adjustment of DRUG1 may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., GE, DRUG2, GE;
LABEL>1
Dose adjustment of DRUG1 may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., GE, GE, DRUG2;
LABEL>1
Elevated plasma levels of DRUG1 have been reported with concomitant use of some DRUG2.
LABEL>1
There have been reports of GE-related side-effects in patients on concomitant DRUG1-DRUG2 therapy.
LABEL>1
DRUG1 have also been shown to interfere with the metabolism of DRUG2.
LABEL>1
Although this interaction has not been reported with GE, caution should be exercised when DRUG1 is given concomitantly with DRUG2-containing products.
LABEL>1
DRUG1 or GE substantially interfere with the absorption of some DRUG2, resulting in low urine levels.
LABEL>1
GE or DRUG1 substantially interfere with the absorption of some DRUG2, resulting in low urine levels.
LABEL>1
Also, concomitant administration of DRUG1 with products containing DRUG2, GE containing GE, or GE (GE) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
LABEL>1
Also, concomitant administration of DRUG1 with products containing GE, GE containing DRUG2, or GE (GE) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
LABEL>1
Also, concomitant administration of DRUG1 with products containing GE, GE containing GE, or DRUG2 (GE) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
LABEL>1
Also, concomitant administration of DRUG1 with products containing GE, GE containing GE, or GE (DRUG2) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.
LABEL>1
DRUG1, including GE, may enhance the effects of oral DRUG2, such as GE or its derivatives.
LABEL>1
DRUG1, including GE, may enhance the effects of oral GE, such as DRUG2 or its derivatives.
LABEL>1
GE, including DRUG1, may enhance the effects of oral DRUG2, such as GE or its derivatives.
LABEL>1
GE, including DRUG1, may enhance the effects of oral GE, such as DRUG2 or its derivatives.
LABEL>1
Seizures have been reported in patients taking another DRUG1 and the DRUG2 GE concurrently.
LABEL>1
Seizures have been reported in patients taking another DRUG1 and the GE DRUG2 concurrently.
LABEL>1
Physicians are provided this information to increase awareness of the potential for serious interactions when DRUG1 and certain DRUG2 are administered concomitantly.
LABEL>1
Elevated GE serum levels have been reported with the concomitant use of DRUG1 and DRUG2.
LABEL>1
Some DRUG1, including GE, have also been shown to interfere with the metabolism of DRUG2.
LABEL>1
Some GE, including DRUG1, have also been shown to interfere with the metabolism of DRUG2.
LABEL>1
Some DRUG1, including GE, have been associated with transient elevations in serum creatinine in patients receiving DRUG2 concomitantly.
LABEL>1
Some GE, including DRUG1, have been associated with transient elevations in serum creatinine in patients receiving DRUG2 concomitantly.
LABEL>1
GE: The concomitant administration of DRUG1 with the DRUG2 GE has, on rare occasions, resulted in severe hypoglycemia.
LABEL>1
GE: The concomitant administration of DRUG1 with the GE DRUG2 has, on rare occasions, resulted in severe hypoglycemia.
LABEL>1
GE Renal tubular transport of DRUG1 may be inhibited by concomitant administration of DRUG2, potentially leading to increased plasma levels of GE.
LABEL>1
Therefore, patients under DRUG1 therapy should be carefully monitored when concomitant DRUG2 therapy is indicated.
LABEL>1
Multivalent Cation-Containing Products: Concurrent administration of a DRUG1, including GE, with multivalent cation-containing products such as DRUG2 or GE GE, GE, GE chewable/buffered tablets or pediatric powder, or products containing GE, GE, or GE may substantially decrease the absorption of GE, resulting in serum and urine levels considerably lower than desired.
LABEL>1
Multivalent Cation-Containing Products: Concurrent administration of a DRUG1, including GE, with multivalent cation-containing products such as GE or DRUG2 GE, GE, GE chewable/buffered tablets or pediatric powder, or products containing GE, GE, or GE may substantially decrease the absorption of GE, resulting in serum and urine levels considerably lower than desired.
LABEL>1
Multivalent Cation-Containing Products: Concurrent administration of a DRUG1, including GE, with multivalent cation-containing products such as GE or GE DRUG2, GE, GE chewable/buffered tablets or pediatric powder, or products containing GE, GE, or GE may substantially decrease the absorption of GE, resulting in serum and urine levels considerably lower than desired.
LABEL>1
Multivalent Cation-Containing Products: Concurrent administration of a DRUG1, including GE, with multivalent cation-containing products such as GE or GE GE, DRUG2, GE chewable/buffered tablets or pediatric powder, or products containing GE, GE, or GE may substantially decrease the absorption of GE, resulting in serum and urine levels considerably lower than desired.
LABEL>1
Multivalent Cation-Containing Products: Concurrent administration of a DRUG1, including GE, with multivalent cation-containing products such as GE or GE GE, GE, DRUG2 chewable/buffered tablets or pediatric powder, or products containing GE, GE, or GE may substantially decrease the absorption of GE, resulting in serum and urine levels considerably lower than desired.
LABEL>1
Multivalent Cation-Containing Products: Concurrent administration of a DRUG1, including GE, with multivalent cation-containing products such as GE or GE GE, GE, GE chewable/buffered tablets or pediatric powder, or products containing DRUG2, GE, or GE may substantially decrease the absorption of GE, resulting in serum and urine levels considerably lower than desired.
LABEL>1
Multivalent Cation-Containing Products: Concurrent administration of a DRUG1, including GE, with multivalent cation-containing products such as GE or GE GE, GE, GE chewable/buffered tablets or pediatric powder, or products containing GE, DRUG2, or GE may substantially decrease the absorption of GE, resulting in serum and urine levels considerably lower than desired.
LABEL>1
Multivalent Cation-Containing Products: Concurrent administration of a DRUG1, including GE, with multivalent cation-containing products such as GE or GE GE, GE, GE chewable/buffered tablets or pediatric powder, or products containing GE, GE, or DRUG2 may substantially decrease the absorption of GE, resulting in serum and urine levels considerably lower than desired.
LABEL>1
Multivalent Cation-Containing Products: Concurrent administration of a GE, including DRUG1, with multivalent cation-containing products such as DRUG2 or GE GE, GE, GE chewable/buffered tablets or pediatric powder, or products containing GE, GE, or GE may substantially decrease the absorption of GE, resulting in serum and urine levels considerably lower than desired.
LABEL>1
Multivalent Cation-Containing Products: Concurrent administration of a GE, including DRUG1, with multivalent cation-containing products such as GE or DRUG2 GE, GE, GE chewable/buffered tablets or pediatric powder, or products containing GE, GE, or GE may substantially decrease the absorption of GE, resulting in serum and urine levels considerably lower than desired.
LABEL>1
Multivalent Cation-Containing Products: Concurrent administration of a GE, including DRUG1, with multivalent cation-containing products such as GE or GE DRUG2, GE, GE chewable/buffered tablets or pediatric powder, or products containing GE, GE, or GE may substantially decrease the absorption of GE, resulting in serum and urine levels considerably lower than desired.
LABEL>1
Multivalent Cation-Containing Products: Concurrent administration of a GE, including DRUG1, with multivalent cation-containing products such as GE or GE GE, DRUG2, GE chewable/buffered tablets or pediatric powder, or products containing GE, GE, or GE may substantially decrease the absorption of GE, resulting in serum and urine levels considerably lower than desired.
LABEL>1
Multivalent Cation-Containing Products: Concurrent administration of a GE, including DRUG1, with multivalent cation-containing products such as GE or GE GE, GE, DRUG2 chewable/buffered tablets or pediatric powder, or products containing GE, GE, or GE may substantially decrease the absorption of GE, resulting in serum and urine levels considerably lower than desired.
LABEL>1
Multivalent Cation-Containing Products: Concurrent administration of a GE, including DRUG1, with multivalent cation-containing products such as GE or GE GE, GE, GE chewable/buffered tablets or pediatric powder, or products containing DRUG2, GE, or GE may substantially decrease the absorption of GE, resulting in serum and urine levels considerably lower than desired.
LABEL>1
Multivalent Cation-Containing Products: Concurrent administration of a GE, including DRUG1, with multivalent cation-containing products such as GE or GE GE, GE, GE chewable/buffered tablets or pediatric powder, or products containing GE, DRUG2, or GE may substantially decrease the absorption of GE, resulting in serum and urine levels considerably lower than desired.
LABEL>1
Multivalent Cation-Containing Products: Concurrent administration of a GE, including DRUG1, with multivalent cation-containing products such as GE or GE GE, GE, GE chewable/buffered tablets or pediatric powder, or products containing GE, GE, or DRUG2 may substantially decrease the absorption of GE, resulting in serum and urine levels considerably lower than desired.
LABEL>1
Multivalent Cation-Containing Products: Concurrent administration of a GE, including DRUG1, with multivalent cation-containing products such as GE or GE GE, GE, GE chewable/buffered tablets or pediatric powder, or products containing GE, GE, or GE may substantially decrease the absorption of DRUG2, resulting in serum and urine levels considerably lower than desired.
LABEL>1
This time window is different than for other oral formulations of DRUG1, which are usually administered 2 hours before or 6 hours after DRUG2.
LABEL>1
GE: Altered serum levels of DRUG1 (increased and decreased) have been reported in patients receiving concomitant DRUG2.
LABEL>1
GE: DRUG1 interferes with renal tubular secretion of DRUG2 and produces an increase in the level of GE in serum.
LABEL>1
GE: DRUG1 interferes with renal tubular secretion of GE and produces an increase in the level of DRUG2 in serum.
LABEL>1
GE: As with some other DRUG1, concurrent administration of GE with DRUG2 may lead to elevated serum concentrations of GE and prolongation of its elimination half-life.
LABEL>1
GE: As with some other GE, concurrent administration of DRUG1 with DRUG2 may lead to elevated serum concentrations of GE and prolongation of its elimination half-life.
LABEL>1
GE: DRUG1 have been reported to enhance the effects of the oral GE DRUG2 or its derivatives.
LABEL>1
GE: In vitro and/or in vivo data show that DRUG1, GE, and GE markedly inhibit the metabolism of DRUG2, which can result in an increase in plasma GE levels and prolongation of the QT interval on the ECG.
LABEL>1
GE: In vitro and/or in vivo data show that GE, DRUG1, and GE markedly inhibit the metabolism of DRUG2, which can result in an increase in plasma GE levels and prolongation of the QT interval on the ECG.
LABEL>1
GE: In vitro and/or in vivo data show that GE, GE, and DRUG1 markedly inhibit the metabolism of DRUG2, which can result in an increase in plasma GE levels and prolongation of the QT interval on the ECG.
LABEL>1
GE: Concurrent administration of certain DRUG1, such as GE and GE, would be expected to compromise the beneficial effects of DRUG2.
LABEL>1
GE: Concurrent administration of certain GE, such as DRUG1 and GE, would be expected to compromise the beneficial effects of DRUG2.
LABEL>1
GE: Concurrent administration of certain GE, such as GE and DRUG1, would be expected to compromise the beneficial effects of DRUG2.
LABEL>1
It is advisable to check coagulation time within the first few days after the start and discontinuation of DRUG1 therapy, with an appropriate adjustment of the DRUG2 dose, if necessary.
LABEL>1
GE: In vitro data indicate that DRUG1 inhibits the metabolism of DRUG2, which can result in an increase in plasma GE levels and prolongation of the QT interval on the ECG.
LABEL>1
GE: In vitro and/or in vivo data indicate that DRUG1, GE, and oral GE markedly inhibit the metabolism of DRUG2, which can result in an increase in plasma GE levels and prolongation of the QT interval on the ECG.
LABEL>1
GE: In vitro and/or in vivo data indicate that GE, DRUG1, and oral GE markedly inhibit the metabolism of DRUG2, which can result in an increase in plasma GE levels and prolongation of the QT interval on the ECG.
LABEL>1
GE: In vitro and/or in vivo data indicate that GE, GE, and oral DRUG1 markedly inhibit the metabolism of DRUG2, which can result in an increase in plasma GE levels and prolongation of the QT interval on the ECG.
LABEL>1
Human pharmacokinetic data indicate that oral DRUG1 markedly inhibits the metabolism of DRUG2, resulting in a mean eight-fold increase in AUC of GE.
LABEL>0
Laboratory Tests Response to DRUG1 should be monitored by measuring serum total DRUG2 concentrations just prior to administration on Day 29 and every 8 weeks thereafter.
LABEL>0
Population pharmacokinetic analyses revealed that DRUG1, DRUG2, GE, and GE did not influence GE clearance.
LABEL>0
Population pharmacokinetic analyses revealed that DRUG1, GE, DRUG2, and GE did not influence GE clearance.
LABEL>0
Population pharmacokinetic analyses revealed that DRUG1, GE, GE, and DRUG2 did not influence GE clearance.
LABEL>0
Population pharmacokinetic analyses revealed that DRUG1, GE, GE, and GE did not influence DRUG2 clearance.
LABEL>0
Population pharmacokinetic analyses revealed that GE, DRUG1, DRUG2, and GE did not influence GE clearance.
LABEL>0
Population pharmacokinetic analyses revealed that GE, DRUG1, GE, and DRUG2 did not influence GE clearance.
LABEL>0
Population pharmacokinetic analyses revealed that GE, DRUG1, GE, and GE did not influence DRUG2 clearance.
LABEL>0
Population pharmacokinetic analyses revealed that GE, GE, DRUG1, and DRUG2 did not influence GE clearance.
LABEL>0
Population pharmacokinetic analyses revealed that GE, GE, DRUG1, and GE did not influence DRUG2 clearance.
LABEL>0
Population pharmacokinetic analyses revealed that GE, GE, GE, and DRUG1 did not influence DRUG2 clearance.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with DRUG1: DRUG2, GE, GE, GE, GE, GE, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with DRUG1: GE, DRUG2, GE, GE, GE, GE, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with DRUG1: GE, GE, DRUG2, GE, GE, GE, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with DRUG1: GE, GE, GE, DRUG2, GE, GE, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with DRUG1: GE, GE, GE, GE, DRUG2, GE, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with DRUG1: GE, GE, GE, GE, GE, DRUG2, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with DRUG1: GE, GE, GE, GE, GE, GE, DRUG2, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with DRUG1: GE, GE, GE, GE, GE, GE, GE, DRUG2, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with DRUG1: GE, GE, GE, GE, GE, GE, GE, GE, DRUG2, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with DRUG1: GE, GE, GE, GE, GE, GE, GE, GE, GE, DRUG2, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with DRUG1: GE, GE, GE, GE, GE, GE, GE, GE, GE, GE, and DRUG2.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: DRUG1, DRUG2, GE, GE, GE, GE, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: DRUG1, GE, DRUG2, GE, GE, GE, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: DRUG1, GE, GE, DRUG2, GE, GE, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: DRUG1, GE, GE, GE, DRUG2, GE, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: DRUG1, GE, GE, GE, GE, DRUG2, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: DRUG1, GE, GE, GE, GE, GE, DRUG2, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: DRUG1, GE, GE, GE, GE, GE, GE, DRUG2, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: DRUG1, GE, GE, GE, GE, GE, GE, GE, DRUG2, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: DRUG1, GE, GE, GE, GE, GE, GE, GE, GE, DRUG2, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: DRUG1, GE, GE, GE, GE, GE, GE, GE, GE, GE, and DRUG2.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, DRUG1, DRUG2, GE, GE, GE, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, DRUG1, GE, DRUG2, GE, GE, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, DRUG1, GE, GE, DRUG2, GE, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, DRUG1, GE, GE, GE, DRUG2, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, DRUG1, GE, GE, GE, GE, DRUG2, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, DRUG1, GE, GE, GE, GE, GE, DRUG2, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, DRUG1, GE, GE, GE, GE, GE, GE, DRUG2, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, DRUG1, GE, GE, GE, GE, GE, GE, GE, DRUG2, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, DRUG1, GE, GE, GE, GE, GE, GE, GE, GE, and DRUG2.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, DRUG1, DRUG2, GE, GE, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, DRUG1, GE, DRUG2, GE, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, DRUG1, GE, GE, DRUG2, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, DRUG1, GE, GE, GE, DRUG2, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, DRUG1, GE, GE, GE, GE, DRUG2, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, DRUG1, GE, GE, GE, GE, GE, DRUG2, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, DRUG1, GE, GE, GE, GE, GE, GE, DRUG2, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, DRUG1, GE, GE, GE, GE, GE, GE, GE, and DRUG2.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, DRUG1, DRUG2, GE, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, DRUG1, GE, DRUG2, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, DRUG1, GE, GE, DRUG2, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, DRUG1, GE, GE, GE, DRUG2, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, DRUG1, GE, GE, GE, GE, DRUG2, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, DRUG1, GE, GE, GE, GE, GE, DRUG2, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, DRUG1, GE, GE, GE, GE, GE, GE, and DRUG2.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, DRUG1, DRUG2, GE, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, DRUG1, GE, DRUG2, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, DRUG1, GE, GE, DRUG2, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, DRUG1, GE, GE, GE, DRUG2, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, DRUG1, GE, GE, GE, GE, DRUG2, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, DRUG1, GE, GE, GE, GE, GE, and DRUG2.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, GE, DRUG1, DRUG2, GE, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, GE, DRUG1, GE, DRUG2, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, GE, DRUG1, GE, GE, DRUG2, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, GE, DRUG1, GE, GE, GE, DRUG2, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, GE, DRUG1, GE, GE, GE, GE, and DRUG2.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, GE, GE, DRUG1, DRUG2, GE, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, GE, GE, DRUG1, GE, DRUG2, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, GE, GE, DRUG1, GE, GE, DRUG2, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, GE, GE, DRUG1, GE, GE, GE, and DRUG2.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, GE, GE, GE, DRUG1, DRUG2, GE, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, GE, GE, GE, DRUG1, GE, DRUG2, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, GE, GE, GE, DRUG1, GE, GE, and DRUG2.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, GE, GE, GE, GE, DRUG1, DRUG2, and GE.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, GE, GE, GE, GE, DRUG1, GE, and DRUG2.
LABEL>0
The majority of patients in RA clinical studies received one or more of the following concomitant medications with GE: GE, GE, GE, GE, GE, GE, GE, GE, GE, DRUG1, and DRUG2.
LABEL>0
Concurrent administration of a DRUG1 with GE has been associated with an increased risk of serious infections and no significant additional efficacy over use of the DRUG2 alone.
LABEL>0
Concurrent administration of a GE with DRUG1 has been associated with an increased risk of serious infections and no significant additional efficacy over use of the DRUG2 alone.
LABEL>0
These medications have included DRUG1, DRUG2, GE, GE, GE, intravenous and oral GE, GE, and GE.
LABEL>0
These medications have included DRUG1, GE, DRUG2, GE, GE, intravenous and oral GE, GE, and GE.
LABEL>0
These medications have included DRUG1, GE, GE, DRUG2, GE, intravenous and oral GE, GE, and GE.
LABEL>0
These medications have included DRUG1, GE, GE, GE, DRUG2, intravenous and oral GE, GE, and GE.
LABEL>0
These medications have included DRUG1, GE, GE, GE, GE, intravenous and oral DRUG2, GE, and GE.
LABEL>0
These medications have included DRUG1, GE, GE, GE, GE, intravenous and oral GE, DRUG2, and GE.
LABEL>0
These medications have included DRUG1, GE, GE, GE, GE, intravenous and oral GE, GE, and DRUG2.
LABEL>0
These medications have included GE, DRUG1, DRUG2, GE, GE, intravenous and oral GE, GE, and GE.
LABEL>0
These medications have included GE, DRUG1, GE, DRUG2, GE, intravenous and oral GE, GE, and GE.
LABEL>0
These medications have included GE, DRUG1, GE, GE, DRUG2, intravenous and oral GE, GE, and GE.
LABEL>0
These medications have included GE, DRUG1, GE, GE, GE, intravenous and oral DRUG2, GE, and GE.
LABEL>0
These medications have included GE, DRUG1, GE, GE, GE, intravenous and oral GE, DRUG2, and GE.
LABEL>0
These medications have included GE, DRUG1, GE, GE, GE, intravenous and oral GE, GE, and DRUG2.
LABEL>0
These medications have included GE, GE, DRUG1, DRUG2, GE, intravenous and oral GE, GE, and GE.
LABEL>0
These medications have included GE, GE, DRUG1, GE, DRUG2, intravenous and oral GE, GE, and GE.
LABEL>0
These medications have included GE, GE, DRUG1, GE, GE, intravenous and oral DRUG2, GE, and GE.
LABEL>0
These medications have included GE, GE, DRUG1, GE, GE, intravenous and oral GE, DRUG2, and GE.
LABEL>0
These medications have included GE, GE, DRUG1, GE, GE, intravenous and oral GE, GE, and DRUG2.
LABEL>0
These medications have included GE, GE, GE, DRUG1, DRUG2, intravenous and oral GE, GE, and GE.
LABEL>0
These medications have included GE, GE, GE, DRUG1, GE, intravenous and oral DRUG2, GE, and GE.
LABEL>0
These medications have included GE, GE, GE, DRUG1, GE, intravenous and oral GE, DRUG2, and GE.
LABEL>0
These medications have included GE, GE, GE, DRUG1, GE, intravenous and oral GE, GE, and DRUG2.
LABEL>0
These medications have included GE, GE, GE, GE, DRUG1, intravenous and oral DRUG2, GE, and GE.
LABEL>0
These medications have included GE, GE, GE, GE, DRUG1, intravenous and oral GE, DRUG2, and GE.
LABEL>0
These medications have included GE, GE, GE, GE, DRUG1, intravenous and oral GE, GE, and DRUG2.
LABEL>0
These medications have included GE, GE, GE, GE, GE, intravenous and oral DRUG1, DRUG2, and GE.
LABEL>0
These medications have included GE, GE, GE, GE, GE, intravenous and oral DRUG1, GE, and DRUG2.
LABEL>0
These medications have included GE, GE, GE, GE, GE, intravenous and oral GE, DRUG1, and DRUG2.
LABEL>0
DRUG1, other DRUG2, GE, and GE are associated with an increase in bleeding.
LABEL>0
DRUG1, other GE, DRUG2, and GE are associated with an increase in bleeding.
LABEL>0
DRUG1, other GE, GE, and DRUG2 are associated with an increase in bleeding.
LABEL>0
GE, other DRUG1, DRUG2, and GE are associated with an increase in bleeding.
LABEL>0
GE, other DRUG1, GE, and DRUG2 are associated with an increase in bleeding.
LABEL>0
GE, other GE, DRUG1, and DRUG2 are associated with an increase in bleeding.
LABEL>0
Patients with HACA titers may have allergic or hypersensitivity reactions when treated with other DRUG1 or DRUG2.
LABEL>0
The concomitant intake of DRUG1 and DRUG2 does not affect the pharmacokinetics of either GE or GE.
LABEL>0
The concomitant intake of DRUG1 and GE does not affect the pharmacokinetics of either DRUG2 or GE.
LABEL>0
The concomitant intake of DRUG1 and GE does not affect the pharmacokinetics of either GE or DRUG2.
LABEL>0
The concomitant intake of GE and DRUG1 does not affect the pharmacokinetics of either DRUG2 or GE.
LABEL>0
The concomitant intake of GE and DRUG1 does not affect the pharmacokinetics of either GE or DRUG2.
LABEL>0
The concomitant intake of GE and GE does not affect the pharmacokinetics of either DRUG1 or DRUG2.
LABEL>0
Pharmacokinetic studies indicate that administration of DRUG1 or DRUG2 does not affect the pharmacokinetics of GE.
LABEL>0
Pharmacokinetic studies indicate that administration of DRUG1 or GE does not affect the pharmacokinetics of DRUG2.
LABEL>0
Pharmacokinetic studies indicate that administration of GE or DRUG1 does not affect the pharmacokinetics of DRUG2.
LABEL>0
Co-administration of DRUG1 with GE produced a 25% increase in AUC and a 33% increase in the Cmax of DRUG2.
LABEL>0
Co-administration of GE with DRUG1 produced a 25% increase in AUC and a 33% increase in the Cmax of DRUG2.
LABEL>0
The pharmacokinetics of DRUG1 and its major metabolite DRUG2 were unaffected following co-administration with GE.
LABEL>0
The pharmacokinetics of DRUG1 and its major metabolite GE were unaffected following co-administration with DRUG2.
LABEL>0
The pharmacokinetics of GE and its major metabolite DRUG1 were unaffected following co-administration with DRUG2.
LABEL>0
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with DRUG1 concomitantly with DRUG2, GE and GE (including GE), or GE was similar to that of subjects taking placebo with these concomitant medications.
LABEL>0
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with DRUG1 concomitantly with GE, DRUG2 and GE (including GE), or GE was similar to that of subjects taking placebo with these concomitant medications.
LABEL>0
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with DRUG1 concomitantly with GE, GE and DRUG2 (including GE), or GE was similar to that of subjects taking placebo with these concomitant medications.
LABEL>0
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with DRUG1 concomitantly with GE, GE and GE (including DRUG2), or GE was similar to that of subjects taking placebo with these concomitant medications.
LABEL>0
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with DRUG1 concomitantly with GE, GE and GE (including GE), or DRUG2 was similar to that of subjects taking placebo with these concomitant medications.
LABEL>0
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with GE concomitantly with DRUG1, DRUG2 and GE (including GE), or GE was similar to that of subjects taking placebo with these concomitant medications.
LABEL>0
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with GE concomitantly with DRUG1, GE and DRUG2 (including GE), or GE was similar to that of subjects taking placebo with these concomitant medications.
LABEL>0
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with GE concomitantly with DRUG1, GE and GE (including DRUG2), or GE was similar to that of subjects taking placebo with these concomitant medications.
LABEL>0
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with GE concomitantly with DRUG1, GE and GE (including GE), or DRUG2 was similar to that of subjects taking placebo with these concomitant medications.
LABEL>0
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with GE concomitantly with GE, DRUG1 and DRUG2 (including GE), or GE was similar to that of subjects taking placebo with these concomitant medications.
LABEL>0
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with GE concomitantly with GE, DRUG1 and GE (including DRUG2), or GE was similar to that of subjects taking placebo with these concomitant medications.
LABEL>0
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with GE concomitantly with GE, DRUG1 and GE (including GE), or DRUG2 was similar to that of subjects taking placebo with these concomitant medications.
LABEL>0
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with GE concomitantly with GE, GE and DRUG1 (including DRUG2), or GE was similar to that of subjects taking placebo with these concomitant medications.
LABEL>0
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with GE concomitantly with GE, GE and DRUG1 (including GE), or DRUG2 was similar to that of subjects taking placebo with these concomitant medications.
LABEL>0
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with GE concomitantly with GE, GE and GE (including DRUG1), or DRUG2 was similar to that of subjects taking placebo with these concomitant medications.
LABEL>0
These drugs include the DRUG1 and other DRUG2, GE, GE, GE, GE, oral GE, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the DRUG1 and other GE, DRUG2, GE, GE, GE, oral GE, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the DRUG1 and other GE, GE, DRUG2, GE, GE, oral GE, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the DRUG1 and other GE, GE, GE, DRUG2, GE, oral GE, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the DRUG1 and other GE, GE, GE, GE, DRUG2, oral GE, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the DRUG1 and other GE, GE, GE, GE, GE, oral DRUG2, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the DRUG1 and other GE, GE, GE, GE, GE, oral GE, DRUG2, GE, GE, GE, and GE.
LABEL>0
These drugs include the DRUG1 and other GE, GE, GE, GE, GE, oral GE, GE, DRUG2, GE, GE, and GE.
LABEL>0
These drugs include the DRUG1 and other GE, GE, GE, GE, GE, oral GE, GE, GE, DRUG2, GE, and GE.
LABEL>0
These drugs include the DRUG1 and other GE, GE, GE, GE, GE, oral GE, GE, GE, GE, DRUG2, and GE.
LABEL>0
These drugs include the DRUG1 and other GE, GE, GE, GE, GE, oral GE, GE, GE, GE, GE, and DRUG2.
LABEL>0
These drugs include the GE and other DRUG1, DRUG2, GE, GE, GE, oral GE, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other DRUG1, GE, DRUG2, GE, GE, oral GE, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other DRUG1, GE, GE, DRUG2, GE, oral GE, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other DRUG1, GE, GE, GE, DRUG2, oral GE, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other DRUG1, GE, GE, GE, GE, oral DRUG2, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other DRUG1, GE, GE, GE, GE, oral GE, DRUG2, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other DRUG1, GE, GE, GE, GE, oral GE, GE, DRUG2, GE, GE, and GE.
LABEL>0
These drugs include the GE and other DRUG1, GE, GE, GE, GE, oral GE, GE, GE, DRUG2, GE, and GE.
LABEL>0
These drugs include the GE and other DRUG1, GE, GE, GE, GE, oral GE, GE, GE, GE, DRUG2, and GE.
LABEL>0
These drugs include the GE and other DRUG1, GE, GE, GE, GE, oral GE, GE, GE, GE, GE, and DRUG2.
LABEL>0
These drugs include the GE and other GE, DRUG1, DRUG2, GE, GE, oral GE, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, DRUG1, GE, DRUG2, GE, oral GE, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, DRUG1, GE, GE, DRUG2, oral GE, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, DRUG1, GE, GE, GE, oral DRUG2, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, DRUG1, GE, GE, GE, oral GE, DRUG2, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, DRUG1, GE, GE, GE, oral GE, GE, DRUG2, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, DRUG1, GE, GE, GE, oral GE, GE, GE, DRUG2, GE, and GE.
LABEL>0
These drugs include the GE and other GE, DRUG1, GE, GE, GE, oral GE, GE, GE, GE, DRUG2, and GE.
LABEL>0
These drugs include the GE and other GE, DRUG1, GE, GE, GE, oral GE, GE, GE, GE, GE, and DRUG2.
LABEL>0
These drugs include the GE and other GE, GE, DRUG1, DRUG2, GE, oral GE, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, DRUG1, GE, DRUG2, oral GE, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, DRUG1, GE, GE, oral DRUG2, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, DRUG1, GE, GE, oral GE, DRUG2, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, DRUG1, GE, GE, oral GE, GE, DRUG2, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, DRUG1, GE, GE, oral GE, GE, GE, DRUG2, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, DRUG1, GE, GE, oral GE, GE, GE, GE, DRUG2, and GE.
LABEL>0
These drugs include the GE and other GE, GE, DRUG1, GE, GE, oral GE, GE, GE, GE, GE, and DRUG2.
LABEL>0
These drugs include the GE and other GE, GE, GE, DRUG1, DRUG2, oral GE, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, DRUG1, GE, oral DRUG2, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, DRUG1, GE, oral GE, DRUG2, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, DRUG1, GE, oral GE, GE, DRUG2, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, DRUG1, GE, oral GE, GE, GE, DRUG2, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, DRUG1, GE, oral GE, GE, GE, GE, DRUG2, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, DRUG1, GE, oral GE, GE, GE, GE, GE, and DRUG2.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, DRUG1, oral DRUG2, GE, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, DRUG1, oral GE, DRUG2, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, DRUG1, oral GE, GE, DRUG2, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, DRUG1, oral GE, GE, GE, DRUG2, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, DRUG1, oral GE, GE, GE, GE, DRUG2, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, DRUG1, oral GE, GE, GE, GE, GE, and DRUG2.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, GE, oral DRUG1, DRUG2, GE, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, GE, oral DRUG1, GE, DRUG2, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, GE, oral DRUG1, GE, GE, DRUG2, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, GE, oral DRUG1, GE, GE, GE, DRUG2, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, GE, oral DRUG1, GE, GE, GE, GE, and DRUG2.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, GE, oral GE, DRUG1, DRUG2, GE, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, GE, oral GE, DRUG1, GE, DRUG2, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, GE, oral GE, DRUG1, GE, GE, DRUG2, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, GE, oral GE, DRUG1, GE, GE, GE, and DRUG2.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, GE, oral GE, GE, DRUG1, DRUG2, GE, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, GE, oral GE, GE, DRUG1, GE, DRUG2, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, GE, oral GE, GE, DRUG1, GE, GE, and DRUG2.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, GE, oral GE, GE, GE, DRUG1, DRUG2, and GE.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, GE, oral GE, GE, GE, DRUG1, GE, and DRUG2.
LABEL>0
These drugs include the GE and other GE, GE, GE, GE, GE, oral GE, GE, GE, GE, DRUG1, and DRUG2.
LABEL>0
When such drugs are withdrawn from patients receiving DRUG1 in combination with DRUG2 or GE, patients should be observed closely for any evidence of hypoglycemia.
LABEL>0
When such drugs are withdrawn from patients receiving DRUG1 in combination with GE or DRUG2, patients should be observed closely for any evidence of hypoglycemia.
LABEL>0
When such drugs are withdrawn from patients receiving GE in combination with DRUG1 or DRUG2, patients should be observed closely for any evidence of hypoglycemia.
LABEL>0
DRUG1 (e. g., DRUG2) and GE containing carbohydrate-splitting enzymes (e. g., GE, GE) may reduce the effect of GE and should not be taken concomitantly.
LABEL>0
DRUG1 (e. g., GE) and DRUG2 containing carbohydrate-splitting enzymes (e. g., GE, GE) may reduce the effect of GE and should not be taken concomitantly.
LABEL>0
DRUG1 (e. g., GE) and GE containing carbohydrate-splitting enzymes (e. g., DRUG2, GE) may reduce the effect of GE and should not be taken concomitantly.
LABEL>0
DRUG1 (e. g., GE) and GE containing carbohydrate-splitting enzymes (e. g., GE, DRUG2) may reduce the effect of GE and should not be taken concomitantly.
LABEL>0
GE (e. g., DRUG1) and DRUG2 containing carbohydrate-splitting enzymes (e. g., GE, GE) may reduce the effect of GE and should not be taken concomitantly.
LABEL>0
GE (e. g., DRUG1) and GE containing carbohydrate-splitting enzymes (e. g., DRUG2, GE) may reduce the effect of GE and should not be taken concomitantly.
LABEL>0
GE (e. g., DRUG1) and GE containing carbohydrate-splitting enzymes (e. g., GE, DRUG2) may reduce the effect of GE and should not be taken concomitantly.
LABEL>0
GE (e. g., GE) and DRUG1 containing carbohydrate-splitting enzymes (e. g., DRUG2, GE) may reduce the effect of GE and should not be taken concomitantly.
LABEL>0
GE (e. g., GE) and DRUG1 containing carbohydrate-splitting enzymes (e. g., GE, DRUG2) may reduce the effect of GE and should not be taken concomitantly.
LABEL>0
GE (e. g., GE) and DRUG1 containing carbohydrate-splitting enzymes (e. g., GE, GE) may reduce the effect of DRUG2 and should not be taken concomitantly.
LABEL>0
GE (e. g., GE) and GE containing carbohydrate-splitting enzymes (e. g., DRUG1, DRUG2) may reduce the effect of GE and should not be taken concomitantly.
LABEL>0
DRUG1 has been shown to change the bioavailabillty GE when they are co-administered, which may require DRUG2 dose adjustment.
LABEL>0
GE has been shown to change the bioavailabillty DRUG1 when they are co-administered, which may require DRUG2 dose adjustment.
LABEL>0
Studies in healthy volunteers have shown that DRUG1 has no effect on either the pharmacokinetics or pharmacodynamics of DRUG2, GE, GE, or GE.
LABEL>0
Studies in healthy volunteers have shown that DRUG1 has no effect on either the pharmacokinetics or pharmacodynamics of GE, DRUG2, GE, or GE.
LABEL>0
Studies in healthy volunteers have shown that DRUG1 has no effect on either the pharmacokinetics or pharmacodynamics of GE, GE, DRUG2, or GE.
LABEL>0
Studies in healthy volunteers have shown that DRUG1 has no effect on either the pharmacokinetics or pharmacodynamics of GE, GE, GE, or DRUG2.
LABEL>0
Studies in healthy volunteers have shown that GE has no effect on either the pharmacokinetics or pharmacodynamics of DRUG1, DRUG2, GE, or GE.
LABEL>0
Studies in healthy volunteers have shown that GE has no effect on either the pharmacokinetics or pharmacodynamics of DRUG1, GE, DRUG2, or GE.
LABEL>0
Studies in healthy volunteers have shown that GE has no effect on either the pharmacokinetics or pharmacodynamics of DRUG1, GE, GE, or DRUG2.
LABEL>0
Studies in healthy volunteers have shown that GE has no effect on either the pharmacokinetics or pharmacodynamics of GE, DRUG1, DRUG2, or GE.
LABEL>0
Studies in healthy volunteers have shown that GE has no effect on either the pharmacokinetics or pharmacodynamics of GE, DRUG1, GE, or DRUG2.
LABEL>0
Studies in healthy volunteers have shown that GE has no effect on either the pharmacokinetics or pharmacodynamics of GE, GE, DRUG1, or DRUG2.
LABEL>0
DRUG1 did not interfere with the absorption or disposition of the DRUG2 GE in diabetic patients.
LABEL>0
DRUG1 did not interfere with the absorption or disposition of the GE DRUG2 in diabetic patients.
LABEL>0
GE did not interfere with the absorption or disposition of the DRUG1 DRUG2 in diabetic patients.
LABEL>0
DRUG1 may affect DRUG2 bioavailabillty and may require dose adjustment of GE by 16% (90% confidence interval: 8-23%), decrease mean C max GE by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of GE by 9% (90% confidence limit: 19% decrease to 2% increase).
LABEL>0
DRUG1 may affect GE bioavailabillty and may require dose adjustment of DRUG2 by 16% (90% confidence interval: 8-23%), decrease mean C max GE by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of GE by 9% (90% confidence limit: 19% decrease to 2% increase).
LABEL>0
DRUG1 may affect GE bioavailabillty and may require dose adjustment of GE by 16% (90% confidence interval: 8-23%), decrease mean C max DRUG2 by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of GE by 9% (90% confidence limit: 19% decrease to 2% increase).
LABEL>0
DRUG1 may affect GE bioavailabillty and may require dose adjustment of GE by 16% (90% confidence interval: 8-23%), decrease mean C max GE by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of DRUG2 by 9% (90% confidence limit: 19% decrease to 2% increase).
LABEL>0
GE may affect DRUG1 bioavailabillty and may require dose adjustment of DRUG2 by 16% (90% confidence interval: 8-23%), decrease mean C max GE by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of GE by 9% (90% confidence limit: 19% decrease to 2% increase).
LABEL>0
GE may affect DRUG1 bioavailabillty and may require dose adjustment of GE by 16% (90% confidence interval: 8-23%), decrease mean C max DRUG2 by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of GE by 9% (90% confidence limit: 19% decrease to 2% increase).
LABEL>0
GE may affect DRUG1 bioavailabillty and may require dose adjustment of GE by 16% (90% confidence interval: 8-23%), decrease mean C max GE by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of DRUG2 by 9% (90% confidence limit: 19% decrease to 2% increase).
LABEL>0
GE may affect GE bioavailabillty and may require dose adjustment of DRUG1 by 16% (90% confidence interval: 8-23%), decrease mean C max DRUG2 by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of GE by 9% (90% confidence limit: 19% decrease to 2% increase).
LABEL>0
GE may affect GE bioavailabillty and may require dose adjustment of DRUG1 by 16% (90% confidence interval: 8-23%), decrease mean C max GE by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of DRUG2 by 9% (90% confidence limit: 19% decrease to 2% increase).
LABEL>0
GE may affect GE bioavailabillty and may require dose adjustment of GE by 16% (90% confidence interval: 8-23%), decrease mean C max DRUG1 by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of DRUG2 by 9% (90% confidence limit: 19% decrease to 2% increase).
LABEL>0
The amount of DRUG1 absorbed while taking DRUG2 was bioequivalent to the amount absorbed when taking placebo, as indicated by the plasma AUC values.
LABEL>0
However, the peak plasma level of DRUG1 was reduced by approximately 20% when taking GE due to a slight delay in the absorption of DRUG2.
LABEL>0
There is little if any clinically significant interaction between DRUG1 and DRUG2.
LABEL>0
DRUG1, such as DRUG2, may have an additive effect when given with GE.
LABEL>0
No significant interactions with DRUG1, DRUG2, GE, GE, oral GE, GE, or GE have been observed.
LABEL>0
No significant interactions with DRUG1, GE, DRUG2, GE, oral GE, GE, or GE have been observed.
LABEL>0
No significant interactions with DRUG1, GE, GE, DRUG2, oral GE, GE, or GE have been observed.
LABEL>0
No significant interactions with DRUG1, GE, GE, GE, oral DRUG2, GE, or GE have been observed.
LABEL>0
No significant interactions with DRUG1, GE, GE, GE, oral GE, DRUG2, or GE have been observed.
LABEL>0
No significant interactions with DRUG1, GE, GE, GE, oral GE, GE, or DRUG2 have been observed.
LABEL>0
No significant interactions with GE, DRUG1, DRUG2, GE, oral GE, GE, or GE have been observed.
LABEL>0
No significant interactions with GE, DRUG1, GE, DRUG2, oral GE, GE, or GE have been observed.
LABEL>0
No significant interactions with GE, DRUG1, GE, GE, oral DRUG2, GE, or GE have been observed.
LABEL>0
No significant interactions with GE, DRUG1, GE, GE, oral GE, DRUG2, or GE have been observed.
LABEL>0
No significant interactions with GE, DRUG1, GE, GE, oral GE, GE, or DRUG2 have been observed.
LABEL>0
No significant interactions with GE, GE, DRUG1, DRUG2, oral GE, GE, or GE have been observed.
LABEL>0
No significant interactions with GE, GE, DRUG1, GE, oral DRUG2, GE, or GE have been observed.
LABEL>0
No significant interactions with GE, GE, DRUG1, GE, oral GE, DRUG2, or GE have been observed.
LABEL>0
No significant interactions with GE, GE, DRUG1, GE, oral GE, GE, or DRUG2 have been observed.
LABEL>0
No significant interactions with GE, GE, GE, DRUG1, oral DRUG2, GE, or GE have been observed.
LABEL>0
No significant interactions with GE, GE, GE, DRUG1, oral GE, DRUG2, or GE have been observed.
LABEL>0
No significant interactions with GE, GE, GE, DRUG1, oral GE, GE, or DRUG2 have been observed.
LABEL>0
No significant interactions with GE, GE, GE, GE, oral DRUG1, DRUG2, or GE have been observed.
LABEL>0
No significant interactions with GE, GE, GE, GE, oral DRUG1, GE, or DRUG2 have been observed.
LABEL>0
No significant interactions with GE, GE, GE, GE, oral GE, DRUG1, or DRUG2 have been observed.
LABEL>0
GE modifies DRUG1 metabolism with increased serum levels of DRUG2.
LABEL>0
By decreasing the gastrointestinal absorption of DRUG1, DRUG2 may decrease serum concentrations of GE and its metabolites, with a consequent possible decrease in anticonvulsant effect.
LABEL>0
By decreasing the gastrointestinal absorption of DRUG1, GE may decrease serum concentrations of DRUG2 and its metabolites, with a consequent possible decrease in anticonvulsant effect.
LABEL>0
DRUG1 increases GE excretion and the DRUG2 may be decreased.
LABEL>0
GE increases DRUG1 excretion and the DRUG2 may be decreased.
LABEL>0
Concomitant use with DRUG1s may result in the reduced absorption of DRUG2.
LABEL>0
DRUG1:Clinical evidence has shown that DRUG2 can be formed with concurrent ingestion of GE and GE.
LABEL>0
DRUG1:Clinical evidence has shown that GE can be formed with concurrent ingestion of DRUG2 and GE.
LABEL>0
DRUG1:Clinical evidence has shown that GE can be formed with concurrent ingestion of GE and DRUG2.
LABEL>0
GE:Clinical evidence has shown that DRUG1 can be formed with concurrent ingestion of DRUG2 and GE.
LABEL>0
GE:Clinical evidence has shown that DRUG1 can be formed with concurrent ingestion of GE and DRUG2.
LABEL>0
DRUG1: In a study of 7 healthy male volunteers, DRUG2 treatment potentiated the blood glucose lowering effect of GE (a GE similar to GE) in 3 of the 7 subjects.
LABEL>0
DRUG1: In a study of 7 healthy male volunteers, GE treatment potentiated the blood glucose lowering effect of DRUG2 (a GE similar to GE) in 3 of the 7 subjects.
LABEL>0
DRUG1: In a study of 7 healthy male volunteers, GE treatment potentiated the blood glucose lowering effect of GE (a DRUG2 similar to GE) in 3 of the 7 subjects.
LABEL>0
DRUG1: In a study of 7 healthy male volunteers, GE treatment potentiated the blood glucose lowering effect of GE (a GE similar to DRUG2) in 3 of the 7 subjects.
LABEL>0
GE: In a study of 7 healthy male volunteers, DRUG1 treatment potentiated the blood glucose lowering effect of GE (a DRUG2 similar to GE) in 3 of the 7 subjects.
LABEL>0
GE: In a study of 7 healthy male volunteers, DRUG1 treatment potentiated the blood glucose lowering effect of GE (a GE similar to DRUG2) in 3 of the 7 subjects.
LABEL>0
GE: In a study of 7 healthy male volunteers, GE treatment potentiated the blood glucose lowering effect of DRUG1 (a DRUG2 similar to GE) in 3 of the 7 subjects.
LABEL>0
GE: In a study of 7 healthy male volunteers, GE treatment potentiated the blood glucose lowering effect of DRUG1 (a GE similar to DRUG2) in 3 of the 7 subjects.
LABEL>0
GE: In a study of 7 healthy male volunteers, GE treatment potentiated the blood glucose lowering effect of GE (a DRUG1 similar to DRUG2) in 3 of the 7 subjects.
LABEL>0
Repeating the study with 6 healthy male volunteers in the absence of DRUG1 did not detect an effect of DRUG2 on glucose tolerance.
LABEL>0
DRUG1: It has not been established if there is a pharmacokinetic interaction between DRUG2 and GE.
LABEL>0
DRUG1: It has not been established if there is a pharmacokinetic interaction between GE and DRUG2.
LABEL>0
GE: It has not been established if there is a pharmacokinetic interaction between DRUG1 and DRUG2.
LABEL>0
It is not known whether other DRUG1, such as implants and injectables, are adequate methods of contraception during DRUG2 therapy.
LABEL>0
DRUG1: An increased risk of hepatitis has been reported to result from combined use of DRUG2 and GE.
LABEL>0
DRUG1: An increased risk of hepatitis has been reported to result from combined use of GE and DRUG2.
LABEL>0
DRUG1: If DRUG2 is given concurrently with GE, the protein binding of GE may be reduced.
LABEL>0
DRUG1: If GE is given concurrently with DRUG2, the protein binding of GE may be reduced.
LABEL>0
DRUG1: If GE is given concurrently with GE, the protein binding of DRUG2 may be reduced.
LABEL>0
GE: If DRUG1 is given concurrently with GE, the protein binding of DRUG2 may be reduced.
LABEL>0
GE: If GE is given concurrently with DRUG1, the protein binding of DRUG2 may be reduced.
LABEL>0
DRUG1: Since both DRUG2 and GE can cause increased intracranial pressure, their combined use is contraindicated.
LABEL>0
DRUG1: Since both GE and DRUG2 can cause increased intracranial pressure, their combined use is contraindicated.
LABEL>0
DRUG1 and oral DRUG2: Concomitant administration of GE and/or other oral GE with GE must be avoided because of the risk of hypervitaminosis A.
LABEL>0
DRUG1 and oral GE: Concomitant administration of DRUG2 and/or other oral GE with GE must be avoided because of the risk of hypervitaminosis A.
LABEL>0
DRUG1 and oral GE: Concomitant administration of GE and/or other oral DRUG2 with GE must be avoided because of the risk of hypervitaminosis A.
LABEL>0
DRUG1 and oral GE: Concomitant administration of GE and/or other oral GE with DRUG2 must be avoided because of the risk of hypervitaminosis A.
LABEL>0
GE and oral DRUG1: Concomitant administration of DRUG2 and/or other oral GE with GE must be avoided because of the risk of hypervitaminosis A.
LABEL>0
GE and oral DRUG1: Concomitant administration of GE and/or other oral DRUG2 with GE must be avoided because of the risk of hypervitaminosis A.
LABEL>0
GE and oral DRUG1: Concomitant administration of GE and/or other oral GE with DRUG2 must be avoided because of the risk of hypervitaminosis A.
LABEL>0
GE and oral GE: Concomitant administration of DRUG1 and/or other oral DRUG2 with GE must be avoided because of the risk of hypervitaminosis A.
LABEL>0
Other: There appears to be no pharmacokinetic interaction between DRUG1 and DRUG2, GE, or GE.
LABEL>0
Other: There appears to be no pharmacokinetic interaction between DRUG1 and GE, DRUG2, or GE.
LABEL>0
Other: There appears to be no pharmacokinetic interaction between DRUG1 and GE, GE, or DRUG2.
LABEL>0
Other: There appears to be no pharmacokinetic interaction between GE and DRUG1, DRUG2, or GE.
LABEL>0
Other: There appears to be no pharmacokinetic interaction between GE and DRUG1, GE, or DRUG2.
LABEL>0
Other: There appears to be no pharmacokinetic interaction between GE and GE, DRUG1, or DRUG2.
LABEL>0
Investigations into the effect of DRUG1 on the protein binding of DRUG2 (GE) revealed no interaction.
LABEL>0
Investigations into the effect of DRUG1 on the protein binding of GE (DRUG2) revealed no interaction.
LABEL>0
Investigations into the effect of GE on the protein binding of DRUG1 (DRUG2) revealed no interaction.
LABEL>0
DRUG1: DRUG2 has been studied in rheumatoid arthritis patients taking concomitant GE.
LABEL>0
DRUG1: GE has been studied in rheumatoid arthritis patients taking concomitant DRUG2.
LABEL>0
GE: DRUG1 has been studied in rheumatoid arthritis patients taking concomitant DRUG2.
LABEL>0
The data do not suggest the need for dose adjustment of either DRUG1 or DRUG2.
LABEL>0
DRUG1: Concurrent administration of DRUG2 (an GE) and another GE has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
LABEL>0
DRUG1: Concurrent administration of GE (an DRUG2) and another GE has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
LABEL>0
DRUG1: Concurrent administration of GE (an GE) and another DRUG2 has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
LABEL>0
GE: Concurrent administration of DRUG1 (an DRUG2) and another GE has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
LABEL>0
The safety and efficacy of DRUG1 used in combination with DRUG2 has not been studied.
LABEL>0
Therefore the, combination of GE with other DRUG1, including DRUG2, may also result i n similar toxicities.
LABEL>0
Particular caution should be exercised in using preparations containing DRUG1, DRUG2, or GE in combination with GE Gel.
LABEL>0
Particular caution should be exercised in using preparations containing DRUG1, GE, or DRUG2 in combination with GE Gel.
LABEL>0
Particular caution should be exercised in using preparations containing DRUG1, GE, or GE in combination with DRUG2 Gel.
LABEL>0
Particular caution should be exercised in using preparations containing GE, DRUG1, or DRUG2 in combination with GE Gel.
LABEL>0
Particular caution should be exercised in using preparations containing GE, DRUG1, or GE in combination with DRUG2 Gel.
LABEL>0
Particular caution should be exercised in using preparations containing GE, GE, or DRUG1 in combination with DRUG2 Gel.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: DRUG1 (e.g., DRUG2, GE), GE, GE, GE drugs (e.g., GE), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: DRUG1 (e.g., GE, DRUG2), GE, GE, GE drugs (e.g., GE), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: DRUG1 (e.g., GE, GE), DRUG2, GE, GE drugs (e.g., GE), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: DRUG1 (e.g., GE, GE), GE, DRUG2, GE drugs (e.g., GE), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: DRUG1 (e.g., GE, GE), GE, GE, DRUG2 drugs (e.g., GE), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: DRUG1 (e.g., GE, GE), GE, GE, GE drugs (e.g., DRUG2), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: DRUG1 (e.g., GE, GE), GE, GE, GE drugs (e.g., GE), DRUG2, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: DRUG1 (e.g., GE, GE), GE, GE, GE drugs (e.g., GE), GE, DRUG2.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., DRUG1, DRUG2), GE, GE, GE drugs (e.g., GE), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., DRUG1, GE), DRUG2, GE, GE drugs (e.g., GE), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., DRUG1, GE), GE, DRUG2, GE drugs (e.g., GE), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., DRUG1, GE), GE, GE, DRUG2 drugs (e.g., GE), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., DRUG1, GE), GE, GE, GE drugs (e.g., DRUG2), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., DRUG1, GE), GE, GE, GE drugs (e.g., GE), DRUG2, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., DRUG1, GE), GE, GE, GE drugs (e.g., GE), GE, DRUG2.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, DRUG1), DRUG2, GE, GE drugs (e.g., GE), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, DRUG1), GE, DRUG2, GE drugs (e.g., GE), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, DRUG1), GE, GE, DRUG2 drugs (e.g., GE), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, DRUG1), GE, GE, GE drugs (e.g., DRUG2), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, DRUG1), GE, GE, GE drugs (e.g., GE), DRUG2, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, DRUG1), GE, GE, GE drugs (e.g., GE), GE, DRUG2.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, GE), DRUG1, DRUG2, GE drugs (e.g., GE), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, GE), DRUG1, GE, DRUG2 drugs (e.g., GE), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, GE), DRUG1, GE, GE drugs (e.g., DRUG2), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, GE), DRUG1, GE, GE drugs (e.g., GE), DRUG2, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, GE), DRUG1, GE, GE drugs (e.g., GE), GE, DRUG2.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, GE), GE, DRUG1, DRUG2 drugs (e.g., GE), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, GE), GE, DRUG1, GE drugs (e.g., DRUG2), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, GE), GE, DRUG1, GE drugs (e.g., GE), DRUG2, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, GE), GE, DRUG1, GE drugs (e.g., GE), GE, DRUG2.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, GE), GE, GE, DRUG1 drugs (e.g., DRUG2), GE, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, GE), GE, GE, DRUG1 drugs (e.g., GE), DRUG2, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, GE), GE, GE, DRUG1 drugs (e.g., GE), GE, DRUG2.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, GE), GE, GE, GE drugs (e.g., DRUG1), DRUG2, GE.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, GE), GE, GE, GE drugs (e.g., DRUG1), GE, DRUG2.
LABEL>0
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: GE (e.g., GE, GE), GE, GE, GE drugs (e.g., GE), DRUG1, DRUG2.
LABEL>0
Intravenous DRUG1 (DRUG2) has been effectively administered in the presence of other cardioactive drugs, such as GE, GE, GE, and GE, without any change in the adverse reaction profile.
LABEL>0
Intravenous DRUG1 (GE) has been effectively administered in the presence of other cardioactive drugs, such as DRUG2, GE, GE, and GE, without any change in the adverse reaction profile.
LABEL>0
Intravenous DRUG1 (GE) has been effectively administered in the presence of other cardioactive drugs, such as GE, DRUG2, GE, and GE, without any change in the adverse reaction profile.
LABEL>0
Intravenous DRUG1 (GE) has been effectively administered in the presence of other cardioactive drugs, such as GE, GE, DRUG2, and GE, without any change in the adverse reaction profile.
LABEL>0
Intravenous DRUG1 (GE) has been effectively administered in the presence of other cardioactive drugs, such as GE, GE, GE, and DRUG2, without any change in the adverse reaction profile.
LABEL>0
Intravenous GE (DRUG1) has been effectively administered in the presence of other cardioactive drugs, such as DRUG2, GE, GE, and GE, without any change in the adverse reaction profile.
LABEL>0
Intravenous GE (DRUG1) has been effectively administered in the presence of other cardioactive drugs, such as GE, DRUG2, GE, and GE, without any change in the adverse reaction profile.
LABEL>0
Intravenous GE (DRUG1) has been effectively administered in the presence of other cardioactive drugs, such as GE, GE, DRUG2, and GE, without any change in the adverse reaction profile.
LABEL>0
Intravenous GE (DRUG1) has been effectively administered in the presence of other cardioactive drugs, such as GE, GE, GE, and DRUG2, without any change in the adverse reaction profile.
LABEL>0
Intravenous GE (GE) has been effectively administered in the presence of other cardioactive drugs, such as DRUG1, DRUG2, GE, and GE, without any change in the adverse reaction profile.
LABEL>0
Intravenous GE (GE) has been effectively administered in the presence of other cardioactive drugs, such as DRUG1, GE, DRUG2, and GE, without any change in the adverse reaction profile.
LABEL>0
Intravenous GE (GE) has been effectively administered in the presence of other cardioactive drugs, such as DRUG1, GE, GE, and DRUG2, without any change in the adverse reaction profile.
LABEL>0
Intravenous GE (GE) has been effectively administered in the presence of other cardioactive drugs, such as GE, DRUG1, DRUG2, and GE, without any change in the adverse reaction profile.
LABEL>0
Intravenous GE (GE) has been effectively administered in the presence of other cardioactive drugs, such as GE, DRUG1, GE, and DRUG2, without any change in the adverse reaction profile.
LABEL>0
Intravenous GE (GE) has been effectively administered in the presence of other cardioactive drugs, such as GE, GE, DRUG1, and DRUG2, without any change in the adverse reaction profile.
LABEL>0
DRUG1 and DRUG2 use may be rarely associated with ventricular fibrillation when combined with GE.
LABEL>0
The effects of GE are antagonized by DRUG1 such as DRUG2 and GE.
LABEL>0
The effects of GE are antagonized by DRUG1 such as GE and DRUG2.
LABEL>0
The effects of GE are antagonized by GE such as DRUG1 and DRUG2.
LABEL>0
In the presence of these GE, larger doses of DRUG1 may be required or DRUG2 may not be effective.
LABEL>0
Co-administration with DRUG1 such as DRUG2 or GE is not recommended.
LABEL>0
Co-administration with DRUG1 such as GE or DRUG2 is not recommended.
LABEL>0
Co-administration with GE such as DRUG1 or DRUG2 is not recommended.
LABEL>0
DRUG1, DRUG2, GE (consider GE dose reduction).
LABEL>0
DRUG1, GE, DRUG2 (consider GE dose reduction).
LABEL>0
GE, DRUG1, DRUG2 (consider GE dose reduction).
LABEL>0
DRUG1, DRUG2, GE, GE, GE (exercise caution).
LABEL>0
DRUG1, GE, DRUG2, GE, GE (exercise caution).
LABEL>0
DRUG1, GE, GE, DRUG2, GE (exercise caution).
LABEL>0
DRUG1, GE, GE, GE, DRUG2 (exercise caution).
LABEL>0
GE, DRUG1, DRUG2, GE, GE (exercise caution).
LABEL>0
GE, DRUG1, GE, DRUG2, GE (exercise caution).
LABEL>0
GE, DRUG1, GE, GE, DRUG2 (exercise caution).
LABEL>0
GE, GE, DRUG1, DRUG2, GE (exercise caution).
LABEL>0
GE, GE, DRUG1, GE, DRUG2 (exercise caution).
LABEL>0
GE, GE, GE, DRUG1, DRUG2 (exercise caution).
LABEL>0
DRUG1: Steady-state trough concentrations of DRUG2 were about 56% higher when 8 mg GE was coadministered with each dose of GE (15 mg/kg/day) in eight neurocysticercosis patients.
LABEL>0
DRUG1: Steady-state trough concentrations of GE were about 56% higher when 8 mg DRUG2 was coadministered with each dose of GE (15 mg/kg/day) in eight neurocysticercosis patients.
LABEL>0
DRUG1: Steady-state trough concentrations of GE were about 56% higher when 8 mg GE was coadministered with each dose of DRUG2 (15 mg/kg/day) in eight neurocysticercosis patients.
LABEL>0
GE: Steady-state trough concentrations of DRUG1 were about 56% higher when 8 mg DRUG2 was coadministered with each dose of GE (15 mg/kg/day) in eight neurocysticercosis patients.
LABEL>0
GE: Steady-state trough concentrations of DRUG1 were about 56% higher when 8 mg GE was coadministered with each dose of DRUG2 (15 mg/kg/day) in eight neurocysticercosis patients.
LABEL>0
DRUG1: In the fed state, DRUG2 (40 mg/kg) increased mean maximum plasma concentration and area under the curve of GE by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given GE alone.
LABEL>0
DRUG1: In the fed state, GE (40 mg/kg) increased mean maximum plasma concentration and area under the curve of DRUG2 by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given GE alone.
LABEL>0
DRUG1: In the fed state, GE (40 mg/kg) increased mean maximum plasma concentration and area under the curve of GE by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given DRUG2 alone.
LABEL>0
GE: In the fed state, DRUG1 (40 mg/kg) increased mean maximum plasma concentration and area under the curve of GE by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given DRUG2 alone.
LABEL>0
GE: In the fed state, GE (40 mg/kg) increased mean maximum plasma concentration and area under the curve of DRUG1 by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given DRUG2 alone.
LABEL>0
The pharmacokinetics of DRUG1 were unchanged following coadministration with DRUG2 (400 mg).
LABEL>0
DRUG1: DRUG2 concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with GE (10 mg/kg/day) (n=7) compared with GE (20 mg/kg/day) alone (n=12).
LABEL>0
DRUG1: GE concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with DRUG2 (10 mg/kg/day) (n=7) compared with GE (20 mg/kg/day) alone (n=12).
LABEL>0
DRUG1: GE concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with GE (10 mg/kg/day) (n=7) compared with DRUG2 (20 mg/kg/day) alone (n=12).
LABEL>0
GE: DRUG1 concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with GE (10 mg/kg/day) (n=7) compared with DRUG2 (20 mg/kg/day) alone (n=12).
LABEL>0
GE: GE concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with DRUG1 (10 mg/kg/day) (n=7) compared with DRUG2 (20 mg/kg/day) alone (n=12).
LABEL>0
DRUG1: The pharmacokinetics of DRUG2 (GE 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of GE (400 mg) in 6 healthy subjects.
LABEL>0
DRUG1: The pharmacokinetics of GE (DRUG2 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of GE (400 mg) in 6 healthy subjects.
LABEL>0
DRUG1: The pharmacokinetics of GE (GE 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of DRUG2 (400 mg) in 6 healthy subjects.
LABEL>0
GE: The pharmacokinetics of DRUG1 (DRUG2 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of GE (400 mg) in 6 healthy subjects.
LABEL>0
GE: The pharmacokinetics of DRUG1 (GE 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of DRUG2 (400 mg) in 6 healthy subjects.
LABEL>0
GE: The pharmacokinetics of GE (DRUG1 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of DRUG2 (400 mg) in 6 healthy subjects.
LABEL>0
Therefore, interactions could occur following concomitant administration of DRUG1 (e.g., DRUG2, GE, GE, GE, GE).
LABEL>0
Therefore, interactions could occur following concomitant administration of DRUG1 (e.g., GE, DRUG2, GE, GE, GE).
LABEL>0
Therefore, interactions could occur following concomitant administration of DRUG1 (e.g., GE, GE, DRUG2, GE, GE).
LABEL>0
Therefore, interactions could occur following concomitant administration of DRUG1 (e.g., GE, GE, GE, DRUG2, GE).
LABEL>0
Therefore, interactions could occur following concomitant administration of DRUG1 (e.g., GE, GE, GE, GE, DRUG2).
LABEL>0
Therefore, interactions could occur following concomitant administration of GE (e.g., DRUG1, DRUG2, GE, GE, GE).
LABEL>0
Therefore, interactions could occur following concomitant administration of GE (e.g., DRUG1, GE, DRUG2, GE, GE).
LABEL>0
Therefore, interactions could occur following concomitant administration of GE (e.g., DRUG1, GE, GE, DRUG2, GE).
LABEL>0
Therefore, interactions could occur following concomitant administration of GE (e.g., DRUG1, GE, GE, GE, DRUG2).
LABEL>0
Therefore, interactions could occur following concomitant administration of GE (e.g., GE, DRUG1, DRUG2, GE, GE).
LABEL>0
Therefore, interactions could occur following concomitant administration of GE (e.g., GE, DRUG1, GE, DRUG2, GE).
LABEL>0
Therefore, interactions could occur following concomitant administration of GE (e.g., GE, DRUG1, GE, GE, DRUG2).
LABEL>0
Therefore, interactions could occur following concomitant administration of GE (e.g., GE, GE, DRUG1, DRUG2, GE).
LABEL>0
Therefore, interactions could occur following concomitant administration of GE (e.g., GE, GE, DRUG1, GE, DRUG2).
LABEL>0
Therefore, interactions could occur following concomitant administration of GE (e.g., GE, GE, GE, DRUG1, DRUG2).
LABEL>0
Concurrent administration of drugs possessing nephrotoxic (e.g., DRUG1, DRUG2), myelotoxic (e.g., GE chemotherapy), cardiotoxic (e.g., GE) or hepatotoxic (e.g., GE, GE) effects with GE may increase toxicity in these organ systems.
LABEL>0
Concurrent administration of drugs possessing nephrotoxic (e.g., DRUG1, GE), myelotoxic (e.g., DRUG2 chemotherapy), cardiotoxic (e.g., GE) or hepatotoxic (e.g., GE, GE) effects with GE may increase toxicity in these organ systems.
LABEL>0
Concurrent administration of drugs possessing nephrotoxic (e.g., DRUG1, GE), myelotoxic (e.g., GE chemotherapy), cardiotoxic (e.g., DRUG2) or hepatotoxic (e.g., GE, GE) effects with GE may increase toxicity in these organ systems.
LABEL>0
Concurrent administration of drugs possessing nephrotoxic (e.g., DRUG1, GE), myelotoxic (e.g., GE chemotherapy), cardiotoxic (e.g., GE) or hepatotoxic (e.g., DRUG2, GE) effects with GE may increase toxicity in these organ systems.
LABEL>0
Concurrent administration of drugs possessing nephrotoxic (e.g., DRUG1, GE), myelotoxic (e.g., GE chemotherapy), cardiotoxic (e.g., GE) or hepatotoxic (e.g., GE, DRUG2) effects with GE may increase toxicity in these organ systems.
LABEL>0
Concurrent administration of drugs possessing nephrotoxic (e.g., GE, DRUG1), myelotoxic (e.g., DRUG2 chemotherapy), cardiotoxic (e.g., GE) or hepatotoxic (e.g., GE, GE) effects with GE may increase toxicity in these organ systems.
LABEL>0
Concurrent administration of drugs possessing nephrotoxic (e.g., GE, DRUG1), myelotoxic (e.g., GE chemotherapy), cardiotoxic (e.g., DRUG2) or hepatotoxic (e.g., GE, GE) effects with GE may increase toxicity in these organ systems.
LABEL>0
Concurrent administration of drugs possessing nephrotoxic (e.g., GE, DRUG1), myelotoxic (e.g., GE chemotherapy), cardiotoxic (e.g., GE) or hepatotoxic (e.g., DRUG2, GE) effects with GE may increase toxicity in these organ systems.
LABEL>0
Concurrent administration of drugs possessing nephrotoxic (e.g., GE, DRUG1), myelotoxic (e.g., GE chemotherapy), cardiotoxic (e.g., GE) or hepatotoxic (e.g., GE, DRUG2) effects with GE may increase toxicity in these organ systems.
LABEL>0
Concurrent administration of drugs possessing nephrotoxic (e.g., GE, GE), myelotoxic (e.g., DRUG1 chemotherapy), cardiotoxic (e.g., DRUG2) or hepatotoxic (e.g., GE, GE) effects with GE may increase toxicity in these organ systems.
LABEL>0
Concurrent administration of drugs possessing nephrotoxic (e.g., GE, GE), myelotoxic (e.g., DRUG1 chemotherapy), cardiotoxic (e.g., GE) or hepatotoxic (e.g., DRUG2, GE) effects with GE may increase toxicity in these organ systems.
LABEL>0
Concurrent administration of drugs possessing nephrotoxic (e.g., GE, GE), myelotoxic (e.g., DRUG1 chemotherapy), cardiotoxic (e.g., GE) or hepatotoxic (e.g., GE, DRUG2) effects with GE may increase toxicity in these organ systems.
LABEL>0
Concurrent administration of drugs possessing nephrotoxic (e.g., GE, GE), myelotoxic (e.g., GE chemotherapy), cardiotoxic (e.g., DRUG1) or hepatotoxic (e.g., DRUG2, GE) effects with GE may increase toxicity in these organ systems.
LABEL>0
Concurrent administration of drugs possessing nephrotoxic (e.g., GE, GE), myelotoxic (e.g., GE chemotherapy), cardiotoxic (e.g., DRUG1) or hepatotoxic (e.g., GE, DRUG2) effects with GE may increase toxicity in these organ systems.
LABEL>0
Concurrent administration of drugs possessing nephrotoxic (e.g., GE, GE), myelotoxic (e.g., GE chemotherapy), cardiotoxic (e.g., GE) or hepatotoxic (e.g., DRUG1, DRUG2) effects with GE may increase toxicity in these organ systems.
LABEL>0
The safety and efficacy of DRUG1 in combination with any DRUG2 have not been established.
LABEL>0
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose GE and DRUG1, specifically, DRUG2, GE, GE and GE.
LABEL>0
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose GE and DRUG1, specifically, GE, DRUG2, GE and GE.
LABEL>0
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose GE and DRUG1, specifically, GE, GE, DRUG2 and GE.
LABEL>0
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose GE and DRUG1, specifically, GE, GE, GE and DRUG2.
LABEL>0
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose GE and GE, specifically, DRUG1, DRUG2, GE and GE.
LABEL>0
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose GE and GE, specifically, DRUG1, GE, DRUG2 and GE.
LABEL>0
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose GE and GE, specifically, DRUG1, GE, GE and DRUG2.
LABEL>0
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose GE and GE, specifically, GE, DRUG1, DRUG2 and GE.
LABEL>0
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose GE and GE, specifically, GE, DRUG1, GE and DRUG2.
LABEL>0
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose GE and GE, specifically, GE, GE, DRUG1 and DRUG2.
LABEL>0
Although DRUG1 have been shown to reduce GE-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with DRUG2 may reduce the antitumor effectiveness of GE and thus should be avoided. 12 GE and other GE may potentiate the hypotension seen with GE.
LABEL>0
Although DRUG1 have been shown to reduce GE-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with GE may reduce the antitumor effectiveness of DRUG2 and thus should be avoided. 12 GE and other GE may potentiate the hypotension seen with GE.
LABEL>0
Although DRUG1 have been shown to reduce GE-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with GE may reduce the antitumor effectiveness of GE and thus should be avoided. 12 DRUG2 and other GE may potentiate the hypotension seen with GE.
LABEL>0
Although DRUG1 have been shown to reduce GE-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with GE may reduce the antitumor effectiveness of GE and thus should be avoided. 12 GE and other DRUG2 may potentiate the hypotension seen with GE.
LABEL>0
Although DRUG1 have been shown to reduce GE-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with GE may reduce the antitumor effectiveness of GE and thus should be avoided. 12 GE and other GE may potentiate the hypotension seen with DRUG2.
LABEL>0
Although GE have been shown to reduce DRUG1-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with DRUG2 may reduce the antitumor effectiveness of GE and thus should be avoided. 12 GE and other GE may potentiate the hypotension seen with GE.
LABEL>0
Although GE have been shown to reduce DRUG1-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with GE may reduce the antitumor effectiveness of DRUG2 and thus should be avoided. 12 GE and other GE may potentiate the hypotension seen with GE.
LABEL>0
Although GE have been shown to reduce DRUG1-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with GE may reduce the antitumor effectiveness of GE and thus should be avoided. 12 DRUG2 and other GE may potentiate the hypotension seen with GE.
LABEL>0
Although GE have been shown to reduce DRUG1-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with GE may reduce the antitumor effectiveness of GE and thus should be avoided. 12 GE and other DRUG2 may potentiate the hypotension seen with GE.
LABEL>0
Although GE have been shown to reduce DRUG1-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with GE may reduce the antitumor effectiveness of GE and thus should be avoided. 12 GE and other GE may potentiate the hypotension seen with DRUG2.
LABEL>0
Although GE have been shown to reduce GE-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with DRUG1 may reduce the antitumor effectiveness of DRUG2 and thus should be avoided. 12 GE and other GE may potentiate the hypotension seen with GE.
LABEL>0
Although GE have been shown to reduce GE-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with DRUG1 may reduce the antitumor effectiveness of GE and thus should be avoided. 12 DRUG2 and other GE may potentiate the hypotension seen with GE.
LABEL>0
Although GE have been shown to reduce GE-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with DRUG1 may reduce the antitumor effectiveness of GE and thus should be avoided. 12 GE and other DRUG2 may potentiate the hypotension seen with GE.
LABEL>0
Although GE have been shown to reduce GE-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with DRUG1 may reduce the antitumor effectiveness of GE and thus should be avoided. 12 GE and other GE may potentiate the hypotension seen with DRUG2.
LABEL>0
Although GE have been shown to reduce GE-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with GE may reduce the antitumor effectiveness of DRUG1 and thus should be avoided. 12 DRUG2 and other GE may potentiate the hypotension seen with GE.
LABEL>0
Although GE have been shown to reduce GE-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with GE may reduce the antitumor effectiveness of DRUG1 and thus should be avoided. 12 GE and other DRUG2 may potentiate the hypotension seen with GE.
LABEL>0
Although GE have been shown to reduce GE-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with GE may reduce the antitumor effectiveness of DRUG1 and thus should be avoided. 12 GE and other GE may potentiate the hypotension seen with DRUG2.
LABEL>0
Although GE have been shown to reduce GE-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with GE may reduce the antitumor effectiveness of GE and thus should be avoided. 12 DRUG1 and other DRUG2 may potentiate the hypotension seen with GE.
LABEL>0
Delayed Adverse Reactions to DRUG1: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various DRUG2 containing regimens who were subsequently administered GE experienced acute, atypical adverse reactions.
LABEL>0
Delayed Adverse Reactions to DRUG1: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various GE containing regimens who were subsequently administered DRUG2 experienced acute, atypical adverse reactions.
LABEL>0
The duration of the period following treatment with DRUG1  before one should consider starting other DRUG2 therapy has not been evaluated.
LABEL>0
Since the effect of DRUG1 on pregnancy and fetal development, including immune system development, is not known, health care providers are encouraged to enroll patients currently taking DRUG2 who become pregnant into the Biogen Pregnancy Registry by calling 1-866-GE (1-866-263-8483).
LABEL>0
Since the effect of DRUG1 on pregnancy and fetal development, including immune system development, is not known, health care providers are encouraged to enroll patients currently taking GE who become pregnant into the Biogen Pregnancy Registry by calling 1-866-DRUG2 (1-866-263-8483).
LABEL>0
Since the effect of GE on pregnancy and fetal development, including immune system development, is not known, health care providers are encouraged to enroll patients currently taking DRUG1 who become pregnant into the Biogen Pregnancy Registry by calling 1-866-DRUG2 (1-866-263-8483).
LABEL>0
An immune response to DRUG1 may interfere with subsequent diagnostic serum tests that utilize DRUG2
LABEL>0
Products containing DRUG1 and other DRUG2 likely will interfere with absorption of GE.
LABEL>0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when GE is administered in combination with other DRUG1 such as DRUG2, GE, GE, or inhalation general GE.
LABEL>0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when GE is administered in combination with other DRUG1 such as GE, DRUG2, GE, or inhalation general GE.
LABEL>0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when GE is administered in combination with other DRUG1 such as GE, GE, DRUG2, or inhalation general GE.
LABEL>0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when GE is administered in combination with other DRUG1 such as GE, GE, GE, or inhalation general DRUG2.
LABEL>0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when GE is administered in combination with other GE such as DRUG1, DRUG2, GE, or inhalation general GE.
LABEL>0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when GE is administered in combination with other GE such as DRUG1, GE, DRUG2, or inhalation general GE.
LABEL>0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when GE is administered in combination with other GE such as DRUG1, GE, GE, or inhalation general DRUG2.
LABEL>0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when GE is administered in combination with other GE such as GE, DRUG1, DRUG2, or inhalation general GE.
LABEL>0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when GE is administered in combination with other GE such as GE, DRUG1, GE, or inhalation general DRUG2.
LABEL>0
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when GE is administered in combination with other GE such as GE, GE, DRUG1, or inhalation general DRUG2.
LABEL>0
Limited clinical experience indicates that requirements for DRUG1 are reduced by 30 to 50% for the first sixty (60) minutes following GE induction The concomitant use of DRUG2 with GE can significantly inhibit GE clearance and may increase the risk of prolonged or delayed respiratory depression.
LABEL>0
Limited clinical experience indicates that requirements for DRUG1 are reduced by 30 to 50% for the first sixty (60) minutes following GE induction The concomitant use of GE with DRUG2 can significantly inhibit GE clearance and may increase the risk of prolonged or delayed respiratory depression.
LABEL>0
Limited clinical experience indicates that requirements for DRUG1 are reduced by 30 to 50% for the first sixty (60) minutes following GE induction The concomitant use of GE with GE can significantly inhibit DRUG2 clearance and may increase the risk of prolonged or delayed respiratory depression.
LABEL>0
Limited clinical experience indicates that requirements for GE are reduced by 30 to 50% for the first sixty (60) minutes following DRUG1 induction The concomitant use of DRUG2 with GE can significantly inhibit GE clearance and may increase the risk of prolonged or delayed respiratory depression.
LABEL>0
Limited clinical experience indicates that requirements for GE are reduced by 30 to 50% for the first sixty (60) minutes following DRUG1 induction The concomitant use of GE with DRUG2 can significantly inhibit GE clearance and may increase the risk of prolonged or delayed respiratory depression.
LABEL>0
Limited clinical experience indicates that requirements for GE are reduced by 30 to 50% for the first sixty (60) minutes following DRUG1 induction The concomitant use of GE with GE can significantly inhibit DRUG2 clearance and may increase the risk of prolonged or delayed respiratory depression.
LABEL>0
Limited clinical experience indicates that requirements for GE are reduced by 30 to 50% for the first sixty (60) minutes following GE induction The concomitant use of DRUG1 with GE can significantly inhibit DRUG2 clearance and may increase the risk of prolonged or delayed respiratory depression.
LABEL>0
Limited clinical experience indicates that requirements for GE are reduced by 30 to 50% for the first sixty (60) minutes following GE induction The concomitant use of GE with DRUG1 can significantly inhibit DRUG2 clearance and may increase the risk of prolonged or delayed respiratory depression.
LABEL>0
Therefore smaller DRUG1 doses will be required with prolonged administration and the duration of action of DRUG2 my be extended.
LABEL>0
Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between DRUG1 and other DRUG2 have not been determined.
LABEL>0
Effects of Other Drugs on DRUG1 Based on in-vitro studies, DRUG2 is metabolized by CYP 3A4.
LABEL>0
Co-administration of DRUG1, DRUG2, GE, GE, GE, GE, GE, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of DRUG1, GE, DRUG2, GE, GE, GE, GE, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of DRUG1, GE, GE, DRUG2, GE, GE, GE, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of DRUG1, GE, GE, GE, DRUG2, GE, GE, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of DRUG1, GE, GE, GE, GE, DRUG2, GE, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of DRUG1, GE, GE, GE, GE, GE, DRUG2, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of DRUG1, GE, GE, GE, GE, GE, GE, DRUG2, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of DRUG1, GE, GE, GE, GE, GE, GE, GE, DRUG2, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of DRUG1, GE, GE, GE, GE, GE, GE, GE, GE, DRUG2 and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of DRUG1, GE, GE, GE, GE, GE, GE, GE, GE, GE and DRUG2 did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of DRUG1, GE, GE, GE, GE, GE, GE, GE, GE, GE and GE did not result in clinically significant increases in DRUG2 exposure.
LABEL>0
Co-administration of GE, DRUG1, DRUG2, GE, GE, GE, GE, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, DRUG1, GE, DRUG2, GE, GE, GE, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, DRUG1, GE, GE, DRUG2, GE, GE, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, DRUG1, GE, GE, GE, DRUG2, GE, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, DRUG1, GE, GE, GE, GE, DRUG2, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, DRUG1, GE, GE, GE, GE, GE, DRUG2, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, DRUG1, GE, GE, GE, GE, GE, GE, DRUG2, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, DRUG1, GE, GE, GE, GE, GE, GE, GE, DRUG2 and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, DRUG1, GE, GE, GE, GE, GE, GE, GE, GE and DRUG2 did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, DRUG1, GE, GE, GE, GE, GE, GE, GE, GE and GE did not result in clinically significant increases in DRUG2 exposure.
LABEL>0
Co-administration of GE, GE, DRUG1, DRUG2, GE, GE, GE, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, DRUG1, GE, DRUG2, GE, GE, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, DRUG1, GE, GE, DRUG2, GE, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, DRUG1, GE, GE, GE, DRUG2, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, DRUG1, GE, GE, GE, GE, DRUG2, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, DRUG1, GE, GE, GE, GE, GE, DRUG2, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, DRUG1, GE, GE, GE, GE, GE, GE, DRUG2 and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, DRUG1, GE, GE, GE, GE, GE, GE, GE and DRUG2 did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, DRUG1, GE, GE, GE, GE, GE, GE, GE and GE did not result in clinically significant increases in DRUG2 exposure.
LABEL>0
Co-administration of GE, GE, GE, DRUG1, DRUG2, GE, GE, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, DRUG1, GE, DRUG2, GE, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, DRUG1, GE, GE, DRUG2, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, DRUG1, GE, GE, GE, DRUG2, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, DRUG1, GE, GE, GE, GE, DRUG2, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, DRUG1, GE, GE, GE, GE, GE, DRUG2 and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, DRUG1, GE, GE, GE, GE, GE, GE and DRUG2 did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, DRUG1, GE, GE, GE, GE, GE, GE and GE did not result in clinically significant increases in DRUG2 exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, DRUG1, DRUG2, GE, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, DRUG1, GE, DRUG2, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, DRUG1, GE, GE, DRUG2, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, DRUG1, GE, GE, GE, DRUG2, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, DRUG1, GE, GE, GE, GE, DRUG2 and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, DRUG1, GE, GE, GE, GE, GE and DRUG2 did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, DRUG1, GE, GE, GE, GE, GE and GE did not result in clinically significant increases in DRUG2 exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, DRUG1, DRUG2, GE, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, DRUG1, GE, DRUG2, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, DRUG1, GE, GE, DRUG2, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, DRUG1, GE, GE, GE, DRUG2 and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, DRUG1, GE, GE, GE, GE and DRUG2 did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, DRUG1, GE, GE, GE, GE and GE did not result in clinically significant increases in DRUG2 exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, GE, DRUG1, DRUG2, GE, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, GE, DRUG1, GE, DRUG2, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, GE, DRUG1, GE, GE, DRUG2 and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, GE, DRUG1, GE, GE, GE and DRUG2 did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, GE, DRUG1, GE, GE, GE and GE did not result in clinically significant increases in DRUG2 exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, GE, GE, DRUG1, DRUG2, GE and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, GE, GE, DRUG1, GE, DRUG2 and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, GE, GE, DRUG1, GE, GE and DRUG2 did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, GE, GE, DRUG1, GE, GE and GE did not result in clinically significant increases in DRUG2 exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, GE, GE, GE, DRUG1, DRUG2 and GE did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, GE, GE, GE, DRUG1, GE and DRUG2 did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, GE, GE, GE, DRUG1, GE and GE did not result in clinically significant increases in DRUG2 exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, GE, GE, GE, GE, DRUG1 and DRUG2 did not result in clinically significant increases in GE exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, GE, GE, GE, GE, DRUG1 and GE did not result in clinically significant increases in DRUG2 exposure.
LABEL>0
Co-administration of GE, GE, GE, GE, GE, GE, GE, GE, GE, GE and DRUG1 did not result in clinically significant increases in DRUG2 exposure.
LABEL>0
DRUG1: Co-administration of 200 mg twice-daily DRUG2 with GE resulted in an approximate 80% increase in plasma levels of GE.
LABEL>0
DRUG1: Co-administration of 200 mg twice-daily GE with DRUG2 resulted in an approximate 80% increase in plasma levels of GE.
LABEL>0
DRUG1: Co-administration of 200 mg twice-daily GE with GE resulted in an approximate 80% increase in plasma levels of DRUG2.
LABEL>0
GE: Co-administration of 200 mg twice-daily DRUG1 with GE resulted in an approximate 80% increase in plasma levels of DRUG2.
LABEL>0
GE: Co-administration of 200 mg twice-daily GE with DRUG1 resulted in an approximate 80% increase in plasma levels of DRUG2.
LABEL>0
Effects of DRUG1 on Other Drugs DRUG2 does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and CYP 3A) or induce CYP 3A4.
LABEL>0
Co-administration of DRUG1 did not significantly affect the pharmacokinetics of DRUG2, GE, GE, GE, GE, GE, GE, GE, GE or GE.
LABEL>0
Co-administration of DRUG1 did not significantly affect the pharmacokinetics of GE, DRUG2, GE, GE, GE, GE, GE, GE, GE or GE.
LABEL>0
Co-administration of DRUG1 did not significantly affect the pharmacokinetics of GE, GE, DRUG2, GE, GE, GE, GE, GE, GE or GE.
LABEL>0
Co-administration of DRUG1 did not significantly affect the pharmacokinetics of GE, GE, GE, DRUG2, GE, GE, GE, GE, GE or GE.
LABEL>0
Co-administration of DRUG1 did not significantly affect the pharmacokinetics of GE, GE, GE, GE, DRUG2, GE, GE, GE, GE or GE.
LABEL>0
Co-administration of DRUG1 did not significantly affect the pharmacokinetics of GE, GE, GE, GE, GE, DRUG2, GE, GE, GE or GE.
LABEL>0
Co-administration of DRUG1 did not significantly affect the pharmacokinetics of GE, GE, GE, GE, GE, GE, DRUG2, GE, GE or GE.
LABEL>0
Co-administration of DRUG1 did not significantly affect the pharmacokinetics of GE, GE, GE, GE, GE, GE, GE, DRUG2, GE or GE.
LABEL>0
Co-administration of DRUG1 did not significantly affect the pharmacokinetics of GE, GE, GE, GE, GE, GE, GE, GE, DRUG2 or GE.
LABEL>0
Co-administration of DRUG1 did not significantly affect the pharmacokinetics of GE, GE, GE, GE, GE, GE, GE, GE, GE or DRUG2.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of DRUG1, DRUG2, GE, GE, GE, GE, GE, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of DRUG1, GE, DRUG2, GE, GE, GE, GE, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of DRUG1, GE, GE, DRUG2, GE, GE, GE, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of DRUG1, GE, GE, GE, DRUG2, GE, GE, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of DRUG1, GE, GE, GE, GE, DRUG2, GE, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of DRUG1, GE, GE, GE, GE, GE, DRUG2, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of DRUG1, GE, GE, GE, GE, GE, GE, DRUG2, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of DRUG1, GE, GE, GE, GE, GE, GE, GE, DRUG2 or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of DRUG1, GE, GE, GE, GE, GE, GE, GE, GE or DRUG2.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, DRUG1, DRUG2, GE, GE, GE, GE, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, DRUG1, GE, DRUG2, GE, GE, GE, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, DRUG1, GE, GE, DRUG2, GE, GE, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, DRUG1, GE, GE, GE, DRUG2, GE, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, DRUG1, GE, GE, GE, GE, DRUG2, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, DRUG1, GE, GE, GE, GE, GE, DRUG2, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, DRUG1, GE, GE, GE, GE, GE, GE, DRUG2 or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, DRUG1, GE, GE, GE, GE, GE, GE, GE or DRUG2.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, DRUG1, DRUG2, GE, GE, GE, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, DRUG1, GE, DRUG2, GE, GE, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, DRUG1, GE, GE, DRUG2, GE, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, DRUG1, GE, GE, GE, DRUG2, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, DRUG1, GE, GE, GE, GE, DRUG2, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, DRUG1, GE, GE, GE, GE, GE, DRUG2 or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, DRUG1, GE, GE, GE, GE, GE, GE or DRUG2.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, DRUG1, DRUG2, GE, GE, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, DRUG1, GE, DRUG2, GE, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, DRUG1, GE, GE, DRUG2, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, DRUG1, GE, GE, GE, DRUG2, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, DRUG1, GE, GE, GE, GE, DRUG2 or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, DRUG1, GE, GE, GE, GE, GE or DRUG2.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, GE, DRUG1, DRUG2, GE, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, GE, DRUG1, GE, DRUG2, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, GE, DRUG1, GE, GE, DRUG2, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, GE, DRUG1, GE, GE, GE, DRUG2 or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, GE, DRUG1, GE, GE, GE, GE or DRUG2.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, GE, GE, DRUG1, DRUG2, GE, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, GE, GE, DRUG1, GE, DRUG2, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, GE, GE, DRUG1, GE, GE, DRUG2 or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, GE, GE, DRUG1, GE, GE, GE or DRUG2.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, GE, GE, GE, DRUG1, DRUG2, GE or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, GE, GE, GE, DRUG1, GE, DRUG2 or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, GE, GE, GE, DRUG1, GE, GE or DRUG2.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, GE, GE, GE, GE, DRUG1, DRUG2 or GE.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, GE, GE, GE, GE, DRUG1, GE or DRUG2.
LABEL>0
Co-administration of GE did not significantly affect the pharmacokinetics of GE, GE, GE, GE, GE, GE, GE, GE, DRUG1 or DRUG2.
LABEL>0
DRUG1: The effects of DRUG2 on GE pharmacokinetics have not been evaluated in a well-controlled clinical trial.
LABEL>0
DRUG1: The effects of GE on DRUG2 pharmacokinetics have not been evaluated in a well-controlled clinical trial.
LABEL>0
GE: The effects of DRUG1 on DRUG2 pharmacokinetics have not been evaluated in a well-controlled clinical trial.
LABEL>0
DRUG1: When DRUG2 was co-administered with GE, the AUC and Cmax of GE were reduced by about 30% and 50%, respectively.
LABEL>0
DRUG1: When GE was co-administered with DRUG2, the AUC and Cmax of GE were reduced by about 30% and 50%, respectively.
LABEL>0
DRUG1: When GE was co-administered with GE, the AUC and Cmax of DRUG2 were reduced by about 30% and 50%, respectively.
LABEL>0
GE: When DRUG1 was co-administered with GE, the AUC and Cmax of DRUG2 were reduced by about 30% and 50%, respectively.
LABEL>0
GE: When GE was co-administered with DRUG1, the AUC and Cmax of DRUG2 were reduced by about 30% and 50%, respectively.
LABEL>0
Patients who are applying GE gel should not concurrently use products that contain DRUG1 (N, DRUG2), a common component of insect repellent products.
LABEL>0
Animal toxicology studies showed increased DRUG1 toxicity when DRUG2 was included as proof of the formulation.
LABEL>0
Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic DRUG1, including DRUG2, GE, and GE, the effect of GE gel on the steady-state concentrations of these drugs is not known.
LABEL>0
Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic DRUG1, including GE, DRUG2, and GE, the effect of GE gel on the steady-state concentrations of these drugs is not known.
LABEL>0
Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic DRUG1, including GE, GE, and DRUG2, the effect of GE gel on the steady-state concentrations of these drugs is not known.
LABEL>0
Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic DRUG1, including GE, GE, and GE, the effect of DRUG2 gel on the steady-state concentrations of these drugs is not known.
LABEL>0
Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic GE, including DRUG1, DRUG2, and GE, the effect of GE gel on the steady-state concentrations of these drugs is not known.
LABEL>0
Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic GE, including DRUG1, GE, and DRUG2, the effect of GE gel on the steady-state concentrations of these drugs is not known.
LABEL>0
Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic GE, including DRUG1, GE, and GE, the effect of DRUG2 gel on the steady-state concentrations of these drugs is not known.
LABEL>0
Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic GE, including GE, DRUG1, and DRUG2, the effect of GE gel on the steady-state concentrations of these drugs is not known.
LABEL>0
Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic GE, including GE, DRUG1, and GE, the effect of DRUG2 gel on the steady-state concentrations of these drugs is not known.
LABEL>0
Although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic GE, including GE, GE, and DRUG1, the effect of DRUG2 gel on the steady-state concentrations of these drugs is not known.
LABEL>0
DRUG1/DRUG2: GE inhibits the enzymatic oxidation of GE and GE to GE.
LABEL>0
DRUG1/GE: DRUG2 inhibits the enzymatic oxidation of GE and GE to GE.
LABEL>0
DRUG1/GE: GE inhibits the enzymatic oxidation of DRUG2 and GE to GE.
LABEL>0
DRUG1/GE: GE inhibits the enzymatic oxidation of GE and DRUG2 to GE.
LABEL>0
DRUG1/GE: GE inhibits the enzymatic oxidation of GE and GE to DRUG2.
LABEL>0
GE/DRUG1: DRUG2 inhibits the enzymatic oxidation of GE and GE to GE.
LABEL>0
GE/DRUG1: GE inhibits the enzymatic oxidation of DRUG2 and GE to GE.
LABEL>0
GE/DRUG1: GE inhibits the enzymatic oxidation of GE and DRUG2 to GE.
LABEL>0
GE/DRUG1: GE inhibits the enzymatic oxidation of GE and GE to DRUG2.
LABEL>0
GE/GE: DRUG1 inhibits the enzymatic oxidation of GE and GE to DRUG2.
LABEL>0
GE/GE: GE inhibits the enzymatic oxidation of DRUG1 and DRUG2 to GE.
LABEL>0
GE/GE: GE inhibits the enzymatic oxidation of DRUG1 and GE to DRUG2.
LABEL>0
GE/GE: GE inhibits the enzymatic oxidation of GE and DRUG1 to DRUG2.
LABEL>0
In patients receiving DRUG1 (DRUG2) or GE (GE), the concomitant administration of 300-600 mg of GE per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of GE or GE.
LABEL>0
In patients receiving DRUG1 (GE) or DRUG2 (GE), the concomitant administration of 300-600 mg of GE per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of GE or GE.
LABEL>0
In patients receiving DRUG1 (GE) or GE (DRUG2), the concomitant administration of 300-600 mg of GE per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of GE or GE.
LABEL>0
In patients receiving DRUG1 (GE) or GE (GE), the concomitant administration of 300-600 mg of DRUG2 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of GE or GE.
LABEL>0
In patients receiving DRUG1 (GE) or GE (GE), the concomitant administration of 300-600 mg of GE per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of DRUG2 or GE.
LABEL>0
In patients receiving DRUG1 (GE) or GE (GE), the concomitant administration of 300-600 mg of GE per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of GE or DRUG2.
LABEL>0
In patients receiving GE (DRUG1) or DRUG2 (GE), the concomitant administration of 300-600 mg of GE per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of GE or GE.
LABEL>0
In patients receiving GE (DRUG1) or GE (DRUG2), the concomitant administration of 300-600 mg of GE per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of GE or GE.
LABEL>0
In patients receiving GE (DRUG1) or GE (GE), the concomitant administration of 300-600 mg of DRUG2 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of GE or GE.
LABEL>0
In patients receiving GE (DRUG1) or GE (GE), the concomitant administration of 300-600 mg of GE per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of DRUG2 or GE.
LABEL>0
In patients receiving GE (DRUG1) or GE (GE), the concomitant administration of 300-600 mg of GE per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of GE or DRUG2.
LABEL>0
In patients receiving GE (GE) or DRUG1 (DRUG2), the concomitant administration of 300-600 mg of GE per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of GE or GE.
LABEL>0
In patients receiving GE (GE) or DRUG1 (GE), the concomitant administration of 300-600 mg of DRUG2 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of GE or GE.
LABEL>0
In patients receiving GE (GE) or DRUG1 (GE), the concomitant administration of 300-600 mg of GE per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of DRUG2 or GE.
LABEL>0
In patients receiving GE (GE) or DRUG1 (GE), the concomitant administration of 300-600 mg of GE per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of GE or DRUG2.
LABEL>0
In patients receiving GE (GE) or GE (DRUG1), the concomitant administration of 300-600 mg of DRUG2 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of GE or GE.
LABEL>0
In patients receiving GE (GE) or GE (DRUG1), the concomitant administration of 300-600 mg of GE per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of DRUG2 or GE.
LABEL>0
In patients receiving GE (GE) or GE (DRUG1), the concomitant administration of 300-600 mg of GE per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of GE or DRUG2.
LABEL>0
In patients receiving GE (GE) or GE (GE), the concomitant administration of 300-600 mg of GE per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of DRUG1 or DRUG2.
LABEL>0
Subsequent adjustment of doses of DRUG1 or DRUG2 should be made on the basis of therapeutic response and the appearance of toxic effects.
LABEL>0
DRUG1: It has been reported that DRUG2 prolongs the half-life of the GE, GE.
LABEL>0
DRUG1: It has been reported that GE prolongs the half-life of the DRUG2, GE.
LABEL>0
DRUG1: It has been reported that GE prolongs the half-life of the GE, DRUG2.
LABEL>0
GE: It has been reported that DRUG1 prolongs the half-life of the DRUG2, GE.
LABEL>0
GE: It has been reported that GE prolongs the half-life of the DRUG1, DRUG2.
LABEL>0
The clinical basis of this drug interaction has not been established but should be noted when DRUG1 is given to patients already on DRUG2 therapy.
LABEL>0
DRUG1: Since the excretion of DRUG2 is similar to that of urate, GE, which increase the excretion of urate, are also likely to increase the excretion of GE and thus lower the degree of inhibition of xanthine oxidase.
LABEL>0
DRUG1: Since the excretion of GE is similar to that of urate, DRUG2, which increase the excretion of urate, are also likely to increase the excretion of GE and thus lower the degree of inhibition of xanthine oxidase.
LABEL>0
DRUG1: Since the excretion of GE is similar to that of urate, GE, which increase the excretion of urate, are also likely to increase the excretion of DRUG2 and thus lower the degree of inhibition of xanthine oxidase.
LABEL>0
GE: Since the excretion of DRUG1 is similar to that of urate, DRUG2, which increase the excretion of urate, are also likely to increase the excretion of GE and thus lower the degree of inhibition of xanthine oxidase.
LABEL>0
GE: Since the excretion of DRUG1 is similar to that of urate, GE, which increase the excretion of urate, are also likely to increase the excretion of DRUG2 and thus lower the degree of inhibition of xanthine oxidase.
LABEL>0
The concomitant administration of DRUG1 and GE has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with DRUG2 alone.
LABEL>0
The concomitant administration of GE and DRUG1 has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with DRUG2 alone.
LABEL>0
Although clinical evidence to date has not demonstrated renal precipitation of oxypurines in patients either on DRUG1 alone or in combination with DRUG2, the possibility should be kept in mind.
LABEL>0
DRUG1: The reports that the concomitant use of DRUG2 and GE may contribute to the enhancement of GE toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
LABEL>0
DRUG1: The reports that the concomitant use of GE and DRUG2 may contribute to the enhancement of GE toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
LABEL>0
DRUG1: The reports that the concomitant use of GE and GE may contribute to the enhancement of DRUG2 toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
LABEL>0
GE: The reports that the concomitant use of DRUG1 and GE may contribute to the enhancement of DRUG2 toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
LABEL>0
GE: The reports that the concomitant use of GE and DRUG1 may contribute to the enhancement of DRUG2 toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
LABEL>0
DRUG1/DRUG2: An increase in the frequency of skin rash has been reported among patients receiving GE or GE concurrently with GE compared to patients who are not receiving both drugs.
LABEL>0
DRUG1/GE: An increase in the frequency of skin rash has been reported among patients receiving DRUG2 or GE concurrently with GE compared to patients who are not receiving both drugs.
LABEL>0
DRUG1/GE: An increase in the frequency of skin rash has been reported among patients receiving GE or DRUG2 concurrently with GE compared to patients who are not receiving both drugs.
LABEL>0
DRUG1/GE: An increase in the frequency of skin rash has been reported among patients receiving GE or GE concurrently with DRUG2 compared to patients who are not receiving both drugs.
LABEL>0
GE/DRUG1: An increase in the frequency of skin rash has been reported among patients receiving DRUG2 or GE concurrently with GE compared to patients who are not receiving both drugs.
LABEL>0
GE/DRUG1: An increase in the frequency of skin rash has been reported among patients receiving GE or DRUG2 concurrently with GE compared to patients who are not receiving both drugs.
LABEL>0
GE/DRUG1: An increase in the frequency of skin rash has been reported among patients receiving GE or GE concurrently with DRUG2 compared to patients who are not receiving both drugs.
LABEL>0
GE/GE: An increase in the frequency of skin rash has been reported among patients receiving DRUG1 or DRUG2 concurrently with GE compared to patients who are not receiving both drugs.
LABEL>0
DRUG1: Enhanced bone marrow suppression by DRUG2 and other GE has been reported among patients with neoplastic disease, except leukemia, in the presence of GE.
LABEL>0
DRUG1: Enhanced bone marrow suppression by GE and other DRUG2 has been reported among patients with neoplastic disease, except leukemia, in the presence of GE.
LABEL>0
DRUG1: Enhanced bone marrow suppression by GE and other GE has been reported among patients with neoplastic disease, except leukemia, in the presence of DRUG2.
LABEL>0
GE: Enhanced bone marrow suppression by DRUG1 and other DRUG2 has been reported among patients with neoplastic disease, except leukemia, in the presence of GE.
LABEL>0
However, in a well-controlled study of patients with lymphoma on combination therapy, DRUG1 did not increase the marrow toxicity of patients treated with DRUG2, GE, GE, GE and/or GE.
LABEL>0
However, in a well-controlled study of patients with lymphoma on combination therapy, DRUG1 did not increase the marrow toxicity of patients treated with GE, DRUG2, GE, GE and/or GE.
LABEL>0
However, in a well-controlled study of patients with lymphoma on combination therapy, DRUG1 did not increase the marrow toxicity of patients treated with GE, GE, DRUG2, GE and/or GE.
LABEL>0
However, in a well-controlled study of patients with lymphoma on combination therapy, DRUG1 did not increase the marrow toxicity of patients treated with GE, GE, GE, DRUG2 and/or GE.
LABEL>0
However, in a well-controlled study of patients with lymphoma on combination therapy, DRUG1 did not increase the marrow toxicity of patients treated with GE, GE, GE, GE and/or DRUG2.
LABEL>0
However, in a well-controlled study of patients with lymphoma on combination therapy, GE did not increase the marrow toxicity of patients treated with DRUG1, DRUG2, GE, GE and/or GE.
LABEL>0
However, in a well-controlled study of patients with lymphoma on combination therapy, GE did not increase the marrow toxicity of patients treated with DRUG1, GE, DRUG2, GE and/or GE.
LABEL>0
However, in a well-controlled study of patients with lymphoma on combination therapy, GE did not increase the marrow toxicity of patients treated with DRUG1, GE, GE, DRUG2 and/or GE.
LABEL>0
However, in a well-controlled study of patients with lymphoma on combination therapy, GE did not increase the marrow toxicity of patients treated with DRUG1, GE, GE, GE and/or DRUG2.
LABEL>0
However, in a well-controlled study of patients with lymphoma on combination therapy, GE did not increase the marrow toxicity of patients treated with GE, DRUG1, DRUG2, GE and/or GE.
LABEL>0
However, in a well-controlled study of patients with lymphoma on combination therapy, GE did not increase the marrow toxicity of patients treated with GE, DRUG1, GE, DRUG2 and/or GE.
LABEL>0
However, in a well-controlled study of patients with lymphoma on combination therapy, GE did not increase the marrow toxicity of patients treated with GE, DRUG1, GE, GE and/or DRUG2.
LABEL>0
However, in a well-controlled study of patients with lymphoma on combination therapy, GE did not increase the marrow toxicity of patients treated with GE, GE, DRUG1, DRUG2 and/or GE.
LABEL>0
However, in a well-controlled study of patients with lymphoma on combination therapy, GE did not increase the marrow toxicity of patients treated with GE, GE, DRUG1, GE and/or DRUG2.
LABEL>0
However, in a well-controlled study of patients with lymphoma on combination therapy, GE did not increase the marrow toxicity of patients treated with GE, GE, GE, DRUG1 and/or DRUG2.
LABEL>0
DRUG1: DRUG2s plasma half-life may be prolonged by GE, since GE and GE may compete for excretion in the renal tubule.
LABEL>0
DRUG1: GEs plasma half-life may be prolonged by DRUG2, since GE and GE may compete for excretion in the renal tubule.
LABEL>0
DRUG1: GEs plasma half-life may be prolonged by GE, since DRUG2 and GE may compete for excretion in the renal tubule.
LABEL>0
DRUG1: GEs plasma half-life may be prolonged by GE, since GE and DRUG2 may compete for excretion in the renal tubule.
LABEL>0
GE: DRUG1s plasma half-life may be prolonged by GE, since DRUG2 and GE may compete for excretion in the renal tubule.
LABEL>0
GE: DRUG1s plasma half-life may be prolonged by GE, since GE and DRUG2 may compete for excretion in the renal tubule.
LABEL>0
GE: GEs plasma half-life may be prolonged by DRUG1, since DRUG2 and GE may compete for excretion in the renal tubule.
LABEL>0
GE: GEs plasma half-life may be prolonged by DRUG1, since GE and DRUG2 may compete for excretion in the renal tubule.
LABEL>0
DRUG1: Reports indicate that DRUG2 levels may be increased during concomitant treatment with GE for injection.
LABEL>0
DRUG1: Reports indicate that GE levels may be increased during concomitant treatment with DRUG2 for injection.
LABEL>0
Monitoring of DRUG1 levels and possible adjustment of DRUG2 dosage should be considered when these drugs are co-administered.
LABEL>0
Because there is a theoretical basis that these effects may be additive, use of DRUG1-containing or DRUG2 (like GE or GE) and GE within 24 hours of each other should be avoided.
LABEL>0
Because there is a theoretical basis that these effects may be additive, use of DRUG1-containing or GE (like DRUG2 or GE) and GE within 24 hours of each other should be avoided.
LABEL>0
Because there is a theoretical basis that these effects may be additive, use of DRUG1-containing or GE (like GE or DRUG2) and GE within 24 hours of each other should be avoided.
LABEL>0
Because there is a theoretical basis that these effects may be additive, use of GE-containing or DRUG1 (like DRUG2 or GE) and GE within 24 hours of each other should be avoided.
LABEL>0
Because there is a theoretical basis that these effects may be additive, use of GE-containing or DRUG1 (like GE or DRUG2) and GE within 24 hours of each other should be avoided.
LABEL>0
Because there is a theoretical basis that these effects may be additive, use of GE-containing or GE (like DRUG1 or DRUG2) and GE within 24 hours of each other should be avoided.
LABEL>0
DRUG1: Coadministration of DRUG2 resulted in a 27% decrease in GE clearance and an increase in Cmax of approximately 6%.
LABEL>0
DRUG1: Coadministration of GE resulted in a 27% decrease in DRUG2 clearance and an increase in Cmax of approximately 6%.
LABEL>0
Other DRUG1 Concomitant use of other DRUG2 within 24 hours of treatment with GE is contraindicated.
LABEL>0
Other DRUG1 Concomitant use of other GE within 24 hours of treatment with DRUG2 is contraindicated.
LABEL>0
DRUG1: The pharmacokinetics of DRUG2 were not affected by coadministration of GE.
LABEL>0
DRUG1: The pharmacokinetics of GE were not affected by coadministration of DRUG2.
LABEL>0
GE: The pharmacokinetics of DRUG1 were not affected by coadministration of DRUG2.
LABEL>0
DRUG1 (DRUG2): GE (e.g., GE, GE, GE, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
DRUG1 (GE): DRUG2 (e.g., GE, GE, GE, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
DRUG1 (GE): GE (e.g., DRUG2, GE, GE, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
DRUG1 (GE): GE (e.g., GE, DRUG2, GE, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
DRUG1 (GE): GE (e.g., GE, GE, DRUG2, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
DRUG1 (GE): GE (e.g., GE, GE, GE, DRUG2) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
DRUG1 (GE): GE (e.g., GE, GE, GE, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2.
LABEL>0
GE (DRUG1): DRUG2 (e.g., GE, GE, GE, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
GE (DRUG1): GE (e.g., DRUG2, GE, GE, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
GE (DRUG1): GE (e.g., GE, DRUG2, GE, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
GE (DRUG1): GE (e.g., GE, GE, DRUG2, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
GE (DRUG1): GE (e.g., GE, GE, GE, DRUG2) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
GE (DRUG1): GE (e.g., GE, GE, GE, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with DRUG2.
LABEL>0
GE (GE): DRUG1 (e.g., DRUG2, GE, GE, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
GE (GE): DRUG1 (e.g., GE, DRUG2, GE, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
GE (GE): DRUG1 (e.g., GE, GE, DRUG2, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
GE (GE): DRUG1 (e.g., GE, GE, GE, DRUG2) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
GE (GE): GE (e.g., DRUG1, DRUG2, GE, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
GE (GE): GE (e.g., DRUG1, GE, DRUG2, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
GE (GE): GE (e.g., DRUG1, GE, GE, DRUG2) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
GE (GE): GE (e.g., GE, DRUG1, DRUG2, GE) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
GE (GE): GE (e.g., GE, DRUG1, GE, DRUG2) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
GE (GE): GE (e.g., GE, GE, DRUG1, DRUG2) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with GE.
LABEL>0
DRUG1: Coadministration of DRUG2 and GE resulted in a 24% increase in plasma concentrations of GE.
LABEL>0
DRUG1: Coadministration of GE and DRUG2 resulted in a 24% increase in plasma concentrations of GE.
LABEL>0
DRUG1: Coadministration of GE and GE resulted in a 24% increase in plasma concentrations of DRUG2.
LABEL>0
GE: Coadministration of DRUG1 and GE resulted in a 24% increase in plasma concentrations of DRUG2.
LABEL>0
GE: Coadministration of GE and DRUG1 resulted in a 24% increase in plasma concentrations of DRUG2.
LABEL>0
Coadministration of DRUG1 and the potent CYP3A4 inhibitor GE (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of DRUG2.
LABEL>0
Coadministration of GE and the potent CYP3A4 inhibitor DRUG1 (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of DRUG2.
LABEL>0
Although the interaction between DRUG1 and other potent CYP3A4 inhibitors (e.g., DRUG2, GE, and GE) has not been studied, increased exposures to GE may be expected when GE is used concomitantly with these medications.
LABEL>0
Although the interaction between DRUG1 and other potent CYP3A4 inhibitors (e.g., GE, DRUG2, and GE) has not been studied, increased exposures to GE may be expected when GE is used concomitantly with these medications.
LABEL>0
Although the interaction between DRUG1 and other potent CYP3A4 inhibitors (e.g., GE, GE, and DRUG2) has not been studied, increased exposures to GE may be expected when GE is used concomitantly with these medications.
LABEL>0
Although the interaction between DRUG1 and other potent CYP3A4 inhibitors (e.g., GE, GE, and GE) has not been studied, increased exposures to DRUG2 may be expected when GE is used concomitantly with these medications.
LABEL>0
Although the interaction between DRUG1 and other potent CYP3A4 inhibitors (e.g., GE, GE, and GE) has not been studied, increased exposures to GE may be expected when DRUG2 is used concomitantly with these medications.
LABEL>0
Although the interaction between GE and other potent CYP3A4 inhibitors (e.g., DRUG1, DRUG2, and GE) has not been studied, increased exposures to GE may be expected when GE is used concomitantly with these medications.
LABEL>0
Although the interaction between GE and other potent CYP3A4 inhibitors (e.g., DRUG1, GE, and DRUG2) has not been studied, increased exposures to GE may be expected when GE is used concomitantly with these medications.
LABEL>0
Although the interaction between GE and other potent CYP3A4 inhibitors (e.g., DRUG1, GE, and GE) has not been studied, increased exposures to DRUG2 may be expected when GE is used concomitantly with these medications.
LABEL>0
Although the interaction between GE and other potent CYP3A4 inhibitors (e.g., GE, DRUG1, and DRUG2) has not been studied, increased exposures to GE may be expected when GE is used concomitantly with these medications.
LABEL>0
Although the interaction between GE and other potent CYP3A4 inhibitors (e.g., GE, DRUG1, and GE) has not been studied, increased exposures to DRUG2 may be expected when GE is used concomitantly with these medications.
LABEL>0
Although the interaction between GE and other potent CYP3A4 inhibitors (e.g., GE, GE, and DRUG1) has not been studied, increased exposures to DRUG2 may be expected when GE is used concomitantly with these medications.
LABEL>0
Although the interaction between GE and other potent CYP3A4 inhibitors (e.g., GE, GE, and GE) has not been studied, increased exposures to DRUG1 may be expected when DRUG2 is used concomitantly with these medications.
LABEL>0
Because DRUG1 is metabolized by a variety of hepatic CYP drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance of DRUG2.
LABEL>0
In a pharmacokinetic study, 40 healthy female subjects received DRUG1 in escalating doses from 50 to 200 mg per day for 16 days, with coadministration of DRUG2 1 mg on the last day.
LABEL>0
Concomitant administration of GE and moderate CYP1A2 inhibitors, including DRUG1 and DRUG2, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.
LABEL>0
In a pharmacokinetic study, 38 healthy female subjects received DRUG1 200 mg twice daily for 7 days, with coadministration of DRUG2 1 mg on the last day.
LABEL>0
Coadministration of GE and strong CYP3A4 inhibitors, such as DRUG1, DRUG2, GE, GE, and GE has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
LABEL>0
Coadministration of GE and strong CYP3A4 inhibitors, such as DRUG1, GE, DRUG2, GE, and GE has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
LABEL>0
Coadministration of GE and strong CYP3A4 inhibitors, such as DRUG1, GE, GE, DRUG2, and GE has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
LABEL>0
Coadministration of GE and strong CYP3A4 inhibitors, such as DRUG1, GE, GE, GE, and DRUG2 has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
LABEL>0
Coadministration of GE and strong CYP3A4 inhibitors, such as GE, DRUG1, DRUG2, GE, and GE has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
LABEL>0
Coadministration of GE and strong CYP3A4 inhibitors, such as GE, DRUG1, GE, DRUG2, and GE has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
LABEL>0
Coadministration of GE and strong CYP3A4 inhibitors, such as GE, DRUG1, GE, GE, and DRUG2 has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
LABEL>0
Coadministration of GE and strong CYP3A4 inhibitors, such as GE, GE, DRUG1, DRUG2, and GE has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
LABEL>0
Coadministration of GE and strong CYP3A4 inhibitors, such as GE, GE, DRUG1, GE, and DRUG2 has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
LABEL>0
Coadministration of GE and strong CYP3A4 inhibitors, such as GE, GE, GE, DRUG1, and DRUG2 has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
LABEL>0
Although not studied with GE, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as DRUG1, DRUG2, and GE.
LABEL>0
Although not studied with GE, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as DRUG1, GE, and DRUG2.
LABEL>0
Although not studied with GE, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as GE, DRUG1, and DRUG2.
LABEL>0
Another study showed that DRUG1 had no clinically significant effect on plasma concentrations of the oral DRUG2 GE and GE (CYP3A4 substrates).
LABEL>0
Another study showed that DRUG1 had no clinically significant effect on plasma concentrations of the oral GE DRUG2 and GE (CYP3A4 substrates).
LABEL>0
Another study showed that DRUG1 had no clinically significant effect on plasma concentrations of the oral GE GE and DRUG2 (CYP3A4 substrates).
LABEL>0
Another study showed that GE had no clinically significant effect on plasma concentrations of the oral DRUG1 DRUG2 and GE (CYP3A4 substrates).
LABEL>0
Another study showed that GE had no clinically significant effect on plasma concentrations of the oral DRUG1 GE and DRUG2 (CYP3A4 substrates).
LABEL>0
Another study showed that GE had no clinically significant effect on plasma concentrations of the oral GE DRUG1 and DRUG2 (CYP3A4 substrates).
LABEL>0
A clinical interaction study was also conducted with DRUG1 and the CYP3A4 substrate DRUG2.
LABEL>0
The DRUG1, including DRUG2, produce additive CNS depressant effects when co-administered with other GE, GE, GE, GE, and other drugs which themselves produce CNS depression.
LABEL>0
The GE, including GE, produce additive CNS depressant effects when co-administered with other DRUG1, DRUG2, GE, GE, and other drugs which themselves produce CNS depression.
LABEL>0
The GE, including GE, produce additive CNS depressant effects when co-administered with other DRUG1, GE, DRUG2, GE, and other drugs which themselves produce CNS depression.
LABEL>0
The GE, including GE, produce additive CNS depressant effects when co-administered with other DRUG1, GE, GE, DRUG2, and other drugs which themselves produce CNS depression.
LABEL>0
The GE, including GE, produce additive CNS depressant effects when co-administered with other GE, DRUG1, DRUG2, GE, and other drugs which themselves produce CNS depression.
LABEL>0
The GE, including GE, produce additive CNS depressant effects when co-administered with other GE, DRUG1, GE, DRUG2, and other drugs which themselves produce CNS depression.
LABEL>0
The GE, including GE, produce additive CNS depressant effects when co-administered with other GE, GE, DRUG1, DRUG2, and other drugs which themselves produce CNS depression.
LABEL>0
The steady state plasma concentrations of DRUG1 and DRUG2 have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of GE tablets in doses up to 4 mg/day.
LABEL>0
Drugs That Inhibit DRUG1 Metabolism Via Cytochrome P450 3A: The initial step in DRUG2 metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP 3A).
LABEL>0
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving DRUG1 (caution is recommended during coadministration with DRUG2): Coadministration of GE with GE increased the maximum plasma concentration of GE by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
LABEL>0
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving DRUG1 (caution is recommended during coadministration with GE): Coadministration of DRUG2 with GE increased the maximum plasma concentration of GE by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
LABEL>0
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving DRUG1 (caution is recommended during coadministration with GE): Coadministration of GE with DRUG2 increased the maximum plasma concentration of GE by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
LABEL>0
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving DRUG1 (caution is recommended during coadministration with GE): Coadministration of GE with GE increased the maximum plasma concentration of DRUG2 by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
LABEL>0
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving GE (caution is recommended during coadministration with DRUG1): Coadministration of DRUG2 with GE increased the maximum plasma concentration of GE by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
LABEL>0
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving GE (caution is recommended during coadministration with DRUG1): Coadministration of GE with DRUG2 increased the maximum plasma concentration of GE by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
LABEL>0
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving GE (caution is recommended during coadministration with DRUG1): Coadministration of GE with GE increased the maximum plasma concentration of DRUG2 by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
LABEL>0
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving GE (caution is recommended during coadministration with GE): Coadministration of DRUG1 with GE increased the maximum plasma concentration of DRUG2 by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
LABEL>0
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving GE (caution is recommended during coadministration with GE): Coadministration of GE with DRUG1 increased the maximum plasma concentration of DRUG2 by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving DRUG1 metabolized similarly to DRUG2 or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving DRUG1 metabolized similarly to GE or on the basis of in vitro studies with DRUG2 or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving DRUG1 metabolized similarly to GE or on the basis of in vitro studies with GE or other DRUG2 (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving DRUG1 metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with DRUG2): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving DRUG1 metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of DRUG2 other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving DRUG1 metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than DRUG2 suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving DRUG1 metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with DRUG2 for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving DRUG1 metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: DRUG2, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving DRUG1 metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, DRUG2, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving DRUG1 metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, DRUG2 such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving DRUG1 metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as DRUG2 and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving DRUG1 metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and DRUG2, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to DRUG1 or on the basis of in vitro studies with DRUG2 or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to DRUG1 or on the basis of in vitro studies with GE or other DRUG2 (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to DRUG1 or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with DRUG2): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to DRUG1 or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of DRUG2 other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to DRUG1 or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than DRUG2 suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to DRUG1 or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with DRUG2 for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to DRUG1 or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: DRUG2, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to DRUG1 or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, DRUG2, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to DRUG1 or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, DRUG2 such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to DRUG1 or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as DRUG2 and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to DRUG1 or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and DRUG2, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with DRUG1 or other DRUG2 (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with DRUG1 or other GE (caution is recommended during coadministration with DRUG2): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with DRUG1 or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of DRUG2 other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with DRUG1 or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than DRUG2 suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with DRUG1 or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with DRUG2 for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with DRUG1 or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: DRUG2, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with DRUG1 or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, DRUG2, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with DRUG1 or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, DRUG2 such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with DRUG1 or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as DRUG2 and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with DRUG1 or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and DRUG2, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other DRUG1 (caution is recommended during coadministration with DRUG2): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other DRUG1 (caution is recommended during coadministration with GE): Available data from clinical studies of DRUG2 other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other DRUG1 (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than DRUG2 suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other DRUG1 (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with DRUG2 for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other DRUG1 (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: DRUG2, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other DRUG1 (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, DRUG2, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other DRUG1 (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, DRUG2 such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other DRUG1 (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as DRUG2 and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other DRUG1 (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and DRUG2, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with DRUG1): Available data from clinical studies of DRUG2 other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with DRUG1): Available data from clinical studies of GE other than DRUG2 suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with DRUG1): Available data from clinical studies of GE other than GE suggest a possible drug interaction with DRUG2 for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with DRUG1): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: DRUG2, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with DRUG1): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, DRUG2, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with DRUG1): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, DRUG2 such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with DRUG1): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as DRUG2 and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with DRUG1): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and DRUG2, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of DRUG1 other than DRUG2 suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of DRUG1 other than GE suggest a possible drug interaction with DRUG2 for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of DRUG1 other than GE suggest a possible drug interaction with GE for the following: DRUG2, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of DRUG1 other than GE suggest a possible drug interaction with GE for the following: GE, DRUG2, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of DRUG1 other than GE suggest a possible drug interaction with GE for the following: GE, GE, DRUG2 such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of DRUG1 other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as DRUG2 and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of DRUG1 other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and DRUG2, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than DRUG1 suggest a possible drug interaction with DRUG2 for the following: GE, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than DRUG1 suggest a possible drug interaction with GE for the following: DRUG2, GE, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than DRUG1 suggest a possible drug interaction with GE for the following: GE, DRUG2, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than DRUG1 suggest a possible drug interaction with GE for the following: GE, GE, DRUG2 such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than DRUG1 suggest a possible drug interaction with GE for the following: GE, GE, GE such as DRUG2 and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than DRUG1 suggest a possible drug interaction with GE for the following: GE, GE, GE such as GE and DRUG2, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: DRUG1, DRUG2, GE such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: DRUG1, GE, DRUG2 such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: DRUG1, GE, GE such as DRUG2 and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: DRUG1, GE, GE such as GE and DRUG2, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, DRUG1, DRUG2 such as GE and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, DRUG1, GE such as DRUG2 and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, DRUG1, GE such as GE and DRUG2, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, DRUG1 such as DRUG2 and GE, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, DRUG1 such as GE and DRUG2, and grapefruit juice.
LABEL>0
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving GE metabolized similarly to GE or on the basis of in vitro studies with GE or other GE (caution is recommended during coadministration with GE): Available data from clinical studies of GE other than GE suggest a possible drug interaction with GE for the following: GE, GE, GE such as DRUG1 and DRUG2, and grapefruit juice.
LABEL>0
Data from in vitro studies of DRUG1 suggest a possible drug interaction with DRUG2 for the following: GE and GE.
LABEL>0
Data from in vitro studies of DRUG1 suggest a possible drug interaction with GE for the following: DRUG2 and GE.
LABEL>0
Data from in vitro studies of DRUG1 suggest a possible drug interaction with GE for the following: GE and DRUG2.
LABEL>0
Data from in vitro studies of GE suggest a possible drug interaction with GE for the following: DRUG1 and DRUG2.
LABEL>0
Data from in vitro studies of DRUG1 other than DRUG2 suggest a possible drug interaction for the following: GE, GE, GE, GE, and GE.
LABEL>0
Data from in vitro studies of GE other than GE suggest a possible drug interaction for the following: DRUG1, DRUG2, GE, GE, and GE.
LABEL>0
Data from in vitro studies of GE other than GE suggest a possible drug interaction for the following: DRUG1, GE, DRUG2, GE, and GE.
LABEL>0
Data from in vitro studies of GE other than GE suggest a possible drug interaction for the following: DRUG1, GE, GE, DRUG2, and GE.
LABEL>0
Data from in vitro studies of GE other than GE suggest a possible drug interaction for the following: DRUG1, GE, GE, GE, and DRUG2.
LABEL>0
Data from in vitro studies of GE other than GE suggest a possible drug interaction for the following: GE, DRUG1, DRUG2, GE, and GE.
LABEL>0
Data from in vitro studies of GE other than GE suggest a possible drug interaction for the following: GE, DRUG1, GE, DRUG2, and GE.
LABEL>0
Data from in vitro studies of GE other than GE suggest a possible drug interaction for the following: GE, DRUG1, GE, GE, and DRUG2.
LABEL>0
Data from in vitro studies of GE other than GE suggest a possible drug interaction for the following: GE, GE, DRUG1, DRUG2, and GE.
LABEL>0
Data from in vitro studies of GE other than GE suggest a possible drug interaction for the following: GE, GE, DRUG1, GE, and DRUG2.
LABEL>0
Data from in vitro studies of GE other than GE suggest a possible drug interaction for the following: GE, GE, GE, DRUG1, and DRUG2.
LABEL>0
Standard therapy includes DRUG1, such as DRUG2 and GE;
LABEL>0
Standard therapy includes DRUG1, such as GE and DRUG2;
LABEL>0
Standard therapy includes GE, such as DRUG1 and DRUG2;
LABEL>0
DRUG1, such as DRUG2 and GE;
LABEL>0
DRUG1, such as GE and DRUG2;
LABEL>0
GE, such as DRUG1 and DRUG2;
LABEL>0
and DRUG1, such as DRUG2.
LABEL>0
DRUG1: The potential for pharmacokinetic drug-drug interactions between DRUG2 and other agents has not been formally studied.
LABEL>0
In addition to bleeding associated with DRUG1 and DRUG2, drugs that alter platelet function (such as GE, GE and GE) may increase the risk of bleeding if administered prior to, during, or after GE therapy.
LABEL>0
In addition to bleeding associated with DRUG1 and GE, drugs that alter platelet function (such as DRUG2, GE and GE) may increase the risk of bleeding if administered prior to, during, or after GE therapy.
LABEL>0
In addition to bleeding associated with DRUG1 and GE, drugs that alter platelet function (such as GE, DRUG2 and GE) may increase the risk of bleeding if administered prior to, during, or after GE therapy.
LABEL>0
In addition to bleeding associated with DRUG1 and GE, drugs that alter platelet function (such as GE, GE and DRUG2) may increase the risk of bleeding if administered prior to, during, or after GE therapy.
LABEL>0
In addition to bleeding associated with GE and DRUG1, drugs that alter platelet function (such as DRUG2, GE and GE) may increase the risk of bleeding if administered prior to, during, or after GE therapy.
LABEL>0
In addition to bleeding associated with GE and DRUG1, drugs that alter platelet function (such as GE, DRUG2 and GE) may increase the risk of bleeding if administered prior to, during, or after GE therapy.
LABEL>0
In addition to bleeding associated with GE and DRUG1, drugs that alter platelet function (such as GE, GE and DRUG2) may increase the risk of bleeding if administered prior to, during, or after GE therapy.
LABEL>0
In addition to bleeding associated with GE and GE, drugs that alter platelet function (such as DRUG1, DRUG2 and GE) may increase the risk of bleeding if administered prior to, during, or after GE therapy.
LABEL>0
In addition to bleeding associated with GE and GE, drugs that alter platelet function (such as DRUG1, GE and DRUG2) may increase the risk of bleeding if administered prior to, during, or after GE therapy.
LABEL>0
In addition to bleeding associated with GE and GE, drugs that alter platelet function (such as GE, DRUG1 and DRUG2) may increase the risk of bleeding if administered prior to, during, or after GE therapy.
LABEL>0
Use of DRUG1 DRUG2 and GE have been administered concomitantly with and following infusions of GE in the management of acute myocardial infarction or pulmonary embolism.
LABEL>0
Use of DRUG1 GE and DRUG2 have been administered concomitantly with and following infusions of GE in the management of acute myocardial infarction or pulmonary embolism.
LABEL>0
Use of DRUG1 GE and GE have been administered concomitantly with and following infusions of DRUG2 in the management of acute myocardial infarction or pulmonary embolism.
LABEL>0
Use of GE DRUG1 and DRUG2 have been administered concomitantly with and following infusions of GE in the management of acute myocardial infarction or pulmonary embolism.
LABEL>0
Use of GE DRUG1 and GE have been administered concomitantly with and following infusions of DRUG2 in the management of acute myocardial infarction or pulmonary embolism.
LABEL>0
Use of GE GE and DRUG1 have been administered concomitantly with and following infusions of DRUG2 in the management of acute myocardial infarction or pulmonary embolism.
LABEL>0
Because DRUG1, DRUG2, or GE may cause bleeding complications, careful monitoring for bleeding is advised, especially at arterial puncture sites.
LABEL>0
Because DRUG1, GE, or DRUG2 may cause bleeding complications, careful monitoring for bleeding is advised, especially at arterial puncture sites.
LABEL>0
Because GE, DRUG1, or DRUG2 may cause bleeding complications, careful monitoring for bleeding is advised, especially at arterial puncture sites.
LABEL>0
The concomitant use of DRUG1 or DRUG2 during the first 24 hours following symptom onset were prohibited in The NINDS t-PA Stroke Trial.
LABEL>0
Concurrent administration of DRUG1 and GE may cause severe orthostatic hypotension.DRUG2, an inhibitor of microsomal drug metabolism, increased GEs half-life and toxicity in a rat model.
LABEL>0
Concurrent administration of DRUG1 and GE may cause severe orthostatic hypotension.GE, an inhibitor of microsomal drug metabolism, increased DRUG2s half-life and toxicity in a rat model.
LABEL>0
Concurrent administration of GE and DRUG1 may cause severe orthostatic hypotension.DRUG2, an inhibitor of microsomal drug metabolism, increased GEs half-life and toxicity in a rat model.
LABEL>0
Concurrent administration of GE and DRUG1 may cause severe orthostatic hypotension.GE, an inhibitor of microsomal drug metabolism, increased DRUG2s half-life and toxicity in a rat model.
LABEL>0
Data from a randomized trial of DRUG1 and GE plus or minus DRUG2 in ovarian cancer indicated that GE significantly reduced neurotoxicity;
LABEL>0
Data from a randomized trial of DRUG1 and GE plus or minus GE in ovarian cancer indicated that DRUG2 significantly reduced neurotoxicity;
LABEL>0
Data from a randomized trial of GE and DRUG1 plus or minus DRUG2 in ovarian cancer indicated that GE significantly reduced neurotoxicity;
LABEL>0
Data from a randomized trial of GE and DRUG1 plus or minus GE in ovarian cancer indicated that DRUG2 significantly reduced neurotoxicity;
LABEL>0
Data from a randomized trial of GE and GE plus or minus DRUG1 in ovarian cancer indicated that DRUG2 significantly reduced neurotoxicity;
LABEL>0
however, it adversely affected response duration suggesting that GE should not be administered with DRUG1 and/or DRUG2.1
LABEL>0
In some patients, the administration of a GE can reduce the diuretic, natriuretic, and antihypertensive effects of DRUG1, DRUG2 and GE.
LABEL>0
In some patients, the administration of a GE can reduce the diuretic, natriuretic, and antihypertensive effects of DRUG1, GE and DRUG2.
LABEL>0
In some patients, the administration of a GE can reduce the diuretic, natriuretic, and antihypertensive effects of GE, DRUG1 and DRUG2.
LABEL>0
Therefore, when DRUG1 and GE are used concomitantly, the patient should be observed closely to determine if the desired effect of the DRUG2 is obtained.
LABEL>0
Therefore, when GE and DRUG1 are used concomitantly, the patient should be observed closely to determine if the desired effect of the DRUG2 is obtained.
LABEL>0
Since GE and DRUG1, including DRUG2, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.
LABEL>0
therefore, if DRUG1 replacement is needed, DRUG2 should be prescribed.
LABEL>0
GE diminishes the effect of DRUG1 and DRUG2.
LABEL>0
Renal clearance measurements of GE cannot be made with any significant accuracy in patients receiving DRUG1, DRUG2, or GE.
LABEL>0
Renal clearance measurements of GE cannot be made with any significant accuracy in patients receiving DRUG1, GE, or DRUG2.
LABEL>0
Renal clearance measurements of GE cannot be made with any significant accuracy in patients receiving GE, DRUG1, or DRUG2.
LABEL>0
It is, however, possible that concomitant use of other known DRUG1 such as DRUG2, GE, GE, GE, GE and GE might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
It is, however, possible that concomitant use of other known DRUG1 such as GE, DRUG2, GE, GE, GE and GE might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
It is, however, possible that concomitant use of other known DRUG1 such as GE, GE, DRUG2, GE, GE and GE might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
It is, however, possible that concomitant use of other known DRUG1 such as GE, GE, GE, DRUG2, GE and GE might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
It is, however, possible that concomitant use of other known DRUG1 such as GE, GE, GE, GE, DRUG2 and GE might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
It is, however, possible that concomitant use of other known DRUG1 such as GE, GE, GE, GE, GE and DRUG2 might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
It is, however, possible that concomitant use of other known GE such as DRUG1, DRUG2, GE, GE, GE and GE might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
It is, however, possible that concomitant use of other known GE such as DRUG1, GE, DRUG2, GE, GE and GE might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
It is, however, possible that concomitant use of other known GE such as DRUG1, GE, GE, DRUG2, GE and GE might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
It is, however, possible that concomitant use of other known GE such as DRUG1, GE, GE, GE, DRUG2 and GE might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
It is, however, possible that concomitant use of other known GE such as DRUG1, GE, GE, GE, GE and DRUG2 might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
It is, however, possible that concomitant use of other known GE such as GE, DRUG1, DRUG2, GE, GE and GE might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
It is, however, possible that concomitant use of other known GE such as GE, DRUG1, GE, DRUG2, GE and GE might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
It is, however, possible that concomitant use of other known GE such as GE, DRUG1, GE, GE, DRUG2 and GE might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
It is, however, possible that concomitant use of other known GE such as GE, DRUG1, GE, GE, GE and DRUG2 might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
It is, however, possible that concomitant use of other known GE such as GE, GE, DRUG1, DRUG2, GE and GE might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
It is, however, possible that concomitant use of other known GE such as GE, GE, DRUG1, GE, DRUG2 and GE might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
It is, however, possible that concomitant use of other known GE such as GE, GE, DRUG1, GE, GE and DRUG2 might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
It is, however, possible that concomitant use of other known GE such as GE, GE, GE, DRUG1, DRUG2 and GE might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
It is, however, possible that concomitant use of other known GE such as GE, GE, GE, DRUG1, GE and DRUG2 might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
It is, however, possible that concomitant use of other known GE such as GE, GE, GE, GE, DRUG1 and DRUG2 might increase the photosensitivity reaction of actinic keratoses treated with the GE for Topical Solution.
LABEL>0
DRUG1 may decrease the amount of GE (GE, DRUG2) that gets absorbed into your body.
LABEL>0
GE may decrease the amount of DRUG1 (DRUG2, GE) that gets absorbed into your body.
LABEL>0
GE may decrease the amount of DRUG1 (GE, DRUG2) that gets absorbed into your body.
LABEL>0
GE may decrease the amount of GE (DRUG1, DRUG2) that gets absorbed into your body.
LABEL>0
In the case that you are taking DRUG1 while taking GE, higher doses of DRUG2 may be needed.
LABEL>0
In the case that you are taking GE while taking DRUG1, higher doses of DRUG2 may be needed.
LABEL>0
DRUG1 is metabolized to DRUG2 by the cytochrome P450 (CYP450) enzyme group, specifically cytochromes P450 3A4 (CYP3A4) and CYP2C8.
LABEL>0
In view of the long and variable half-life of DRUG1, potential for drug interactions exists not only with concomitant medication but also with drugs administered after discontinuation of DRUG2.
LABEL>0
Since DRUG1 is a substrate for CYP3A4 and CYP2C8, drugs/substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of DRUG2.
LABEL>0
Reported examples include the following: DRUG1: DRUG2 are known to inhibit CYP3A4 to varying degrees.
LABEL>0
A case report of one patient taking DRUG1 200 mg and GE 800 mg three times a day resulted in increases in DRUG2 concentrations from 0.9 mg/L to 1.3 mg/L.
LABEL>0
A case report of one patient taking GE 200 mg and DRUG1 800 mg three times a day resulted in increases in DRUG2 concentrations from 0.9 mg/L to 1.3 mg/L.
LABEL>0
Monitoring for DRUG1 toxicity and serial measurement of DRUG2 serum concentration during concomitant GE therapy should be considered.
LABEL>0
Monitoring for DRUG1 toxicity and serial measurement of GE serum concentration during concomitant DRUG2 therapy should be considered.
LABEL>0
DRUG1: GE inhibits CYP3A4 and can increase serum DRUG2 levels.
LABEL>0
GE: DRUG1 inhibits CYP3A4 and can increase serum DRUG2 levels.
LABEL>0
Other substances: Grapefruit juice given to healthy volunteers increased DRUG1 AUC by 50% and Cmax by 84%, resulting in increased plasma levels of DRUG2.
LABEL>0
This information should be considered when changing from intravenous DRUG1 to oral DRUG2 .
LABEL>0
DRUG1 may suppress certain CYP450 enzymes, including DRUG2, GE, GE, and GE.
LABEL>0
DRUG1 may suppress certain CYP450 enzymes, including GE, DRUG2, GE, and GE.
LABEL>0
DRUG1 may suppress certain CYP450 enzymes, including GE, GE, DRUG2, and GE.
LABEL>0
DRUG1 may suppress certain CYP450 enzymes, including GE, GE, GE, and DRUG2.
LABEL>0
GE may suppress certain CYP450 enzymes, including DRUG1, DRUG2, GE, and GE.
LABEL>0
GE may suppress certain CYP450 enzymes, including DRUG1, GE, DRUG2, and GE.
LABEL>0
GE may suppress certain CYP450 enzymes, including DRUG1, GE, GE, and DRUG2.
LABEL>0
GE may suppress certain CYP450 enzymes, including GE, DRUG1, DRUG2, and GE.
LABEL>0
GE may suppress certain CYP450 enzymes, including GE, DRUG1, GE, and DRUG2.
LABEL>0
GE may suppress certain CYP450 enzymes, including GE, GE, DRUG1, and DRUG2.
LABEL>0
Reported examples of this interaction include the following: DRUG1s: DRUG2 (GE substrate) administered in combination with oral GE has been reported to produce persistently elevated plasma concentrations of GE resulting in elevated creatinine, despite reduction in dose of GE.
LABEL>0
Reported examples of this interaction include the following: DRUG1s: GE (DRUG2 substrate) administered in combination with oral GE has been reported to produce persistently elevated plasma concentrations of GE resulting in elevated creatinine, despite reduction in dose of GE.
LABEL>0
Reported examples of this interaction include the following: DRUG1s: GE (GE substrate) administered in combination with oral DRUG2 has been reported to produce persistently elevated plasma concentrations of GE resulting in elevated creatinine, despite reduction in dose of GE.
LABEL>0
Reported examples of this interaction include the following: DRUG1s: GE (GE substrate) administered in combination with oral GE has been reported to produce persistently elevated plasma concentrations of DRUG2 resulting in elevated creatinine, despite reduction in dose of GE.
LABEL>0
Reported examples of this interaction include the following: DRUG1s: GE (GE substrate) administered in combination with oral GE has been reported to produce persistently elevated plasma concentrations of GE resulting in elevated creatinine, despite reduction in dose of DRUG2.
LABEL>0
Reported examples of this interaction include the following: GEs: DRUG1 (DRUG2 substrate) administered in combination with oral GE has been reported to produce persistently elevated plasma concentrations of GE resulting in elevated creatinine, despite reduction in dose of GE.
LABEL>0
Reported examples of this interaction include the following: GEs: DRUG1 (GE substrate) administered in combination with oral DRUG2 has been reported to produce persistently elevated plasma concentrations of GE resulting in elevated creatinine, despite reduction in dose of GE.
LABEL>0
Reported examples of this interaction include the following: GEs: DRUG1 (GE substrate) administered in combination with oral GE has been reported to produce persistently elevated plasma concentrations of DRUG2 resulting in elevated creatinine, despite reduction in dose of GE.
LABEL>0
Reported examples of this interaction include the following: GEs: DRUG1 (GE substrate) administered in combination with oral GE has been reported to produce persistently elevated plasma concentrations of GE resulting in elevated creatinine, despite reduction in dose of DRUG2.
LABEL>0
Reported examples of this interaction include the following: GEs: GE (DRUG1 substrate) administered in combination with oral DRUG2 has been reported to produce persistently elevated plasma concentrations of GE resulting in elevated creatinine, despite reduction in dose of GE.
LABEL>0
Reported examples of this interaction include the following: GEs: GE (DRUG1 substrate) administered in combination with oral GE has been reported to produce persistently elevated plasma concentrations of DRUG2 resulting in elevated creatinine, despite reduction in dose of GE.
LABEL>0
Reported examples of this interaction include the following: GEs: GE (DRUG1 substrate) administered in combination with oral GE has been reported to produce persistently elevated plasma concentrations of GE resulting in elevated creatinine, despite reduction in dose of DRUG2.
LABEL>0
Reported examples of this interaction include the following: GEs: GE (GE substrate) administered in combination with oral DRUG1 has been reported to produce persistently elevated plasma concentrations of DRUG2 resulting in elevated creatinine, despite reduction in dose of GE.
LABEL>0
Reported examples of this interaction include the following: GEs: GE (GE substrate) administered in combination with oral DRUG1 has been reported to produce persistently elevated plasma concentrations of GE resulting in elevated creatinine, despite reduction in dose of DRUG2.
LABEL>0
Reported examples of this interaction include the following: GEs: GE (GE substrate) administered in combination with oral GE has been reported to produce persistently elevated plasma concentrations of DRUG1 resulting in elevated creatinine, despite reduction in dose of DRUG2.
LABEL>0
DRUG1: DRUG2 (GE substrate) in combination with GE has been associated with reports of myopathy/rhabdomyolysis.
LABEL>0
DRUG1: GE (DRUG2 substrate) in combination with GE has been associated with reports of myopathy/rhabdomyolysis.
LABEL>0
DRUG1: GE (GE substrate) in combination with DRUG2 has been associated with reports of myopathy/rhabdomyolysis.
LABEL>0
GE: DRUG1 (DRUG2 substrate) in combination with GE has been associated with reports of myopathy/rhabdomyolysis.
LABEL>0
GE: DRUG1 (GE substrate) in combination with DRUG2 has been associated with reports of myopathy/rhabdomyolysis.
LABEL>0
GE: GE (DRUG1 substrate) in combination with DRUG2 has been associated with reports of myopathy/rhabdomyolysis.
LABEL>0
Cardiovasculars: DRUG1: In patients receiving DRUG2 therapy, administration of oral GE regularly results in an increase in serum GE concentration that may reach toxic levels with resultant clinical toxicity.
LABEL>0
Cardiovasculars: DRUG1: In patients receiving GE therapy, administration of oral DRUG2 regularly results in an increase in serum GE concentration that may reach toxic levels with resultant clinical toxicity.
LABEL>0
Cardiovasculars: DRUG1: In patients receiving GE therapy, administration of oral GE regularly results in an increase in serum DRUG2 concentration that may reach toxic levels with resultant clinical toxicity.
LABEL>0
Cardiovasculars: GE: In patients receiving DRUG1 therapy, administration of oral DRUG2 regularly results in an increase in serum GE concentration that may reach toxic levels with resultant clinical toxicity.
LABEL>0
Cardiovasculars: GE: In patients receiving DRUG1 therapy, administration of oral GE regularly results in an increase in serum DRUG2 concentration that may reach toxic levels with resultant clinical toxicity.
LABEL>0
Cardiovasculars: GE: In patients receiving GE therapy, administration of oral DRUG1 regularly results in an increase in serum DRUG2 concentration that may reach toxic levels with resultant clinical toxicity.
LABEL>0
DRUG1 taken concomitantly with DRUG2 increases the serum GE concentration by 70% after one day.
LABEL>0
DRUG1 taken concomitantly with GE increases the serum DRUG2 concentration by 70% after one day.
LABEL>0
GE taken concomitantly with DRUG1 increases the serum DRUG2 concentration by 70% after one day.
LABEL>0
DRUG1: Other DRUG2 drugs, such as GE, GE, GE, and GE, have been used concurrently with GE.
LABEL>0
DRUG1: Other GE drugs, such as DRUG2, GE, GE, and GE, have been used concurrently with GE.
LABEL>0
DRUG1: Other GE drugs, such as GE, DRUG2, GE, and GE, have been used concurrently with GE.
LABEL>0
DRUG1: Other GE drugs, such as GE, GE, DRUG2, and GE, have been used concurrently with GE.
LABEL>0
DRUG1: Other GE drugs, such as GE, GE, GE, and DRUG2, have been used concurrently with GE.
LABEL>0
DRUG1: Other GE drugs, such as GE, GE, GE, and GE, have been used concurrently with DRUG2.
LABEL>0
GE: Other DRUG1 drugs, such as DRUG2, GE, GE, and GE, have been used concurrently with GE.
LABEL>0
GE: Other DRUG1 drugs, such as GE, DRUG2, GE, and GE, have been used concurrently with GE.
LABEL>0
GE: Other DRUG1 drugs, such as GE, GE, DRUG2, and GE, have been used concurrently with GE.
LABEL>0
GE: Other DRUG1 drugs, such as GE, GE, GE, and DRUG2, have been used concurrently with GE.
LABEL>0
GE: Other DRUG1 drugs, such as GE, GE, GE, and GE, have been used concurrently with DRUG2.
LABEL>0
GE: Other GE drugs, such as DRUG1, DRUG2, GE, and GE, have been used concurrently with GE.
LABEL>0
GE: Other GE drugs, such as DRUG1, GE, DRUG2, and GE, have been used concurrently with GE.
LABEL>0
GE: Other GE drugs, such as DRUG1, GE, GE, and DRUG2, have been used concurrently with GE.
LABEL>0
GE: Other GE drugs, such as DRUG1, GE, GE, and GE, have been used concurrently with DRUG2.
LABEL>0
GE: Other GE drugs, such as GE, DRUG1, DRUG2, and GE, have been used concurrently with GE.
LABEL>0
GE: Other GE drugs, such as GE, DRUG1, GE, and DRUG2, have been used concurrently with GE.
LABEL>0
GE: Other GE drugs, such as GE, DRUG1, GE, and GE, have been used concurrently with DRUG2.
LABEL>0
GE: Other GE drugs, such as GE, GE, DRUG1, and DRUG2, have been used concurrently with GE.
LABEL>0
GE: Other GE drugs, such as GE, GE, DRUG1, and GE, have been used concurrently with DRUG2.
LABEL>0
GE: Other GE drugs, such as GE, GE, GE, and DRUG1, have been used concurrently with DRUG2.
LABEL>0
There have been case reports of increased steady-state levels of DRUG1, DRUG2, and GE during concomitant therapy with GE.
LABEL>0
There have been case reports of increased steady-state levels of DRUG1, GE, and DRUG2 during concomitant therapy with GE.
LABEL>0
There have been case reports of increased steady-state levels of DRUG1, GE, and GE during concomitant therapy with DRUG2.
LABEL>0
There have been case reports of increased steady-state levels of GE, DRUG1, and DRUG2 during concomitant therapy with GE.
LABEL>0
There have been case reports of increased steady-state levels of GE, DRUG1, and GE during concomitant therapy with DRUG2.
LABEL>0
There have been case reports of increased steady-state levels of GE, GE, and DRUG1 during concomitant therapy with DRUG2.
LABEL>0
DRUG1 taken concomitantly with DRUG2 increases GE serum concentration by 33% after two days.
LABEL>0
DRUG1 taken concomitantly with GE increases DRUG2 serum concentration by 33% after two days.
LABEL>0
GE taken concomitantly with DRUG1 increases DRUG2 serum concentration by 33% after two days.
LABEL>0
DRUG1 taken concomitantly with DRUG2 for less than seven days increases plasma concentrations of GE and n-acetyl GE by 55% and 33%, respectively.
LABEL>0
DRUG1 taken concomitantly with GE for less than seven days increases plasma concentrations of DRUG2 and n-acetyl GE by 55% and 33%, respectively.
LABEL>0
DRUG1 taken concomitantly with GE for less than seven days increases plasma concentrations of GE and n-acetyl DRUG2 by 55% and 33%, respectively.
LABEL>0
GE taken concomitantly with DRUG1 for less than seven days increases plasma concentrations of DRUG2 and n-acetyl GE by 55% and 33%, respectively.
LABEL>0
GE taken concomitantly with DRUG1 for less than seven days increases plasma concentrations of GE and n-acetyl DRUG2 by 55% and 33%, respectively.
LABEL>0
GE taken concomitantly with GE for less than seven days increases plasma concentrations of DRUG1 and n-acetyl DRUG2 by 55% and 33%, respectively.
LABEL>0
DRUG1 and procainamide doses should be reduced by one-third when either is administered with DRUG2.
LABEL>0
Plasma levels of DRUG1 have been reported to increase in the presence of oral DRUG2;
LABEL>0
because of this, the dosage of DRUG1 should be adjusted when these DRUG2 are administered concomitantly.
LABEL>0
Combination of DRUG1 with other DRUG2 therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to GE.
LABEL>0
Combination of DRUG1 with other GE therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to DRUG2.
LABEL>0
Combination of GE with other DRUG1 therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to DRUG2.
LABEL>0
During transfer to oral DRUG1, the dose levels of previously administered agents should be reduced by 30 to 50% several days after the addition of oral DRUG2.
LABEL>0
The continued need for the other DRUG1 agent should be reviewed after the effects of DRUG2 have been established, and discontinuation ordinarily should be attempted.
LABEL>0
In DRUG1-treated patients who require additional DRUG2 therapy, the initial dose of such agents should be approximately half of the usual recommended dose.
LABEL>0
DRUG1: DRUG2 should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., GE, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
DRUG1: GE should be used with caution in patients receiving  -DRUG2 blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., GE, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
DRUG1: GE should be used with caution in patients receiving  -GE blocking agents (e.g., DRUG2, a GE inhibitor) or GE antagonists (e.g., GE, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
DRUG1: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a DRUG2 inhibitor) or GE antagonists (e.g., GE, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
DRUG1: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or DRUG2 antagonists (e.g., GE, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
DRUG1: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., DRUG2, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
DRUG1: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., GE, a DRUG2 substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
DRUG1: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., GE, a GE substrate, and DRUG2, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
DRUG1: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., GE, a GE substrate, and GE, a DRUG2 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: DRUG1 should be used with caution in patients receiving  -DRUG2 blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., GE, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: DRUG1 should be used with caution in patients receiving  -GE blocking agents (e.g., DRUG2, a GE inhibitor) or GE antagonists (e.g., GE, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: DRUG1 should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a DRUG2 inhibitor) or GE antagonists (e.g., GE, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: DRUG1 should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or DRUG2 antagonists (e.g., GE, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: DRUG1 should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., DRUG2, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: DRUG1 should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., GE, a DRUG2 substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: DRUG1 should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., GE, a GE substrate, and DRUG2, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: DRUG1 should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., GE, a GE substrate, and GE, a DRUG2 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -DRUG1 blocking agents (e.g., DRUG2, a GE inhibitor) or GE antagonists (e.g., GE, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -DRUG1 blocking agents (e.g., GE, a DRUG2 inhibitor) or GE antagonists (e.g., GE, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -DRUG1 blocking agents (e.g., GE, a GE inhibitor) or DRUG2 antagonists (e.g., GE, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -DRUG1 blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., DRUG2, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -DRUG1 blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., GE, a DRUG2 substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -DRUG1 blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., GE, a GE substrate, and DRUG2, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -DRUG1 blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., GE, a GE substrate, and GE, a DRUG2 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., DRUG1, a DRUG2 inhibitor) or GE antagonists (e.g., GE, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., DRUG1, a GE inhibitor) or DRUG2 antagonists (e.g., GE, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., DRUG1, a GE inhibitor) or GE antagonists (e.g., DRUG2, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., DRUG1, a GE inhibitor) or GE antagonists (e.g., GE, a DRUG2 substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., DRUG1, a GE inhibitor) or GE antagonists (e.g., GE, a GE substrate, and DRUG2, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., DRUG1, a GE inhibitor) or GE antagonists (e.g., GE, a GE substrate, and GE, a DRUG2 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a DRUG1 inhibitor) or DRUG2 antagonists (e.g., GE, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a DRUG1 inhibitor) or GE antagonists (e.g., DRUG2, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a DRUG1 inhibitor) or GE antagonists (e.g., GE, a DRUG2 substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a DRUG1 inhibitor) or GE antagonists (e.g., GE, a GE substrate, and DRUG2, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a DRUG1 inhibitor) or GE antagonists (e.g., GE, a GE substrate, and GE, a DRUG2 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or DRUG1 antagonists (e.g., DRUG2, a GE substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or DRUG1 antagonists (e.g., GE, a DRUG2 substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or DRUG1 antagonists (e.g., GE, a GE substrate, and DRUG2, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or DRUG1 antagonists (e.g., GE, a GE substrate, and GE, a DRUG2 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., DRUG1, a DRUG2 substrate, and GE, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., DRUG1, a GE substrate, and DRUG2, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., DRUG1, a GE substrate, and GE, a DRUG2 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., GE, a DRUG1 substrate, and DRUG2, a GE inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., GE, a DRUG1 substrate, and GE, a DRUG2 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
GE: GE should be used with caution in patients receiving  -GE blocking agents (e.g., GE, a GE inhibitor) or GE antagonists (e.g., GE, a GE substrate, and DRUG1, a DRUG2 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;
LABEL>0
DRUG1: Potentiation of DRUG2-type (GE and GE substrate) GE response is almost always seen in patients receiving GE and can result in serious or fatal bleeding.
LABEL>0
DRUG1: Potentiation of GE-type (DRUG2 and GE substrate) GE response is almost always seen in patients receiving GE and can result in serious or fatal bleeding.
LABEL>0
DRUG1: Potentiation of GE-type (GE and DRUG2 substrate) GE response is almost always seen in patients receiving GE and can result in serious or fatal bleeding.
LABEL>0
DRUG1: Potentiation of GE-type (GE and GE substrate) DRUG2 response is almost always seen in patients receiving GE and can result in serious or fatal bleeding.
LABEL>0
DRUG1: Potentiation of GE-type (GE and GE substrate) GE response is almost always seen in patients receiving DRUG2 and can result in serious or fatal bleeding.
LABEL>0
GE: Potentiation of DRUG1-type (DRUG2 and GE substrate) GE response is almost always seen in patients receiving GE and can result in serious or fatal bleeding.
LABEL>0
GE: Potentiation of DRUG1-type (GE and DRUG2 substrate) GE response is almost always seen in patients receiving GE and can result in serious or fatal bleeding.
LABEL>0
GE: Potentiation of DRUG1-type (GE and GE substrate) DRUG2 response is almost always seen in patients receiving GE and can result in serious or fatal bleeding.
LABEL>0
GE: Potentiation of DRUG1-type (GE and GE substrate) GE response is almost always seen in patients receiving DRUG2 and can result in serious or fatal bleeding.
LABEL>0
GE: Potentiation of GE-type (DRUG1 and DRUG2 substrate) GE response is almost always seen in patients receiving GE and can result in serious or fatal bleeding.
LABEL>0
GE: Potentiation of GE-type (DRUG1 and GE substrate) DRUG2 response is almost always seen in patients receiving GE and can result in serious or fatal bleeding.
LABEL>0
GE: Potentiation of GE-type (DRUG1 and GE substrate) GE response is almost always seen in patients receiving DRUG2 and can result in serious or fatal bleeding.
LABEL>0
GE: Potentiation of GE-type (GE and DRUG1 substrate) DRUG2 response is almost always seen in patients receiving GE and can result in serious or fatal bleeding.
LABEL>0
GE: Potentiation of GE-type (GE and DRUG1 substrate) GE response is almost always seen in patients receiving DRUG2 and can result in serious or fatal bleeding.
LABEL>0
GE: Potentiation of GE-type (GE and GE substrate) DRUG1 response is almost always seen in patients receiving DRUG2 and can result in serious or fatal bleeding.
LABEL>0
Since the concomitant administration of DRUG1 with DRUG2 increases the prothrombin time by 100% after 3 to 4 days, the dose of the GE should be reduced by one-third to one-half, and prothrombin times should be monitored closely.
LABEL>0
Since the concomitant administration of DRUG1 with GE increases the prothrombin time by 100% after 3 to 4 days, the dose of the DRUG2 should be reduced by one-third to one-half, and prothrombin times should be monitored closely.
LABEL>0
Since the concomitant administration of GE with DRUG1 increases the prothrombin time by 100% after 3 to 4 days, the dose of the DRUG2 should be reduced by one-third to one-half, and prothrombin times should be monitored closely.
LABEL>0
Some DRUG1/substances are known to accelerate the metabolism of DRUG2 by stimulating the synthesis of GE (enzyme induction).
LABEL>0
Some DRUG1/substances are known to accelerate the metabolism of GE by stimulating the synthesis of DRUG2 (enzyme induction).
LABEL>0
Some GE/substances are known to accelerate the metabolism of DRUG1 by stimulating the synthesis of DRUG2 (enzyme induction).
LABEL>0
Reported examples of this interaction include the following: DRUG1: DRUG2 is a potent inducer of GE.
LABEL>0
Reported examples of this interaction include the following: DRUG1: GE is a potent inducer of DRUG2.
LABEL>0
Reported examples of this interaction include the following: GE: DRUG1 is a potent inducer of DRUG2.
LABEL>0
Administration of DRUG1 concomitantly with oral DRUG2 has been shown to result in decreases in serum concentrations of GE and GE.
LABEL>0
Administration of DRUG1 concomitantly with oral GE has been shown to result in decreases in serum concentrations of DRUG2 and GE.
LABEL>0
Administration of DRUG1 concomitantly with oral GE has been shown to result in decreases in serum concentrations of GE and DRUG2.
LABEL>0
Administration of GE concomitantly with oral DRUG1 has been shown to result in decreases in serum concentrations of DRUG2 and GE.
LABEL>0
Administration of GE concomitantly with oral DRUG1 has been shown to result in decreases in serum concentrations of GE and DRUG2.
LABEL>0
Administration of GE concomitantly with oral GE has been shown to result in decreases in serum concentrations of DRUG1 and DRUG2.
LABEL>0
Since DRUG1 is a substrate for DRUG2, there is the potential that the use of St. John s Wort in patients receiving GE could result in reduced GE levels.
LABEL>0
Since DRUG1 is a substrate for GE, there is the potential that the use of St. John s Wort in patients receiving DRUG2 could result in reduced GE levels.
LABEL>0
Since DRUG1 is a substrate for GE, there is the potential that the use of St. John s Wort in patients receiving GE could result in reduced DRUG2 levels.
LABEL>0
Since GE is a substrate for DRUG1, there is the potential that the use of St. John s Wort in patients receiving DRUG2 could result in reduced GE levels.
LABEL>0
Since GE is a substrate for DRUG1, there is the potential that the use of St. John s Wort in patients receiving GE could result in reduced DRUG2 levels.
LABEL>0
Since GE is a substrate for GE, there is the potential that the use of St. John s Wort in patients receiving DRUG1 could result in reduced DRUG2 levels.
LABEL>0
Other reported interactions with DRUG1: DRUG2 (GE substrate) in combination with GE may cause hypotension, bradycardia, and decreased cardiac output.
LABEL>0
Other reported interactions with DRUG1: GE (DRUG2 substrate) in combination with GE may cause hypotension, bradycardia, and decreased cardiac output.
LABEL>0
Other reported interactions with DRUG1: GE (GE substrate) in combination with DRUG2 may cause hypotension, bradycardia, and decreased cardiac output.
LABEL>0
Other reported interactions with GE: DRUG1 (DRUG2 substrate) in combination with GE may cause hypotension, bradycardia, and decreased cardiac output.
LABEL>0
Other reported interactions with GE: DRUG1 (GE substrate) in combination with DRUG2 may cause hypotension, bradycardia, and decreased cardiac output.
LABEL>0
Other reported interactions with GE: GE (DRUG1 substrate) in combination with DRUG2 may cause hypotension, bradycardia, and decreased cardiac output.
LABEL>0
Sinus bradycardia has been reported with oral DRUG1 in combination with DRUG2 (GE substrate) given for local GE.
LABEL>0
Sinus bradycardia has been reported with oral DRUG1 in combination with GE (DRUG2 substrate) given for local GE.
LABEL>0
Sinus bradycardia has been reported with oral DRUG1 in combination with GE (GE substrate) given for local DRUG2.
LABEL>0
Sinus bradycardia has been reported with oral GE in combination with DRUG1 (DRUG2 substrate) given for local GE.
LABEL>0
Sinus bradycardia has been reported with oral GE in combination with DRUG1 (GE substrate) given for local DRUG2.
LABEL>0
Sinus bradycardia has been reported with oral GE in combination with GE (DRUG1 substrate) given for local DRUG2.
LABEL>0
Seizure, associated with increased DRUG1 concentrations, has been reported with concomitant administration of intravenous DRUG2.
LABEL>0
DRUG1 is a substrate for both DRUG2 and GE.
LABEL>0
DRUG1 is a substrate for both GE and DRUG2.
LABEL>0
GE is a substrate for both DRUG1 and DRUG2.
LABEL>0
DRUG1 inhibits DRUG2.
LABEL>0
DRUG1 increases enterohepatic elimination of DRUG2 and may reduce its serum levels and GE/2.
LABEL>0
DRUG1 increases enterohepatic elimination of GE and may reduce its serum levels and DRUG2/2.
LABEL>0
GE increases enterohepatic elimination of DRUG1 and may reduce its serum levels and DRUG2/2.
LABEL>0
DRUG1, DRUG2, and azoles are known to cause QTc prolongation.
LABEL>0
There have been reports of QTc prolongation, with or without TdP, in patients taking DRUG1 when DRUG2, GE, or azoles were administered concomitantly.
LABEL>0
There have been reports of QTc prolongation, with or without TdP, in patients taking DRUG1 when GE, DRUG2, or azoles were administered concomitantly.
LABEL>0
There have been reports of QTc prolongation, with or without TdP, in patients taking GE when DRUG1, DRUG2, or azoles were administered concomitantly.
LABEL>0
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with DRUG1, DRUG2, and GE.
LABEL>0
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with DRUG1, GE, and DRUG2.
LABEL>0
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with GE, DRUG1, and DRUG2.
LABEL>0
In addition to the interactions noted above, chronic (  2 weeks) oral DRUG1 administration impairs metabolism of DRUG2, GE, and GE.
LABEL>0
In addition to the interactions noted above, chronic (  2 weeks) oral DRUG1 administration impairs metabolism of GE, DRUG2, and GE.
LABEL>0
In addition to the interactions noted above, chronic (  2 weeks) oral DRUG1 administration impairs metabolism of GE, GE, and DRUG2.
LABEL>0
In addition to the interactions noted above, chronic (  2 weeks) oral GE administration impairs metabolism of DRUG1, DRUG2, and GE.
LABEL>0
In addition to the interactions noted above, chronic (  2 weeks) oral GE administration impairs metabolism of DRUG1, GE, and DRUG2.
LABEL>0
In addition to the interactions noted above, chronic (  2 weeks) oral GE administration impairs metabolism of GE, DRUG1, and DRUG2.
LABEL>0
Poor metabolizers have higher than expected plasma concentrations of DRUG1 (DRUG2) when given usual doses.
LABEL>0
DRUG1) and many that are substrates for P450 2D6 (many other DRUG2, GE, and the GE GE and GE).
LABEL>0
DRUG1) and many that are substrates for P450 2D6 (many other GE, DRUG2, and the GE GE and GE).
LABEL>0
DRUG1) and many that are substrates for P450 2D6 (many other GE, GE, and the DRUG2 GE and GE).
LABEL>0
DRUG1) and many that are substrates for P450 2D6 (many other GE, GE, and the GE DRUG2 and GE).
